Characterisation of keratinocyte-derived epidermal signals in the initiation of contact hypersensitivity to chemicals by Summerfield, VL
1 
 
 
  
 
 
 
 
Characterisation of keratinocyte-derived epidermal signals in 
the initiation of contact hypersensitivity to chemicals 
 
 
 
A thesis submitted by 
Vicki Louise Summerfield  
For the degree of  
Doctor of Philosophy  
University College London  
2015 
 
 
 
 
 
 
 
 
Division of Infection and Immunity 
University College London  
 
 
 
 
 2 
 
 
 
 
 
 
 
 
Declaration  
 
I, Vicki Louise Summerfield confirm that the work presented in this thesis is my own.  
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis.   
 
 
 
 
…………..……………………. 
Vicki Summerfield B.Sc, M.Sc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
 
Abstract 
 
Contact hypersensitivity reactions result from an adaptive immune response following 
topical  exposure  to  chemical  allergen.    The  initiation  of  this  response  requires  the 
production  of  an  inflammatory  micro-environment,  however  the  contribution  of 
epidermal  keratinocytes  in  creating  this  environment  is  not  well-characterised.    In 
particular,  the  molecular  processes  that  regulate  inflammatory  mediator  release  in 
response to chemical allergen, and the function of keratinocyte-derived mediators in 
dendritic cell migration and maturation, have not been fully explored.  
 
Keratinocytes (HaCaT cell line) and three-dimensional reconstructed human epidermis 
were evaluated as possible models for investigating these questions.  We have found 
that, in response to chemical allergen, keratinocytes transcribe and release inflammatory 
mediators (interleukin-6 (IL-6) and IL-8), and a cytokine known to induce dendritic cell 
migration (IL-1).  Furthermore, the production of these mediators was greater than that 
induced by a simple chemical irritant, and different to lipopolysaccharide/interferon- 
stimulation.    Transcriptomic  analysis  was  performed  to  investigate  the  molecular 
mechanisms behind the inflammatory mediator release.  Principal component analysis 
of  the  data  showed  distinct  clustering  of  gene  expression  profiles  associated  with 
different  doses  of  2,4-dinitrochlorobenzene  (DNCB,  allergen)  and  sodium  dodecyl 
sulfate  (SDS,  irritant)  exposed  keratinocytes.    Many  of  the  differentially  expressed 
genes  that  were  found  in  response  to  DNCB  map  to  components  of  stress-induced 
pathways such as nuclear factor -light-chain-enhancer of activated B cells (NF-B) 
and nuclear factor erythroid 2-related factor 2 (Nrf2).  Investigation of the upstream 
signal  transduction  cascades  revealed  activation  of  mitogen-activated  protein  kinase 
(MAPK) pathways, specifically phosphorylation of p38MAPK and c-Jun N-terminal 
kinase  (JNK),  with  a  simultaneous  decrease  in  the  phosphorylation  level  of 
extracellular-signal-regulated  kinase  (ERK).    There  was  also  evidence  of  partial 
activation of the NF-B pathway.  The mechanism by which chemical allergens initiate 
these  responses  is  unknown,  however  we  have  identified  two  possible  triggers: 
production of reactive oxygen species, and activation of a receptor tyrosine kinase. 
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S100p   S100 calcium binding protein 
SARM   Selective androgen receptor modulator 
SDS     Sodium dodecyl sulphate 
SLS    Sodium lauryl sulphate 
SMAC   Supramolecular activation cluster 
SOD     Superoxide dismutase  
SP1     Specificity Protein 1 
SSC     Side scatter 
STAT    Signal transducer and activators of transcription  
T cells   T lymphocytes 
TBS     Tris-buffered saline 
Tc    Cytotoxic T cell 
TCR     T cell receptor 
TF     Transcription factor 20 
 
TGF    Transforming growth factor 
Th    T helper cell 
TIR     Toll/IL-1 receptor 
TIRAP   Toll-Interleukin-1 receptor domain-containing adaptor protein 
TLR     Toll-like receptor 
TNBS    2,4,6 Trinitrobenzene sulfonic acid 
TNCB    2,4,6-Trinitrochlorobenzene 
TNF     Tumour necrosis factor 
TNFAIP  TNF induced protein 
TNFR   Tumour necrosis factor receptor 
TNFRSF  Tumor necrosis factor receptor superfamily, member 
TRAF    TNF-receptor-associated factor 
TRAM   TRIF-related adaptor molecule 
Treg     Regulatory T cells 
TRIF    TIR-domain-contatining adapter-inducing interferon-beta 
TSLP    Thymic stromal lymphopoietin 
TxA2     Thromboxane 
TXNRD  Thioredoxin reductase 
UV     Ultraviolet 
VEGF    Vascular epidermal growth factor 
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1  INTRODUCTION  
1.1 Human skin  
Human skin is  an effective physical barrier that restricts the penetration of harmful 
chemicals and pathogens into the body, and prevents water loss.  It is comprised of three 
general layers (Figure 1-1): the epidermis, the dermis and the hypodermis (Montagna 
and Parakkal, 1974). 
 
The  epidermis  is  a  stratified  epithelium,  largely  consisting  of  a  continuously  self-
regenerating  population  of  terminally  differentiating  keratinocytes,  which  make  up 
>90% of the total epidermal cell mass (Montagna and Lobitz, 1964).  Resident cell 
types with specialised functions, such as melanocytes (pigmentation), Langerhans cells 
(antigen presentation) and Merkel cells (sensory perception) occupy the majority of the 
remaining  cell  mass  (Marzulli  and  Maibach,  Dermatotoxicology,  1996;  Urmacher, 
1990). 
 
The  dermal  compartment  provides  tensile  strength  and  elasticity  to  the  skin  and 
supports  appendages  such  as  nerves,  hair  follicles,  sweat  glands  and  lymphatic  and 
blood  vessels  (Urmacher,  1990).    The  dermis  largely  consists  of  fibroblasts,  which 
secrete  extra-ceullular  matrix  (ECM)  components  such  as  collagen,  elastin, 
glycosaminoglycans and hyaluronic acid.  In addition to fibroblasts, the dermis also 
contains other resident cell types, such as mast cells, macrophages, dermal dendritic 
cells (Urmacher, 1990) and a small number of T lymphocytes.  The tissue of the dermis 
and  epidermis  are  linked  via  a  basement  membrane  containing  types  IV  and  VII 
collagen and laminin, which are secreted by both fibroblasts and keratinocytes (Lee and 
Cho, 2005). 
 
The hypodermis is a sub-cutaneous layer consisting mainly of adipocytes, which have 
cytoplasms packed with lipids such as triglycerides and fatty acids. These lipids provide 
insulation and thermoregulation, and act as a major store of energy.  
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Figure 1-1 Haematoxylin and Eosin (H&E) stained human skin (sun protected), 
reproduced with permission from Nikki Hudson 
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1.2 Epidermal keratinocytes  
Epidermal keratinocytes continually migrate from the basement membrane to the skin 
apical surface (over 5-30 days), where they undergo a cell shedding process termed 
desquamation.  As they migrate, they differentiate to form 4 distinct layers or strata 
(keratinisation)  (Smith  and  Hotchkiss,  2001).    From  the  dermal-epidermal  junction 
(DEJ) outwards, these are: stratum basale, stratum spinosum, stratum granulosum and 
stratum  corneum.    Each  well-defined  stratum  can  be  identified  by  a  particular 
keratinocyte  morphology  and  pattern  of  protein  and  lipid  expression.    The  stratum 
basale is a single cell layer of epidermal stem cells and transit-amplifying cells that 
proliferate  to  continuously  regenerate  the  epidermis  (Watt,  2001).    They  can  be 
distinguished  by  their  expression  of  keratins  5  and  14,  in  contrast  to  suprabasal 
keratinocytes,  which  express  keratins  1  and  10  (Fuchs  and  Green,  1980).    Basal 
keratinocytes are attached, via  and  integrins, to the basement membrane.  As they 
proliferate  by  asymmetric  mitosis,  their  daughter  keratinocytes  enter  the  stratum 
spinosum,  where  they  grow  and  develop  strong  cellular  interactions  through  the 
formation  of  desmosomes.    As  the  cells  migrate  into  the  stratum  granulosum,  they 
develop tight junctions (Morita and Miyachi, 2003).  They also produce intracellular 
keratohyalin granules containing filaggrin (Lavker and Matoltsy, 1971), and smaller 
lamellar granules or Odland bodies (Odland, 1991), which contain lipid to contribute 
towards the permeability barrier.  Finally, the keratinocytes of the stratum corneum 
(termed  corneocytes)  lack  intracellular  organelles  following  the  action  of  lysosomal 
enzymes.    These  dead,  keratinised  cells  contain  relatively  little  water  and  have 
insoluble, cornified plasma membranes, which are formed by cross-linking of proteins 
such  as  involucrin  and  loricrin  (Rice  and  Green,  1977;  Candi  et  al,  2005).    The 
intercellular space in the stratum corneum is packed with lipid, such as free fatty acids, 
cholesterol and ceramides, which make up the lipid lamellae (Coderch et al, 2003).   
 
The homeostatic process of basement to apical turnover of epidermis is regulated by a 
complex  balance  between  proliferation,  differentiation  and  cell  death.    Growth  and 
proliferation are mediated via the epidermal growth factor receptor (EGFR) in response 
to  EGF,  transforming  growth  factor-alpha  (TGF-)  (Coffey  et  al,  1987)  and 
amphiregulin (Plowman et al, 1990; Piepkorn et al, 1994).  Keratinocyte growth is also 
tightly  regulated  by  fibroblast  growth  factor  (FGF)  and  keratinocyte  growth  factor 24 
 
(KGF) secreted by dermal fibroblasts (reviewed in Basilico et al, 1992).   The rate of 
programmed  cell  death  (cornification)  is  closely  balanced  with  the  basal  cell 
proliferation rate to maintain homeostasis. 
 
1.3 The skin immune system 
It  is  essential  that  any  perturbation  of  epidermal  barrier  homeostasis  by  wounding, 
pathogenic infection or exposure to harmful chemicals is controlled by the skin immune 
system.    Cutaneous  immune  responses  occur  in  the  dermal  and  epidermal  layers 
(Kupper  and  Fuhlbridge,  2004).    Resident  immune  cells  in  the  epidermis  include 
Langerhans cells (LC) and T lymphocytes (T cells), and in the dermis include dermal 
(dDC) and plasmacytoid dendritic cells (pDC), T cells, natural killer T (NKT) cells, 
mast cells and macrophages (Nestle et al, 2009).  The T cell population in human skin 
(epidermis  and  dermis)  is  mostly  comprised  of  cutaneous  lymphocyte-associated 
antigen (CLA)+ cluster of differentiation 4 positive (CD4+) T helper 1 (Th1) effector 
memory cells, with minority populations of central memory, Th2 and regulatory T cells 
(Treg) (Clark et al, 2006).  Human epidermis contains both CD4+ and CD8+ T cells, 
mostly memory or effector phenotype (Spetz et al, 1996).  Long-lived resident memory 
CD8+  T  cells  that  have  potent  effector  function  have  been  found  following  skin 
infection to vaccinia virus in mice (Jiang et al, 2012).  Following herpes simplex virus 
infection in mice, CD8+ skin resident T cells were confined largely to the original site of 
infection, while CD4+ T cells migrated rapidly through the skin (Gebhardt et al, 2011).  
In  addition  to  circulating  T  cells,  other  immune  cells  infiltrate  into  dermal  and 
epidermal  tissue  during  inflammation,  such  as  monocytes  (which  differentiate  into 
macrophages and dendritic cells), granulocytes (neutrophils, basophils and eosinophils) 
and natural killer (NK) cells (Kupper and Fuhlbridge, 2004).  Co-ordination of this 
diverse set of immune cells occurs by communication involving a complex network of 
endogenous mediators, such as cytokines, chemokines and growth factors, expressed by 
immune and skin resident cells. 
 
Innate lymphoid cells (ILCs) have also recently been shown to be present in human 
skin, and their important role in inflammatory skin disease is becoming apparent.  ILCs 
are of lymphoid lineage, but do not express antigen specific B cell or T cell receptors 
(BCR or TCR), therefore although some of their cytokine responses are analogous to 25 
 
those produced by helper T cells, ILCs are not adaptive immune cells and respond to 
innate  stimuli.    ILCs  are  categorised  into  three  subsets  based  on  their  transcription 
factor profile and cytokine production.  
 
Group 1 ILCs include natural killer (NK) cells and ILC1 cells.  Both of these cell types 
produce IFN in response to IL-12 and IL-15 (via their expression of CD161) and are 
dependent on the transcription factor T-bet.  ILC1 differ from NK cells in that they do 
not express granzyme B or perforin and therefore are not cytolytic.  ILC1s are present in 
skin  but  infrequent  (Teunissen  et  al,  2014),  and  their  role  has  not  been  well 
characterised.    However,  due  to  expression  of  IFN,  they  have  the  potential  to  be 
involved in skin inflammation and Th1-associated pathologies such as allergic contact 
dermatitis (Kim, 2015).   
 
Group 2 ILCs (ILC2) produce the type 2 cytokines IL-4, IL-5 and IL-13 in response to 
IL-25, IL-33, thymic stromal lymphopoietin (TSLP) and prostaglandin D2 (PGD2) and 
are dependent on the transcription factors ROR and GATA-3.  ILC2 obtained from 
blood  express  skin  homing  markers  CLA,  CCR4  and  CCR10  (Salimi  et  al,  2013).  
ILC2s  are  found  to  be  resident  in  healthy  skin  and  significantly  enriched  in  atopic 
dermatitis lesions (Salimi et al, 2013).  In addition to driving innate responses, ILC2s 
express MHCII and co-stimulatory molecules (CD80, CD86) (Oliphant et al, 2014) and 
are capable of direct interaction with T cells, skewing naïve T cells towards a Th2 
phenotype (Mirchandani et al, 2014).   
 
Group 3 ILCs (ILC3) produce cytokines IL-17 and IL-22 in response to IL-1 and IL-
23 and are dependent on the transcription factor RORt.  Group 3 ILCs include three 
subtypes.  The first type identified were the lymphoid tissue inducers (LTi), which are 
essential for the development of lymphoid organs.  Another subtype have the potential 
to induce cytotoxicity due to expression of the natural cytotoxicity triggering receptor 
(NCR), and hence are termed NCR+ ILC3.  Finally, the NCR- ILC3 population express 
large amounts of MHCII and can process and present antigen, but do not express co-
stimulatory molecules.  Therefore, they are unable to trigger T cell differentiation and 
may instead act as regulators to reduce T cell responses (Salimi and Ogg, 2014).  Recent 
studies have linked ILC3s with psoriasis.  Th17 cells were previously considered to be 26 
 
the  dominant  source  of  IL-17  and  IL-22  driving  inflammation  in  psoriatic  skin.  
However, it is  now thought  that NCR+ ILC3 also  contribute to  production of these 
cytokines, and furthermore NCR+ ILC3 levels were found to be elevated in blood and 
skin  from  psoriasis  patients  compared  to  healthy  controls  (Villanova  et  al,  2014; 
Dyring-Anderson et  al,  2014).  The role of  ILCs  in  inflammatory skin disease will 
become better understood as they are further studied. 
 
1.4 Molecular pattern recognition  
Diverse  immune  responses  to  viral,  fungal,  bacterial  and  parasitic  pathogens  are 
possible  due  to  cellular  expression  of  evolutionarily  conserved  innate  pattern 
recognition receptors (PRRs), which allow cells to sense the environment and signal 
appropriately  to  the  immune  system.    Once  stimulated,  these  receptors  are  able  to 
trigger phagocytosis and/or intracellular signalling cascades. 
 
PRRs that lead to phagocytosis include: Fc receptors, C-type lectin receptors (CLR), 
which recognise carbohydrate patterns, such as dectin-1, and the mannose receptor.  In 
addition to phagocytic PRRs, there are other PRRs that cause activation of intracellular 
signalling cascades, such as: cytoplasmic nod-like receptors (NLRs); RIG-1 (retinoic 
acid-inducible  gene  1)  like  receptors  (RLRs);  and  membrane-associated  toll-like 
receptors (TLRs) (Iwasaki and Medzhitov, 2004).  TLRs broadly recognise molecules 
commonly  expressed  by  pathogens,  termed  pathogen  associated  molecular  patterns 
(PAMPs).  There are 10 distinct membranous TLRs in humans (TLR 1-10), some of 
which reside on endosomal membranes (TLR 3, 7, 8 and 9).   
 
In addition to PAMPs, endogenous danger signals released by stressed, damaged or 
necrotic  cells  (Galluci  and  Matzinger,  2001),  termed  damage  associated  molecular 
patterns (DAMPs), can also trigger cell activation through binding to innate pattern 
recognition receptors (reviewed in Palm and Medzhitov, 2009).  DAMPs include: heat 
shock proteins (Hsp), uric acid, high-mobility group protein box 1 (HMGB1), adenosine 
triphosphate  (ATP),  S100  proteins,  cathelicidins,  defensins  (Kono  and  Rock  2008), 
nucleotides,  reactive  oxygen  species  (ROS),  neuromediators  and  ECM  breakdown 
products  (such  as  hyaluronic  acid,  heparan  sulphate  and  fibrinogen)  (reviewed  in 
Gallucci and Matzinger 2001).   27 
 
 
In addition to recognising PAMPs, TLRs are also thought to be able to sense DAMPs.  
TLR 2 and/or TLR 4 can sense endogenous molecules produced through tissue damage, 
such as fibronectin (Okamura et al, 2001), Hsp60 (Ohashi et al 2000), Hsp70 (Asea et 
al, 2002), HspGp96 (Vabulas et al, 2002), Hsp22 (B8), A crystallin (Roelofs et al, 
2006),  fibrinogen  (Smiley  et  al,  2001),  surfactant  protein  A  (Guillot  et  al,  2002), 
heparan sulphate (Johnson et al, 2002), -defensin (Biragyn et al, 2002; Funderburg et 
al, 2007), HMGB1 (Park et al, 2004; Yu et al 2006), hyaluronic acid (Termeer et al, 
2002) and uric acid (Liu-Bryan et al, 2005).  Nucleic acids are also endogenous ligands 
for TLR 7 and 9 (Barrat et al, 2005).  The identification of endogenous ligands for 
TLRs, in particular the heat shock proteins, remains controversial due to the potential 
for microbial contamination, which has not been well characterised in a number of these 
studies (Bausinger et al, 2002). 
 
NLRs are also known to detect both PAMPs and DAMPs.  There are many different 
subtypes  of  NLRs,  including  nucleotide-binding  oligomerization  domain-containing 
protein  1  (NOD1)  and  NOD2.    Many  NLRs  are  directly  involved  in  mediating 
inflammation,  and  hence  the  complexes  they  form  are  termed  inflammasomes 
(Martinon et al, 2009).  The NACHT, LRR and PYD domains-containing protein 3 
(NALP3)  inflammasome  has  a  direct  role  in  mediating  adaptive  immune  responses 
(Watanabe et al, 2006).  It is activated by adjuvant signals (such as alum) (Li et al, 
2008; Franchi and Nunez, 2008; Eisenbarth et al, 2008) and can also be activated by 
DAMPs such as ATP or uric acid (Mariathasan et al 2006; Giamarellos-Bourboulis et al 
2009; Martinon et al, 2006), or ROS generated by mitochondria from damaged cells 
(Iyer  et  al,  2009,  Zhou  et  al  2011).    Recent  literature  suggests  that  the  apoptosis-
associated  speck-like  protein  containing  a  CARD  (ASC)  component  of  the  NALP3 
inflammasome can be released from macrophages as a danger signal to amplify the 
inflammatory  response  (Baroja-Mazo  et  al,  2014)  and  may  function  extracellularly 
(Franklin et al, 2014). 
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Intracellular signalling in response to PRR activation  
Stimulation of most of these receptors results in activation of the transcription factor 
nuclear  factor  kappa-light-chain-enhancer  of  activated  B  cells  (NF-B)  (Kawai  and 
Akira,  2007),  which  up-regulates  production  of  pro-inflammatory  cytokines  and 
chemokines.  For example, following TLR activation, signalling is initiated through a 
family  of  five  adaptor  proteins:  myeloid  differentiation  primary  response  gene  88 
(MyD88),  TIR-domain-contatining  adapter-inducing  interferon-beta  (TRIF),  TRIF-
related adaptor molecule (TRAM), Selective androgen receptor modulator (SARM) and 
Toll-Interleukin-1 receptor domain-containing adaptor protein (TIRAP) (also known as 
MyD88 adaptor-like or Mal).  All of these adaptor proteins contain a Toll-interleukin-1 
receptor (TIR) domain (reviewed in O’Neill and Bowie, 2007), which can interact with 
the cytosolic face of the TLR.  All of the TLRs (except for TLR3, which uses TRIF) 
signal via MyD88, and activate downstream protein kinase cascades that culminate in 
the activation of the transcription factors NF-B, activator protein-1 (AP1) and cAMP 
response element-binding 1 (CREB) (via MAPK), leading to the transcription of pro-
inflammatory cytokines.  The transcription factors of the interferon regulatory factor 
(IRF)  family  (IRF3  and  IRF7)  are  also  activated  leading  to  transcription  of  type  1 
interferons, such as IFN and IFN (reviewed in O’Neill and Bowie, 2007). 
 
Activation of dendritic cells by DAMPs and PAMPs 
DC maturation can be achieved via recognition of DAMPs from the microenvironment 
at the site of infection, as well as PAMP recognition.  This concept, that the immune 
system is activated by substances that cause tissue damage (or cellular stress), rather 
than  to  those  which  are  simply  foreign,  was  independently  proposed  by  Matzinger 
(1994) and Ibrahim et al (1995).  It allows an explanation for scenarios that do not fit 
the self vs. non-self hypothesis, such as the ability of tumorigenic protein to evade the 
immune system and the requirement of adjuvant for immunisation with purified protein 
antigen.    It  is  hypothesised  that  LCs  and  DCs  act  as  sentinels  that  receive  both 
immunogenic protein and danger signals and convey the information to the adaptive 
immune system.   Dendritic cells  mature in  response to  PAMPs or DAMPs  through 
binding to innate PRRs (reviewed in Palm and Medzhitov, 2009).  The resultant DC 29 
 
maturation  state  depends  on  the  type,  combination,  duration  and  timing  of  stimuli 
received (reviewed in Macagno et al, 2007). 
 
The response of the DC to dangerous environments differs depending on the mode of 
cell death by bystander cells.  In the presence of apoptosis, DC engulf apoptotic cells 
and induce tolerance due to a lack of full maturation (Steinman et al, 2000, Lutz and 
Schuler, 2002).  In response to necrotic cells, but not apoptotic cells, DC are triggered to 
fully mature (Galllucci et al 1999, Sauter et al, 2000).  However, in situations where 
bystander apoptosis is prolonged or at high level, end stage/secondary necrosis occurs 
and full DC maturation is also triggered (Rovere et al, 1998; Ip and Lau, 2004).  In this 
situation, DCs are able to present both apoptotic cells debris (via MHCI and MHCII) 
(Rovere et al, 1998) and co-stimulatory molecules to T-cells to initiate immunity.   
DAMPs  that  have  been  shown  to  directly  stimulate  expression  of  co-stimulatory 
molecules  on  DCs  include;  IL-1  (Matjeka  et  al,  2012),  Hsps  (Basu  et  al,  2000), 
HMGB1 (Messmer et al, 2004) and ATP (Schnurr et al, 2000). 
 
1.5 Inflammation    
Cutaneous  trauma  following  exposure  to  ultraviolet  (UV)  radiation,  toxic/corrosive/ 
irritant  chemicals,  foreign  organisms  and/or  mechanical  wounding  all  provoke  a 
reaction from the innate immune system to clear infection and repair damaged tissue.  
The resultant cutaneous inflammation is largely co-ordinated by inflammatory cytokine 
cascades and lipid mediators released within the epidermis, arising from many different 
cell types.   The kinin and arachidonic acid  systems  become activated and trigger a 
cascade of proteins and lipids that produce pro-inflammatory mediators.  Arachidonic 
acid released from membrane phospholipid can be metabolised via a series of enzymes 
(Leslie  et  al,  1987)  to  produce  prostaglandins,  prostacylins,  thromboxanes  and 
leukotrienes.  These lipid mediators are pro-inflammatory (Goldyne et al, 1975) and 
cause direct effects on the hypothalamus (affecting body temperature via prostaglandin 
E1 (PGE1) and PGE2) (Nistico et al, 1979) and on local pain receptors (PGE2) (Ferreira 
et al, 1979).  Lipid mediators also affect local blood vessels, causing vasoconstriction 
and vasodilation (thromboxane, TxA2; and PGE2) (Feigen et al, 1981) and alteration in 
endothelial permeability (leukotriene LTB4) (Dahlen et al, 1981), allowing recruitment 
of innate cell types (Janeway, 2004).  These processes correspond to the characteristic 30 
 
clinical  signs  of inflammation:  heat,  pain,  redness  and oedema.  The initial  cellular 
infiltrate  recruited  during  inflammation  is  largely  made  up  of  neutrophils  and 
monocytes (which differentiate into macrophages).  In addition to removing cellular 
debris,  both  neutrophils  and  macrophages  are  able  and  recognise  and  phagocytose 
common pathogens and destroy them by acidification, lysosomal activity (antimicrobial 
enzymes, proteins and peptides) or production of respiratory burst (consisting of nitric 
oxide (NO), superoxide (O2-) and hydrogen peroxide (H2O2) (Babior et al, 1984). 
 
 
Pro-inflammatory cytokines  
The pro-inflammatory cytokines that control inflammation are: interleukin-1 alpha (IL-
1, IL-1, IL-18, IL-6, IL-8 and tumour necrosis factor-alpha (TNF-.  IL-1 IL-
1IL-18 and TNF are termed primary cytokines (Williams and Kupper, 1996) as they 
are  capable  of  inducing  processes  that  directly  result  in  rapid,  local  inflammation.  
Primary  cytokines  (IL-1  and  TNF-  are  able  to  induce  the  release  of  secondary 
mediators (such as IL-6 and IL-8) in an autocrine or a paracrine manner from other cell 
types to amplify and assist the inflammatory response (Larsen et al, 1989).  In order to 
regulate this process, there exist anti-inflammatory counterparts to these, namely IL-10 
and interleukin-1 receptor antagonist (IL-1ra).   
 
1.6 Proinflammatory cytokines & chemokines produced by keratinocytes 
Human keratinocytes have been shown to express these key pro- and anti-inflammatory 
cytokines,  along  with  many  others  cytokines,  chemokines  and  growth  factors  that 
contribute to the inflammatory response (summarised in Table 1-1).   
 
IL-1 family (IL-1, IL-1, IL-18, IL-33) 
Human keratinocytes are capable of producing IL-1, IL-1and structurally related IL-
18 and IL-33, which are all synthesised as pro-cytokines lacking a signal sequence.  The 
predominant  IL-1 species  produced by keratinocytes  is  IL-1 (Kupper et  al,  1986), 
which is active in its precursor form (Mosley et al, 1987) and is pre-stored in epidermis 
(Hauser et al, 1986).  Upon cellular damage, IL1- is instantly (within 10 minutes) 31 
 
released from pre-made intracellular stores in murine epidermis (Wood et al, 1996).  
Keratinocyte IL1- release has been shown to occur following exposure to mitogens, 
UV, LPS, irritants and allergens both in vitro and in vivo (Luger and Schwarz, 1990; 
Coquette et al, 2003; Van Och et al, 2005).  IL-1 and IL-18 are produced in an inactive 
form (Mizutani et al, 1991; Companjen et al, 2000) and must be cleaved into a fully 
bioactive form by caspase-1 (Thornberry et al,  1992, Ghayur et  al, 1997; Gu et al, 
1997),  which  is  itself  regulated  by  the  inflammasome  (Martinon  et  al,  2002).    In 
contrast, IL-1 and IL-33 are cleaved by calcium-activated calpain to produce mature 
forms (Kobayashi et al, 1990; Meephanson et al, 2012).   
 
IL-1 andIL-1 compete to signal through the IL-1 receptor (IL-1R) on target cells.  
This  receptor  contains  a  cytoplasmic  Toll/IL1R  (TIR)  domain  and  shares  some 
homology  with  MyD88  TLR  signalling  domains  (Medzhitov  et  al,  1998).    IL-1 
signalling triggers production of numerous pro-inflammatory cytokines, for example IL-
6 (Kupper et al, 1989) and IL-8 (Larsen et al, 1989; Andrew et al, 1999).  It is also able 
to cause systemic effects, such as fever or stimulation of the acute phase response, as 
well  as  augmented  lymphocyte  responses  (Dinarello,  1996),  maturation  of  antigen 
presenting cells (Ozawa et al, 1996) and up-regulation of adhesion molecules (Groves et 
al, 1992).  In addition to extracellular function, IL-1 has nuclear function, causing 
activation of pro-inflammatory genes, potentially via NF-B and AP-1 (Werman et al, 
2004).  IL-33 also has dual functionality in the nucleus as a suppressor of transcription 
(Carriere et al, 2007) and as an extracellular ligand for IL-1RL1 (Schmitz et al, 2005).  
IL-33 signalling induces pro-inflammatory and Th2 cytokines (Schmitz et al, 2005) and 
CD8+ responses (Bonilla et al, 2012).  IL-18, in combination with IL-12, stimulates T 
cells and NK cells to produce IFN (Okamura et al, 1995), drives the development of 
type 1 CD8+ effector T cells (Okamoto et al, 1999) and triggers DC maturation (Li et al, 
2004). 
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IL-1  Luger et al, 1981; Ansel et al, 1983; Kupper et al, 1986; Phillips 
et al, 1995 
IL-1  Kupper et al, 1986; Zepter et al, 1997 
IL-1RA  Haskill et al, 1991; Phillips et al, 1995; Bigler et al, 1992 
IL-6  Kupper et al, 1989; Khan et al, 1993; Ishimaru et al, 2013 
IL-7  Heufler et al, 1993; Ariizumi et al, 1995  
IL-8 (CXCL8)  Larsen et al, 1989; Li et al, 1996; Barker et al, 1990; Andrew et 
al, 1999 
IL-10  Rivas and Ullrich, 1992 
IL-12  Aragane et al, 1994; Yawalkar et al, 1996  
IL-15  Blauvelt et al, 1996 
IL-18  Stoll et al, 1997; Naik et al, 1999 
IL-23  Larsen, 2009 
IL-33  Meephansan et al, 2012; Taniguchi et al, 2013 
IFN  Fujisawa et al, 1997 
TNF-  Kock et al, 1990 
MCP-1 (CCL2)  Barker et al, 1990, 1991 
RANTES (CCL5)  Li et al, 1996 
TGF  Coffey et al, 1987 
TGF  Bascom et al, 1989 
GM-CSF   Kupper et al, 1988; Pastore et al, 1997   
VEGF  Trompezinski et al, 2004 
 
 
 
 
Table 1-1 Cytokines and chemokines produced by keratinocytes 
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TNF- 
In addition to the IL-1 family of cytokines, TNF- is a primary cytokine that is able to 
activate effector mechanisms to trigger cutaneous inflammation (Barker, 1991).  TNF- 
has  been  shown  to  be  released  from  both  primary  keratinocytes  and  epidermoid 
carcinoma cells in response to LPS, UV light (Kock et al, 1990; Trefzer et al, 1993) and 
contact sensitisers (Piguet et al, 1991).  TNF- is pro-inflammatory and modulates pro-
inflammatory cytokines such as IL-1, IL-6 and IL-8 (Larsen et al, 1989; Partridge et al, 
1991), and cutaneous adhesion molecule expression including ICAM-1 (Groves et al, 
1995; Trefzer et al, 1991).  TNF- also induces apoptosis (reviewed in Smith et al, 
2003). 
 
IL-6 
IL-6  is  not  produced  in  abundance  in  either  normal  epidermis  or  un-induced 
keratinocytes  in  vitro,  but  is  significantly  increased  in  keratinocytes  in  response  to 
primary cytokines such as IL-1 and TNF, mitogens, LPS and UVB radiation (Kupper 
et al, 1989; Luger and Schwarz, 1990).  An increase in IL-6 production is induced in 
dermal fibroblasts in response to keratinocyte derived IL-1 (Boxman et al, 1996).  IL-6 
is  involved  in  local  lymphocyte  activation,  and  has  systemic  effects  on  both  the 
hypothalamus  (Mastorakos  et  al,  1993) as  an endogenous  pyrogen to  increase body 
temperature (Helle et al, 1988), and on the liver to induce acute phase response (Gauldie 
et al, 1990; reviewed in Heinrich et al, 1990).  IL-6 signals through the IL-6R and 
gp130 signalling receptor subunits to trigger JAK/STAT and MAPK cascades (Heinrich 
et al, 2003).  IL-6 has been shown to enhance B cell growth and differentiation (Van 
Damme et al, 1987) and more recently to promote differentiation of Th17 cells and alter 
the Th17/Treg balance (Goodman et al, 2009).  
 
IL-8 
IL-8  (CXCL8)  is  a  secondary  mediator  essential  for  acute  inflammation.    Primary 
human  keratinocytes  have  low  background  levels  of  IL-8,  both  at  the  protein  and 
transcript level, but its release is stimulated in response to primary cytokines such as IL-
1, TNF- and IFN- (Baggiolini et al, 1989; Li et al, 1996).  IL-8 is a potent activator 34 
 
and chemokine for neutrophils (Harada et al, 1994).  Its production is responsible for 
targeting immune cell traffic out of the bloodstream into the epidermis (Esche et al, 
2005) and it also activates respiratory burst (by superoxide generation) in neutrophils to 
aid pathogen destruction (Peveri et al, 1988). 
 
Anti-inflammatory cytokines 
Anti-inflammatory cytokines have immunosuppressive properties in that they inhibit the 
function of, or antagonise pro-inflammatory cytokines.  IL-10, for example, inhibits T 
cell  proliferation  and  suppresses  the  synthesis  of  IL-2,  IL-3,  GM-CSF  and  TNF- 
(Feliciani, 1996).  IL-1 receptor antagonist (IL-1ra) antagonises the effect of IL-1 by 
competing with the active forms of IL-1 and IL-1 for binding to the IL-1 membrane 
receptor 1 (IL-1R1).  In normal skin, this binding occurs at a ratio of approximately 
100:1 (IL-1ra:IL-1, Arend, 1990), although the relative levels of IL-1ra, IL-1 and IL-
1 are different in differentiated vs. non-differentiated keratinocytes (Gruaz-Chatellard 
et al, 1991).  Production of the antagonist (IL-1ra) must be significantly greater than 
that of the pro-inflammatory mediator IL-1 to competitively inhibit IL-1 activity and 
reduce inflammation (Kong et al, 2006). 
 
1.7 Inflammatory signalling cascades  
The transcription of many pro-inflammatory cytokines is controlled by the NF-B and 
MAPK signalling cascades.  IL-1, IL-6, IL-8 and have promoter binding sites for NF-
B (Kunsch and Rosen, 1993; Libermann and Baltimore, 1990; Hiscott et al, 1993) and 
transcription factors downstream of MAPK, such as c-Jun and Fos /AP-1 (Faggioli et al, 
2004; Cucinotta et al, 2008; Roman et al, 2000).   Both signalling cascades are triggered 
by receptor tyrosine kinases.   
 
NF-B 
There are 5 proteins in the NF-B family of transcription factors that share N-terminal 
Rel  homology  domains  (RHD)  these  are;  RelA  (p65),  RelB,  c-Rel,  NF-B1  (p105 
cleaved to p50) and NF-B2 (p100 cleaved to p52).  Rel A, Rel B and c-Rel have 35 
 
transactivation domains that drive transcription.   The 5 proteins form homo- or hetero-
dimers, for example one of the most common is RelA/p50.  Two main pathways for NF-
B  activation  exist;  the  classical  (canonical)  and  the  alternative  (non-canonical) 
pathway (Figure 1-2).  Cytokines (e.g via IL-1R, TNFR), PAMPs (e.g. via TLRs) and 
cellular stress (UV or ROS) trigger the classical pathway, in which receptor activated 
IKK  (complex  of  IKK  and  IKKand  NEMO)  phosphorylates  IB  allowing 
ubiquitination and targeting it for proteasomal degradation.  As IB inhibits NF-B 
(RelA/p50) function by sequestering it in the cytosol, its degradation allows NF-B 
(RelA/p50)  to  translocate  to  the  nucleus  and  initiate  transcription.    The  alternative 
pathway is triggered by BAFF (B-cell activating factor) or lymphotoxin  receptors, 
leading  to  IKK  phosphorylation,  which  in  turn  phosphorylates  p100  dimerised  to 
RelB, this enables cleavage of p100 to p52 and subsequent nuclear translocation of 
RelB/p52 which binds to NF-B promoter sites.   
 
In general, NF-B signalling is involved in maintaining the balance of keratinocyte cell 
proliferation,  differentiation  and  death  required  for  epidermal  homeostasis.  
Keratinocytes  in  the  basal  layer  have  been  shown  to  express  NF-B  (p50)  in  the 
cytoplasm, whereas suprabasal keratinocytes demonstrate only nuclear expression (Seitz 
et  al,  1998).  NF-B has  been shown to  prevent  premature apoptosis  in  suprabasal 
epidermal keratinocytes committed to terminal differentiation (Qin et al, 1999; Seitz et 
al,  2000).    Mutations  in  NEMO  (IKK  cause  the  genetic  disorder  incontinentia 
pigmenti,  with  symptoms  including  skin  lesions  and  abnormal  pigmentation.    Also, 
epidermis-specific deletion of IKK leads to the development of severe inflammatory 
skin disease (Pasparakis et al, 2002), suggesting NF-B is required for normal immune 
homeostasis in skin.    
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Figure 1-2 NF-B signalling cascades (classical and alternative pathways) 
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Mitogen activated protein kinase (MAPK) 
The  MAPK  signalling  cascades  are  evolutionarily  conserved  pathways  that  regulate 
inflammation,  cell  survival,  proliferation  and  differentiation,  allowing  extracellular 
signals (e.g. from EGFR or PRR) to be transduced to target gene transcription.  There 
are 14 known MAPKs in mammalian cells: ERK1-2; JNK1-3; p38MAPK, ,  and ; 
ERK3-5,  7  and  NLK.    MAPK  signalling  is  predominantly  stimulated  by  mitogens, 
growth factors, stress or inflammatory stimuli.  All of the MAPK pathways feature a 3-
tier kinase cascade (Figure 1-3), beginning with a serine/threonine MAPKKK that can 
phosphorylate a serine/threonine/tyrosine MAPKK, which in turn phosphorylates the 
target  threonine/tyrosine  MAPK  (e.g.  ERK,  JNK,  p38MAPK).    The  action  of  the 
kinases  is  counteracted  by  dual  specificity  phosphatases  (DUSP),  also  called  MAP 
kinase  phosphatases  (MKP),  which  help  regulate  MAPK  signalling  via  complex 
feedback  loops.    ERK1  and  2  are  p44  and  p42  proteins,  respectively,  and  are 
phosphorylated by MEK1/2 (MAPKK), which are activated by Raf (MAPKKK).  For 
JNK  (p46  and  p54)  and  p38MAPK,  the  MAPKK  are  MKK4/7  and  MKK3/6 
respectively.    Downstream  of  ERK,  JNK  and  p38MAPK  are  common  transcription 
factors ELK1, c-Fos, c-Jun, ATF2, AP-1, STAT1, MEF2, c-Myc, CREB and C/EBP. 
Specifically in epidermis, ERK has a role in keratinocyte proliferation and survival, 
while  p38MAPK  affects  differentiation  and  apoptosis  (Efimova  et  al,  1998).    The 
MAPKKK ASK1, upstream  of p38MAPK,  has also  been shown to  be important  in 
keratinocyte differentiation (Sayama et al, 2001). 
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Figure 1-3  MAPK signalling cascades  
MAPK pathways have three tiers of sequential kinases and activate a wide range of 
target transcription factors to produce diverse functional effects. 
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1.8 Skin diseases  
Dermatitis (inflammatory) skin diseases include atopic, allergic, irritant and seborrhoeic 
dermatitis.  Contact dermatitis is the clinical term given to an inflammatory reaction in 
the skin resulting from direct contact with exogenous chemicals.  There are two forms 
of contact dermatitis; irritant contact dermatitis (ICD) and allergic contact dermatitis 
(ACD).    Both  of  these  conditions  present  in  the  clinic  as  epidermal  erythema  and 
oedema, which may progress to development of vesicles or blisters.  The clinical signs 
of  ICD  are  difficult  to  distinguish  from  ACD  as  very  little  difference  exists  in  the 
responding cell types and sequence of cellular events during elicitation (Brasch et al, 
1992).    ACD  reactions  are,  however,  predominantly  eczematous  whereas  ICD 
pathologies  vary  between  chemicals,  concentration,  type  and  duration  of  exposure 
(Burns et al, 2004).  Under histological examination, these pathologies are characterised 
by spongiosis, intracellular vacuolation and nuclear pyknosis of keratinocytes (Brasch et 
al, 1992; Willis et al, 1986).  This is followed by infiltration of macrophages and T-
lymphocytes (CD4+ and CD8+) and CD1a+ cells (Carr et al, 1984; Lipkow et al, 1991; 
Scheynius  et  al,  1984;  Willis  et  al,  1993).    Both  acute  and  chronic  exposure  to 
surfactants such as sodium dodecyl sulphate (SDS) and other chemical irritants, such as 
lactic acid and benzalkonium chloride, can result in ICD (Basketter et al, 2004).  ACD 
develops following contact exposure to metal allergens, such as nickel (Cavelier et al, 
1985),  and  chemical  allergens,  such  as  1-chloro-2,  4-dinitrobenzene  (DNCB) 
(Friedmann et al, 1983) and p-phenylenediamine (PPD) (McFadden et al, 1998).  ACD 
is one of the most prevalent occupational skin diseases (Cherry et al, 2000). 
 
Clinically, ICD and ACD are very similar, however, they do differ in the kinetics of 
their response.  ACD is a delayed reaction that occurs 24-72 hours post initial exposure.  
This delayed response can be explained by the differing cellular mechanisms controlling 
these two immunological responses.   
 
ICD is the result of a local inflammatory reaction, caused by direct damage to epidermal 
cells  and  release  of  pro-inflammatory  mediators,  which  involves  cells  of  the  innate 
immune system.  Whereas for ACD, in addition to elements of inflammation, the final 
elicitation is the result of a delayed (type IV) contact hypersensitivity (CHS) reaction 
which causes an adaptation of immunological memory. 40 
 
1.9 Allergic contact dermatitis (ACD)  
ACD is an adaptive immune response that involves not only cells required for innate 
responses and inflammation but also cells involved in adaptive immune processes.  The 
mechanism driving ACD involves two distinct phases; the asymptomatic sensitisation 
phase, where the immune system first encounters the antigen, and the elicitation phase 
which generates the ACD clinical response (Figure 1-4).  
 
Sensitisation phase 
Sensitisation is the process by which exposure to non-self antigen (e.g. from invading 
pathogen)  results  in  an  ‘immunological  memory’  of  the  encounter.    Following 
epidermal  penetration,  chemical  allergens  (sensitisers)  cannot  directly  stimulate  an 
immunogenic  response.    The  most  well-studied  hypothesis  for  CHS  responses  to 
chemical allergen is the hapten hypothesis, in which a chemical must first covalently 
modify self protein to produce an immunogenic entity (a process termed haptenation) 
(Landsteiner and Jacobs, 1936; Eisen et al, 1952).  Chemical allergens tend to be highly 
reactive electrophiles, and protein haptenation is hypothesised to be achieved through 
nucleophilic substitution mechanisms (Aleksic et al, 2007).  It is not yet clear which 
proteins  in  the  epidermis  are  specifically  targeted  for  haptenation.    Following 
modification,  the  resultant  immunogenic  protein  is  engulfed  by  resident  immature 
antigen presenting cells (APCs), such as epidermal Langerhans cells (LCs) or dermal 
dendritic cells (DCs), due to their capacity for endocytosis (Levine and Chain, 1992).  
Both DCs and LCs are able to phagocytose particulates (Reis e Sousa et al, 1993; Inaba 
et al, 1993) and capture antigen by macropinocytosis or via endocytic receptors (e.g. 
mannose receptor) (Sallusto et al 1995).  It is not known which of these mechanisms is 
responsible for the association of chemical allergen (such as DNCB) with APCs (Carr et 
al, 1984).  In addition to the hapten hypothesis, there are alternative hypotheses from the 
delayed-drug hypersensitivity field, which could be relevant  to  ACD and should be 
investigated  further.    The  pharmacological  interaction  with  immune  receptors 
hypothesis  (p-i  hypothesis) proposes  that reversible, high affinity  binding of  a drug 
directly to MHC and/or the TCR can trigger T cell proliferation and cytokine release 
(e.g sulfamethoxazole, carbamazepine) (Adam et al, 2011; Pichler, 2008).  The altered-
self repertoire hypothesis suggests that drug binding to empty MHC allows peptides that 41 
 
normally have low affinity for MHC to bind and be presented to T cells (e.g abacavir) 
(Illing et al, 2012; Ostrov et al, 2012).    
 
DC subsets involved in CHS 
There are three main skin resident DC subtypes in the skin: epidermal (basal and supra-
basal) LCs which express CD1a++, langerin+ (CD207), CD36- and CD103-, dermal DCs 
(dDC), which are CD1a+, langerin- and CD36+ (Lenz et al, 1993) and langerin+ dermal 
DC  that  are  CD103+  (Bursch  et  al,  2007).  Most  types  of  DC  are  derived  from 
haematopoietic precursors in blood, whereas LCs have a distinct origin.  LCs are seeded 
from precursors during mid-embryogenesis (Ginhoux and Merad, 2010; Schuster et al, 
2014), following which TGF1 and M-CSFR ligands are key for their development in 
the epidermis (Ginhoux and Merad, 2010; Schuster et al, 2009).  LCs are therefore able 
to  self-renew  from  resident  haematopoietic  precursors  in  skin  (Merad  et  al,  2002).  
However, in situations where there is substantial tissue inflammation, LCs can also be 
repopulated from monocyte precursors (Merad et al, 2002).  In adult skin, LCs express 
CD45, HLA-DR, CD1a and Langerin, which forms their characteristic Birbeck granules 
(Schuster et al, 2009).  There is some evidence to suggest that LCs might promote 
tolerance by activation of regulatory T cells and limited capacity to present bacterial 
antigen (van der Aar et al, 2013; Kautz-Neu et al, 2011), in contrast dermal DCs can 
induce a strong effector response (Shklovskaya et al, 2011).  However, a recent study 
has shown that LCs may be capable of activating effector cells during infection, whilst 
also maintaining tolerance by activating Treg cells during homeostasis (Seneschal et al, 
2012).  It is not clear whether LCs or dermal DCs are responsible for driving CHS 
reactions, as the literature surrounding the relative roles for LC, dDC and langerin+ dDC 
in the initiation of CHS remains contradictory.  LC deficient mice have been shown to 
develop enhanced (Kaplan et al, 2005) or normal (Streilein, 1989) CHS reactions, and 
dDC  have  been  shown  to  play  a  dominant  role  (Funkunaga  et  al,  2008).    The 
antigen/hapten concentration is a critical factor in determining which subset is activated 
in vivo (Bacci et al, 1997). 
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Figure 1-4  Sensitisation and elicitation phases of ACD.  
During the sensitisation phase, chemical allergen (red circles) penetrates the skin and 
haptenates epidermal proteins.  Langerhans cells (purple) and dermal dendritic cells 
(yellow) are triggered to migrate to the local draining lymph node, where they present 
antigen to T cells (blue, green).  Antigen-specific T cells undergo proliferation and 
differentiation to generate a memory T cell population.  T cells enter the circulation and 
distribute to tissues, including skin.  Following sensitisation, re-exposure to a low 
amount of chemical allergen triggers elicitation involving cutaneous antigen presenting 
cells and memory T cells.  
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DC migration 
In  order  to  initiate  naïve  T-cell  proliferation  and  differentiation,  skin-resident 
Langerhans cells (LC) and dendritic cells (DC) migrate out of the epidermis and dermis, 
and  travel  through  the  afferent  lymphatic  system  (Silberberg  et  al,  1976;  Frey  and 
Wenk, 1956) to the paracortex of the local draining lymph node.  The migration of 
antigen  presenting  cells  from  the  skin  occurs  in  response  to  chemical  sensitisers 
(Silberberg et al, 1976) and irritants (Willis et al, 1990; Brand et al, 1993; Jacobs et al, 
2006),  as  well  as  pathogens,  mechanical  stress  and  UV  exposure.    The  process  of 
migration is controlled by a number of molecular factors.  It is initiated primarily by 
inflammatory cytokines: TNF-; IL-1 and IL-18 (Cumberbatch and Kimber, 1992; 
Cumberbatch  et  al, 1995, 1997, 2001;  Shornick et  al,  2001), and the  danger signal 
HMGB1 (Dumitriu et al, 2007), and can be inhibited by IL-10 (Wang et al, 1999) and 
IL-4  (Takayama  et  al,  1999).    The  combined  effect  of  these  signals  causes  down-
regulation of E-cadherin (Jakob and Udey, 1998), and hence dissociation of LC from 
neighbouring keratinocytes (however the cells do not move) (Jakob and Udey, 1998). A 
down-regulation in E-cadherin has been seen in skin in response to contact allergen 
(Schwarzenberger  and  Udey,  1996).    Following  detachment,  migration  out  of  the 
epidermis  is  driven  by  a  CXCL12  chemokine  gradient  originating  from  dermal 
fibroblasts (in response to CXCR4 on LC) (Ouwehand et al, 2008).  For epidermal LC 
to move along this CXCL12 gradient into the dermis, they must cross the basement 
membrane (BM).  In order to do this they express 6-integrin, which allows interaction 
with  laminin  in  the  BM  (Price  et  al,  1997);  and  produce  matrix-metalloproteinases 
(MMP2 and MMP9) to facilitate movement through the BM by enzymatic degradation 
(Ratzinger et al, 2002; Saalbach et al, 2010). 
 
Once in the dermis, LC and dDC follow the same route to the lymph node.  Movement 
though  the  dermis  is  facilitated  by  up-regulation  (in  response  to  TNF-)  of  CD44, 
which binds hyaluronic acid in the ECM (Haegel-kronenberger et al, 1998).  Integrins 
CD54 (ICAM-1) and 2-integrin (in response to CCL21) (Johnson and Jackson, 2010) 
are also upregulated allowing LC and dDC to cross the endothelium of the afferent 
lymphatic  vessel.    The  chemokine  receptor  CCR7  is  up-regulated  upon  LC/DC 
maturation (Saeki et al, 1999; Forster et al, 1999), allowing movement (Ohl et al, 2004) 
towards  CCL19  (produced  in  stromal  cells  in  the  paracortex),  and  towards  CCL21 44 
 
(Saeki et al, 1999; Gunn et al, 1999; Haessler et al, 2011), which originates from lymph 
node HEV and fibroblastic reticular cells, and lymphatic vessels (Gunn et al, 1998).  
The production of CCL21 is increased by oncostatin M (IL-6 family cytokine) (Sugaya 
et  al,  2006)  and  TNF-  (Martin-Fontecha  et  al,  2003),  which  may  represent 
systemically acting inflammatory initiators of DC migration. 
 
In humans, chemical allergens stimulate LC migration out of the epidermis with a mean 
epidermal  reduction  of  LC  of  ~18%  (DNCB)  and  29.4%  (diphencyprone),  when 
assessed 17-18 hours following exposure (Pickard et al, 2009; Griffiths et al, 2001).  In 
these studies, migration was not observed at 4 hours post exposure, indicating that the 
time-course of this response is between 4 and 18 hours.  Whilst total LC migration is 
consistently 20-30% following trauma (Griffiths et al, 2005), the kinetics of migration 
vary upon stimulus, for example in response to intradermal injection of tumour necrosis 
factor alpha (TNF-) there is a mean epidermal LC reduction of 24.2% in just 2 hours 
(in mice this response occurs in 30 min with concurrent arrival in the lymph node within 
2 hours) (Cumberbatch 1999).  In mice, the arrival of hapten-loaded DC in the LN 
peaks  2  days  after  exposure  and  LN  proliferation  peaks  4  days  after  exposure 
(Macatonia et al, 1987).  Murine dDC have been observed to arrive in the LN first, and 
colonise  distinct  areas,  compared  to  the  slower  migrating  LC  (Kissenpfennig  et  al, 
2005), however, this has not yet been shown in humans.   
DC maturation 
As immature LCs/DCs migrate, they differentiate into mature antigen presenting cells 
(Schuler and Steinman, 1985; Larsen et al, 1990; Aiba and Katz, 1990).  The maturation 
status of the DC is critical to driving a proliferative T cell response.  
 
DC  maturation  is  recognised  by  a  loss  of  expression  of  molecules  and  receptors 
involved in antigen capture, and an up-regulation of molecules and receptors involved 
in antigen presentation (MHC) (Aiba and Katz, 1990) and co-stimulation (CD40, CD80 
and CD86) (reviewed in Cella et al, 1997; Merad et al, 2008).  Chemokine receptor 
expression  is  also  altered,  with  up-regulation  of  CCR7  and  a  concurrent  down-
regulation  of  CCR5,  CCR1  and  CCR6.    To  enable  migration  from  neighbouring 
keratinocytes, e-cadherin is also down-regulated and ICAM-1 up-regulated.  CD83 and 
DC-SIGN are also often used as markers of mature DCs.  IL-1, IL-18 and GM-CSF 45 
 
have been shown to promote DC maturation (Witmer-Pack et al, 1987; Heufler et al, 
1988; Ozawa et al, 1996; Li et al, 2004).  Although it is not clear by which mechanism, 
chemical haptens have been shown to cause up-regulation of these markers in human 
PBMC-DC in vitro (Aiba et al. 1997; Tuschl et al.2000; Arrighi et al. 2001; Aiba et al. 
2003; De Smedt et al. 2005).   
 
TLR/ NLR activation in DC during CHS 
The involvement of skin-derived DAMPs in CHS is beginning to be investigated.  In the 
absence  of  PAMPs,  in  response  to  chemical  allergens,  it  is  hypothesised  that 
endogenous  DAMPs  provide the necessary  adjuvant  for  activation of  LC and dDC.  
TLR 2 and 4 deficient mice have been shown to have reduced CHS responses (Martin et 
al, 2008).  The activation of TLR 2 and 4 is likely to be through DAMPs, although 
direct activation of TLR4 cannot be ruled out, as is the case for Nickel and Cobalt metal 
allergy  (Raghavan  et  al,  2012;  Schmidt  et  al,  2010).    Further  evidence  for  the 
involvement of DAMPs in CHS includes the finding that P2X7 deficient mice have 
reduced CHS responses (Weber et al, 2010) and the DAMP that signals via P2X7, ATP, 
is released in response to sensitisers (Onami et al, 2014; Weber et al, 2010). Hyaluronic 
acid, which signals via TLR2/4 is also found to be associated with ACD (Esser et al, 
2012; Termeer et al, 2002).  
 
NLRs have also been demonstrated to be involved in CHS.  Inflammasome component 
knock-out mice display impaired CHS responses (Watanabe et al, 2006; Sutterwala et al 
2006), and the degree of danger signalling to the inflammasome can be modulated to 
turn tolerizers into sensitisers and sensitisers into tolerizers (Watanabe et al, 2008).  The 
inflammasome also controls IL-1activation (Thornberry et al, 1992), hence its role in 
CHS  is  beginning  to  be  explored.    IL-1R  and  IL-18R/MyD88  pathways  are  also 
required during the sensitisation phase of CHS, but only appear to be required in certain 
cell types (Klekotka et al, 2010). 
 
To drive a response to chemical-derived antigen, haptenated protein must be processed 
and  loaded  onto  cell  surface  major  histocompatibility  complex  (MHC)  molecules.  
There is, however, no direct evidence of the contribution of MHCI, MHCII or cross-
presentation antigen processing in response to chemical hapten.  In the lymph node, 46 
 
mature  DCs  present  processed  antigen  on  MHC  (Macatonia  et  al,  1987)  to  naive, 
antigen-specific T lymphocytes (T-cells). 
 
DC:T cell synapse and initiation of T cell signalling  
During an immune response, the recognition of a dendritic cell (DC) presenting antigen 
by  a  T  cell  with  a  cognate  T-cell  receptor  (TCR)  results  in  the  formation  of  the 
immunological synapse.  This association between cells can last from minutes to hours, 
however 2-4 hours of contact is required for naïve CD8+ (van Stipdonk et al, 2001) and 
at least 6 hours for naïve CD4+ T cell clonal expansion (Celli et al, 2007).  Contact at 
the immunological synapse consists of a number of specific molecular interactions.  
 
Initially, as T cells move through the lymph node, they transiently interact with DC via 
adhesion  molecules  (CD58  (LFA-3),  ICAM-1  (CD54),  ICAM-2  (CD102)  and  DC-
SIGN (CD209)) associating with their T cell counterparts (CD2, LFA-1 ( integrin 
CD11a:CD18), LFA-1 and ICAM-3 (CD50) respectively).  This brief encounter with a 
DC is enough to stall further migration of the T cell, which provides time to sample the 
complementarity  of  the  TCR  (CD3)  for  the  large  number  of  diverse  peptide  MHC 
(pMHC) on the DC.  Where there is a positive encounter (~1 in 2 x105 T cells; Blattman 
et al, 2002), signalling through the TCR induces a conformational change in the LFA-1 
molecule, increasing its affinity for ICAM-1/2 and stabilising the interaction.  Binding 
of the TCR to pMHC also requires co-receptor association (for MHCI presentation this 
needs CD8 and for MHCII, CD4).  In addition to antigen presentation (signal 1), there 
must be interaction of co-stimulatory molecules on DC (CD80 (B7.1) and CD86 (B7.2)) 
with  CD28 on T cells.   This  co-stimulation (signal 2) is fundamentally  required to 
produce antigen-specific clonal expansion, and without it the T cell becomes anergic.  
In response to activation, the T cell up-regulates CD40L to the synapse, which binds to 
CD40 on DC and triggers further DC co-stimulatory molecule expression to further 
potentiate the signal.  4-1BB (CD137) on T cells and its DC ligand 4-1BBL perform a 
similar role to CD40.  Activated T cells also express ICOS, which interacts with its DC 
ligand LICOS to induce IL-10 production, which inhibits Th1 differentiation (Janeway 
et al, 2004, unless specified).  
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The initial interaction of the TCR with cognate pMHC triggers the formation of TCR 
microclusters;  these  then  rearrange  to  form  defined  concentric  rings  termed 
supramolecular activation clusters (SMAC) (Monks et al, 1998).  The central cluster 
(cSMAC)  contains  the  TCR,  CD4/CD8,  CD28  and  CD2.    Blocking  of  CD28 
interactions  have  been  shown  to  result  in  a  lack  of  defined  cSMAC  (reviewed  in 
Thauland et al, 2010).  The next ring domain of molecules is termed the peripheral 
SMAC  (pSMAC)  which  consists  of  adhesion  molecule  interactions  such  as  LFA-1 
(Monks et al, 1998).   
 
In order to terminate the interaction, activated T cells up-regulate CTLA4 (CD152), 
which binds to CD80 and CD86 on DC with a higher affinity than CD28, and hence 
negatively  blocks  the  signal  (Walunas  et  al,  1994).    Like  CTLA4,  PD-1  is  also  a 
negative regulator of the response and binds PDL-1 and PDL-2 on DC to suppress T-
cell activation (Butte et al, 2007).  Cellular apoptosis can be signalled by the interaction 
of Fas and FasL on both T cells and DCs.  TCRs are also constitutively internalised and 
recycled, but are internalised and targeted for degradation once triggered by pMHC 
(Bachmann  et  al,  1997);  this  serves  as  a  potential  mechanism  to  protect  against 
excessive signalling.  
 
T cell populations involved in ACD 
Both CD4+ Th1 and CD8+ type 1 cytotoxic T cells have been shown to be involved in 
developing CHS to chemical allergens (Wang et al, 2000).  However, the response is 
thought to be predominantly CD8-driven (Kalish et al, 1994, Gocinski and Tigelaar, 
1990; Martin et al, 2000, 2003), which indicates that MHCI might be the dominant 
antigen  processing  pathway  in  DC  in  response  to  contact  allergens.    IL-4/IL-10 
producing CD4+ (Th2) T-cells are also induced in CHS, which are thought to negatively 
regulate the response (Xu et al, 1996).   
 
Activated T-cells increase their expression of cutaneous lymphocyte associated antigen 
(CLA) and CCR10, which interacts with basal keratinocyte-derived CCL27 to direct the 
T-cells back to the skin (Homey et al, 2002).   
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When an antigen specific memory T-cell population is produced, the host is said to be 
sensitised to that particular antigen.  Upon subsequent exposure to the same allergen, 
the host already has antigen-specific memory T-cells available to respond, which allows 
rapid elicitation of ACD. 
 
Elicitation 
Re-exposure to antigen results in recruitment of antigen specific T-cells to the site of 
contact.  These are initially CD8+ T-cells followed by an infiltration of CD4+ T-cells 
(Okazaki et al, 2002).  Th17/Tc17 cells (Zhao et al, 2009) and activated NK T-cells 
(Gober  et  al,  2008) have also  been shown to  be present  during elicitation  of CHS, 
although their roles remain to be fully characterised.  The responding T-cells produce 
cytokines  (such  as  IFN  and  IL-17),  which  drive  production  of  pro-inflammatory 
cytokines,  and  chemokines  (Barker  et  al,  1990;  Albanesi  et  al,  2000)  that  promote 
infiltration of innate immune cells.  This cellular infiltrate, together with cytotoxic T-
cell-induced keratinocyte apoptosis (Trautmann et al, 2000), drive the clinical signs of 
allergic  contact  dermatitis.    It  is  possible  that  naturally  occurring  CD4+CD25+ 
regulatory T-cells (Tregs) are able to  suppress CHS reactions by production of IL-10 
(Ring et al, 2006).  
 
1.10 The role of keratinocytes in immune responses and CHS 
In addition to providing the structural and barrier properties of the skin, keratinocytes 
have been shown to be capable of influencing skin immune responses.  Their role in the 
initiation of innate and adaptive responses (including CHS) is driven by their ability to 
signal to immune cells, and sense and take up antigen.   
 
During  T  cell-mediated  adaptive  immune  responses,  keratinocytes  are  also  able  to 
present  antigen  on  major  histocompatibility  complex  I  (MHCI)  and  on  interferon-
gamma (IFN induced MHC II (Black et al, 2007).  In addition to MHCII, IFN also 
induces  intercellular  adhesion  molecule-1  (ICAM-1)  expression  on  keratinocytes 
(Griffiths  et  al,  1989;  Basham  et  al,  1984),  assisting  interactions  between  basal 
keratinocytes and T cells (Barker et al, 1989). 
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Keratinocytes express phagocytic PRRs that lead to endocytosis of pathogen or protein 
including: Fc receptors (Livden et al, 1988; Bjerke et al, 1994); CLRs, such as dectin-1 
(Lee et al, 2009), and the mannose receptor (Cerdan et al, 1991; Szolnoky et al, 2001).  
Complement  receptors  and  regulatory  proteins  are  also  produced  by  keratinocytes, 
which may aid endocytosis of opsonised particles (Dovezenski et al, 1992).   
 
There is some debate in the literature as to which TLRs can be expressed by human 
keratinocytes.  Some authors have reported that human keratinocytes express TLR 1-6, 
9 and 10 (Song et al, 2002; Kollisch et al, 2005; Lebre et al, 2007),  whereas  Mempel et 
al  (2003)  state  that  TLRs  4,  6,  7,  8  and  10  cannot  be  detected  in  primary  human 
keratinocytes.  It is possible that the differentiation state of the keratinocytes in vitro 
might account for some of these differences in TLR detection, as TLR 5 and TLR 9 
have  been  shown  to  exist  in  different  strata  of  the  epidermis  (TLR  5  in  basal 
keratinocytes, and TLR 9 more diffuse throughout the epidermis, but concentrated in 
the stratum granulosum) (Miller et al, 2005).  Keratinocytes are also able to up-regulate 
TLRs in response to pathogen.  TLR 4 has been shown to be up-regulated in response to 
lipopolysaccharide (LPS) (Song 2002).  TGF can increase levels of TLR 5 and TLR 9 
(Miller et al, 2005), and IFN increases TLR 3 expression (Prens et al, 2008).  NLRs 
are also expressed by keratinocytes, such as NOD1 and NOD2 (Harder and Nunez, 
2009; Voss et al, 2006; Kobayashi et al., 2009).  The NALP3 inflammasome has a 
direct role in mediating adaptive immune responses and is expressed by keratinocytes 
(Watanabe et al, 2006).   
 
NF-B signalling in keratinocytes has been shown to be driven by TLRs.  For example, 
in  response  to  TLR  activation  in  keratinocytes,  NF-B  RelA  translocated  into  the 
nucleus,  and  intereukin-8  (IL-8)  was  secreted  (Kollisch  et  al,  2005).    Both 
Staphylococccus aureus  and its purified cell wall components (lipoteichoic acid and 
peptidoglycan) cause NF-B activation via TLR2 in keratinocytes (Mempel et al, 2003). 
  
DAMPs produced by keratinocytes  
Keratinocytes are able to produce DAMPs such as Hsps (Wang et al, 2011), hyaluronic 
acid (by expression of hyaluronidase, Kurdykowski et al, 2011; Malaisse et al, 2014), 50 
 
ATP (Inoue et al, 2014) and HMGB1 in response to erythema toxicum (Marchini et al, 
2007).  Pre-stored cytokines in keratinocytes, such as IL-1 and IL-33 (Luthi et al, 
2009)  may  also  be  considered  DAMPs.    Keratinocytes  also  produce  potent  anti-
microbial  peptides,  which  act  as  DAMPs,  as  part  of  the  epithelial  innate  defence 
mechanism, for example humandefensin (HBD) 1 and 2 (Harder et al, 1997; Ali et al, 
2001), HBD 3 (Sørensen et al, 2006), and cathelicidin (LL-37, Frohm et al, 1997).   
 
Cytokines and chemokines produced in skin in response to chemical sensitiser 
At an early time-point in the skin following exposure to chemical allergens, detectable 
levels  of cytokines  and chemokines  are stimulated in  the epidermis  (summarised in 
Table 1-2).  However, in many studies it is difficult to identify which skin cell type is 
responsible for the production of each cytokine.  
 
In mouse skin, in response to chemical allergens (oxazolone/urushiol/TNCB/DNFB), 
epidermal keratinocytes have been shown to transcribe or release IL-1 IL-1, IL-6, 
IL-10, IL-12, IL-18, IFN TNFa, IP-10, MIP-2, and GM-CSF (referenced in Table 1-
2).  IL-1 mRNA increases in mouse skin following exposure to TNCB at 2 hours and 
remains  elevated  until  18  hours  (Enk  and  Katz,  1992a),  and  also  following  4  hour 
exposure  to  TNCB,  DNFB  and  DNCB,  but  not  non-sensitiser  analogues  DCNB  or 
DNTB (Enk and Katz, 1992c).  IL-1 mRNA was also up-regulated following 6 hour 
stimulation with oxazolone, DNFB or urushiol (Haas et al, 1992).   
 
Up-regulation  of  IL-1  mRNA  expression  was  faster  than  IL-1  in  mouse  skin 
following exposure to TNCB.  It was elevated after just 15 minutes and continued to 
rise until 2 hours where it remained constant for 24 hours (Enk and Katz, 1992a).  Like 
IL-1, IL-1 expression was also seen following a 4 hour exposure to TNCB, DNFB 
and DNCB, but not non-sensitiser analogues DCNB or DNTB (Enk and Katz, 1992c).  
Another  sensitiser,  oxazolone,  also  caused  a  rapid  and  transient  increase  (5  to  90 
minutes)  in  IL-1  mRNA  in  mouse  skin  (Kermani  et  al,  2000).    Impaired  CHS 
responses have been seen to TNCB in IL-1 deficient mice (Shornick et al, 1996).   
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IL-6 protein was detected in mouse skin following topical exposure to oxazolone, which 
peaks at 4 to 8 hours, and is dose dependent (Holliday et al, 1996; Flint et al, 1998).  IL-
6 expression is reported to be mostly attributable to epidermal DCs (Cumberbatch et al, 
1996).    T  cell  responses  to  DNP-HSA  have  been  shown  to  be  dependent  on  IL-6 
(supplementary data, Palm and Medzhitov, 2009).   
 
IL-10 mRNA increases in response to TNCB at 4-12 hours, peaking at 12 hours and 
appears to be specific to sensitiser and not irritants (Enk and Katz, 1992b).  In contrast, 
IL-10 was not seen to be released in mouse skin up to 24 hours following exposure to 
oxazolone (Holliday et al, 1996).   
  
IL-18 mRNA was increased in mouse skin in response to TNCB at 2 hours, peaking at 6 
hours; this was also seen following exposure to DNFB but not irritants SDS and BKC 
(Stoll et al, 1997).  
 
The expression of TNF (mRNA and protein) in mouse skin following exposure to 
oxazolone was found to be under tight temporal constraints.  A transient and localised 
transcriptional  expression  peaked  and  dropped  within  20  minutes,  and  protein 
expression was found to be maximal at 2 hours, returning to normal by 4 hours (Flint et 
al, 1998).  TNF mRNA was up-regulated following 6 hour stimulation with oxazolone, 
DNFB, urushiol (Haas et al, 1992).   
 
Cytokines produced by keratinocytes in response to chemical sensitiser 
In  response  to  chemical  allergens,  keratinocytes  (primary,  3D  models  or  cell  lines) 
specifically have been shown to transcribe or release IL-1IL-1IL-8, IL-12, IL-18, 
IL-23 and TNF- (referenced in Table 1-3). 
 
IL-1expression, in response to sensitisers and irritants has been well studied.  In the 
mouse  keratinocyte  cell  line,  HEL30,  cell-associated  (and  to  a  much  lesser  extent 
released) IL-1 was found to be induced by allergens (DNCB, oxazolone, eugenol and 
Ni) (Corsini et al, 1998).  In reconstructed epidermal models, IL-1release was very 52 
 
low in response to allergens, but much higher in response to irritant exposure (Coquette 
et al, 2003). 
 
IL-1was found to be constitutively expressed in normal human keratinocytes and the 
mature form was seen in response to urushiol (Zepter et al, 1997).  In this study, 
keratinocytes were also found to synthesize ICE (caspase-1) which could be induced to 
process IL-1 into mature form by urushiol (Zepter et al, 1997).   

IL-8 was released following exposure of normal human keratinocytes, and the HaCaT 
cell line, in response to 6-24 hours exposure to DNFB (Mohamadzadeh et al, 1994).  IL-
8  was  also  strongly  expressed  in  reconstructed  epidermal  models  in  response  to 
allergens, but to a much lesser degree in response to irritants (Coquette et al, 2003). 
 
IL-12p35 was found to be constitutively produced by human epidermal cells.  IL-12p40, 
however, was only detected in epidermis treated with Nickel (Larsen et al, 2009).   IL-
12p40 was also shown to be stimulated in human skin following exposure to TNCB at 6 
and 12 hours, and could be induced in keratinocyte cells by TNBS or IL-1 (Muller et 
al, 1994).    
 
IL-18 was found to be expressed constitutively (stored intracellularly) by keratinocytes 
in the inactive unprocessed form (24kDa) and in the epidermis (Companjen et al, 2000).  
The active form of IL-18 was found to be expressed and secreted following exposure to 
DNCB (Naik et al, 1999).  Intracellular IL-18 was found to increase in response to a 
number of sensitisers, but not irritants (Corsini et al, 2009; van Och et al, 2005)  
 
A very low level  release of TNF- from keratinocytes  was  detected in  response to 
phenol and resorcinol (Newby et al, 2000).  These low levels (<50 pg/ml) are consistent 
with TNF release from keratinocytes in other studies (Kock et al, 1990). 
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IL-1  Enk and Katz 1992a/c;  Haas et al, 1992  
IL-1  Enk and Katz 1992a/c; Kermani et al, 2000 
IL-6  Cumberbatch et al, 1996; Holliday et al, 1996; Flint et al, 1998  
IL-10  Enk and Katz 1992b; Nickoloff et al, 1994 
IL-12  Muller et al, 1994 
IL-18  Stoll et al 1997 
IFN  Enk and Katz 1992a; Howie et al, 1996 
TNF-  Piguet et al,1991., Haas et al, 1992; Flint 1998; Enk and Katz 
1992a/c 
IP-10  Enk and Katz 1992a/c 
MIP-2  Enk and Katz 1992a/c 
GM-CSF   Enk and Katz 1992a/c 
 
 
Table 1-2 Cytokines and chemokines produced in response to sensitisers in skin  
 
 
IL-1  Corsini 1998, Curtis et al, 2007; Coquette et al, 2003; Newby et 
al, 2000 
IL-1  Zepter, 1997 
IL-8 (CXCL8)  Newby et al, 2000, Coquette et al, 2003; Mohamadzadeh, 1994 
IL-12  Larsen et al, 2009 
IL-18  Stoll et al 1997; Naik et al, 1999 
IL-23  Larsen et al, 2009 
TNF-  Newby et al, 2000 
 
 
Table  1-3  Cytokines  and  chemokines  produced  in  response  to  sensitisers  in 
keratinocytes  
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1.11 Risk assessment for skin sensitisation  
To  ensure  consumer  safety,  risk  assessments  are  produced  on  novel  chemical 
ingredients for cosmetic, home and personal care (HPC) products.  Risk assessments 
involve the consideration of both hazard and exposure scenario information, in order to 
evaluate  the  likelihood  of  adverse  ACD  reactions  in  consumer  populations.  
Historically,  to  identify  a  chemical  as  an  irritant  (causing  ICD)  or  as  a  sensitiser 
(causing  ACD),  animal  tests  such  as  the  mouse  local  lymph  node  assay  (LLNA) 
(Kimber  et  al,  1994)  or  the  guinea  pig  maximisation  test  (GPMT;  Magnusson  and 
Kligman, 1969) have been used.  However, due to a desire to base risk assessments on 
human rather than animal biology, and ethical considerations, the cosmetics and HPC 
industries are committed to invest in the development of alternatives to animal testing.  
The 7th Amendment to the EU cosmetics directive, which bans the marketing in Europe 
of  products  containing  chemicals  tested  on  animals,  came  into  effect  in  2013.  The 
industry  has  had  success  in  replacing  many  of  the  acute  toxicity  endpoints.    For 
example, the Draize animal test (Draize et al, 1944) was used for many years to identify 
irritancy potential, but was replaced by an in vitro assay that measures cell death in a 
human  artificial  skin  model  (Spielmann  et  al,  2007).    This  assay  is  now  ECVAM 
validated and serves as a direct replacement of animal tests for irritancy.  The repeat 
exposure toxicity endpoints such as allergy, cancer and reproductive toxicity are more 
challenging as they involve co-ordinated responses between many different cell types 
and/or organs.  There has been substantial research into the development of in vitro 
assays to predict the potential of chemicals to induce ACD. 
 
Historically, the identification of chemicals with sensitisation potential was assessed 
using  the  LLNA  (Kimber  et  al,  2001).    This  assay  involves  three  consecutive 
applications of chemical to the mouse ear, and the measurement of cell proliferation in 
the lymph nodes using tritiated thymidine incorporation.  The proliferation is assumed 
to correlate with the generation of a chemical-derived antigen specific memory T cell 
population.    A  chemical  is  identified  as  positive  if  the  proliferation  reaches  3-fold 
higher  than  control.    The  concentration  at  which  the  chemical-induced  proliferation 
reaches this threshold (termed EC3) is used to assign potency classes for sensitisers as: 
weak, moderate, strong or extreme (Gerberick et al, 2004).   
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1.12 In vitro assays for skin sensitisation potential 
The development of in vitro assays to predict sensitiser potential and potency fall into 
four  main  themes:  the  ability  of  chemicals  to  modify  protein;  stress  responses  of 
keratinocytes to chemical; the ability of chemical to activate/mature dendritic cells; and 
the simulation of DC-induced T cell proliferation.  
  
Peptide reactivity assays 
The  direct  peptide  reactivity  assay  (DPRA)  measures  the  binding  of  chemicals  to 
synthetic  cysteine  and  lysine  peptides  (by  depletion)  and  is  motivated  by  the 
electrophilic  nature  of  sensitisers  (Gerberick  et  al,  2004).    A  similar  assay  uses 
additional  peptides,  and  the  detection  of  chemical  adducts  by  mass  spectroscopy 
(Aleksic et al, 2009).  The DPRA was extended by the addition of a peroxidase step to 
oxidise  chemicals  that  are  metabolised  into  haptens  (pro-haptens),  termed  the 
peroxidase peptide reactivity assay (PPRA) (Troutman et al, 2011).  Surface plasmon 
resonance has also been used to screen allergen binding to nucleophilic amino acids 
(Achilleos et al, 2009).   
 
Keratinocyte assays 
Several assays have been developed that measure different aspects of keratinocyte or 
skin model responses to chemicals: cytokine release; gene expression; and signalling 
pathway  activation.    In  many  of  these  studies,  cell  death  is  not  controlled  to  be 
comparable between test chemicals and is a confounding factor. 
 
Assays  have  been  proposed  involving  measurement  of  intracellular  IL-1Corsini 
1998; Van Och et al, 2005), or IL-18 (Corsini et al, 2009; Van Och et al, 2005; Galbiati 
et al, 2011), in primary keratinocytes or keratinocyte cell lines.  The release of cytokines 
from  3D  skin  models  has  also  been  investigated  as  a  possible  predictor  of  skin 
sensitisation potential.  Examples include: IL-1 (dos Santos et al, 2011); and IL-1 
and IL-8 in combination (Coquette et al, 2003; Poumay et al, 2004; Spiekstra et al, 
2009).  
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Sensitiser-induced transcriptome changes in keratinocytes have also been investigated 
to find predicative subsets of genes that discriminate sensitisers from non-sensitisers.    
In  general,  these  genes  are transcription factors (ATF3,  cFOS); heat shock proteins 
(HSPA1B, HSPA6, HSPH1, DNAJB1, DNAJB4); cytokines and related proteins (IL-
1, IL-8, TNFAIP3); or genes associated with oxidative stress response/Nrf2 (HMOX1, 
NQO1,  TXNRD1,  GCLC,  GCLM)  (Yoshikawa  et  al,  2010;  Saito  et  al,  2013; 
Vandebriel et al, 2010; Van der Veen et al, 2013).  Other assays are based on a small 
number of genes from these studies in keratinocytes (Emter et al, 2013; McKim et al, 
2010) or skin models (McKim et al, 2012).   
 
Attempts are also being made to predict sensitisation potential based on activation of 
intracellular signalling cascades in keratinocytes in response to sensitiser.  KeratinoSens 
is an assay based on nuclear factor (erythroid derived 2)-like 2 (Nrf-2) activation, which 
utilises a luciferase reporter gene under the control of the ARE in HaCaT cells, and has 
been extensively evaluated (Natsch et al, 2011; Emter et al, 2010).  In a small study, 
Koeper et al (2007) proposed the use of MAPK signalling for discriminating between 
sensitisers and irritants in skin models.  
 
Dendritic cell assays  
PBMC-derived dendritic cell and dendritic-like (monocytic) cells, such as THP-1, U937 
and  MUTZ3,  are  also  being  explored  for  the  prediction  of  sensitisation  potential.  
Predictive biomarkers include: cell surface molecule expression (as a measure of DC 
activation);  cytokine  release;  gene  expression;  signalling  pathway  activation;  and 
generation of ROS.   
 
The activation status of the DC or DC-like cell line is often measured as a possible 
predictor of the sensitisation potential of chemicals.  Co-stimulatory molecules such as 
HLA-DR,  CD80,  CD83,  CD86,  ICAM-1  and  CD40,  DC-SIGN  and  the  chemokine 
receptor CCR7 are used as indicators of DC activation.  The human cell line activation 
test  (hCLAT)  (Ashikaga  et  al,  2005;  Sakaguchi  et  al,  2006,  2009)  aims  to  predict 
allergens  from  irritants  based  on  expression  of  CD86  and  CD54  on  THP-1  cells 
following chemical exposure.  The myeloid U937 skin sensitisation test (MUSST) is a 
similar assay measuring CD86 in U937 cells (Python et al, 2007; Ade et al, 2006).  57 
 
CD86 also features in a PBMC-DC assay by Reuter et al (2011), and was found to be 
the most reliable biomarker in a comparison of 8 markers across 6 DC cell lines (Azam 
et al, 2006).  In many of these studies cell death is a confounding factor, given that, in 
the cell surface expression studies in particular, the cells are often up to 50% dead.  To 
circumvent  this,  the  loose  fit  co-culture  based  sensitisation  assay  (LCSA)  was 
developed  measuring  CD86  and  cytokines  from  a  co-culture  of  monocytes  with 
keratinocytes (Schreiner et al, 2007, 2008).   In another co-culture assay, containing 
HaCaT and THP-1 cells, CD86 CD40 and CD54 on THP-1 were measured (Hennen et 
al, 2011).  Other DC-based assays measured IL-8 release from monocyte-derived DCs 
or THP-1 cells instead of cell surface markers (Toebak et al, 2006; Mitjans et al 2008; 
Nukada et al, 2008).   
 
Transcriptional changes in response to sensitising chemicals have been  explored in 
dendritic or dendritic-like cells (Ryan et al, 2004; Johansson et al, 2011; Miyazawa and 
Takashima, 2012; Yoshikawa et al, 2010; Schoeters et al, 2007; Python et al, 2009; 
Szameit et al, 2009), with the objective of finding a small number of genes to predict 
sensitisation potential (Gildea et al, 2006; Hooyberghs et al, 2008; Lambrechts et al, 
2010; Johansson et al, 2013).   
 
Other groups have investigated activation of intracellular signalling pathways in DC in 
response to sensitisers.  Two studies have focused on transcription of genes associated 
with Nrf2 signalling (HMOX, NQO1) in THP-1 and CD34+ DCs or MoDCs (Ade et al, 
2009; Migdal et al, 2013).  MAPK signalling in MoDCs was evaluated as a possible 
sensitiser screening tool (Trompezinski et al, 2008), and p38MAPK phosphorylation in 
THP-1 cells was a positive signal for sensitisers (Suzuki et al, 2009; Mitjans et al 2008).  
ROS generated in XS106 or THP-1 DC-like cells was used as a biomarker in response 
to sensitisers (Miyazawa et al, 2012; Saito et al, 2013).   
 
Proliferation and IFN secretion from T cells in response to DC exposed to haptenated 
peptide (Martin et al, 2010) led to development of the human T cell priming assay 
(hTCPA).    In  this  assay,  MoDC  are  pulsed  with  test  chemical  or  chemical  protein 
conjugates, and co-cultured with T cells, and the IFN/TNF positive CD4+ or CD8+ T 58 
 
cells are measured (Richter et al, 2013).  This assay has been improved by the depletion 
of Tregs (Vocanson et al, 2014).  
 
Developments of in vitro assays in all of these areas are continuing, in particular many 
authors are now attempting to extend their assays to predict sensitisation potency in 
addition to potential.   
 
1.13 HaCaT cell line 
The HaCaT cell line is widely used to study human keratinocyte behaviour.  HaCaT 
cells  are  a  spontaneously  immortalised  cell  line,  originally  derived  from  the  distant 
periphery  of  an  adult  human  skin  melanoma  (Boukamp  et  al,  1988).    They  are 
cytogenetically abnormal, and have mutations in both alleles of the p53 gene, which 
results in mutant p53 protein with an extended half life (Lehman et al, 1993), however, 
they are non-tumorigenic (Boukamp et al, 1988, 1997). 
 
HaCaT cells are thought to represent basal keratinocytes, expressing keratins 5 and 14 
(Boukamp et al, 1988).  However, they can be induced to differentiate by culture at high 
concentrations of calcium, or at confluency > 85%, leading to increased expression of 
differentiation  markers  keratin  1  and  involucrin  (Deyroeux  and  Wilson,  2007).    As 
HaCaT  cells  retain  the  ability  to  differentiate,  they  can  provide  stratified  epidermal 
tissue when grafted onto mice (Boukamp et al, 1988).  However, attempts to produce 
3D  skin  models  with  HaCaT  cells  were  not  successful,  due  to  a  lack  of  terminal 
differentiation (Boelsma et al, 1999).   
 
1.14 3D skin models  
3D  skin  models,  also  known  as  reconstructed  human  epidermis  (RHE),  living  skin 
equivalents (LSE), or epidermal equivalents (EE), were first developed to provide skin 
grafts from in vitro culture (Bell et al, 1983).  They are models of stratified epidermal 
keratinocytes, layered on a collagen or polycarbonate matrix, or a matrix containing 
dermal  fibroblasts.    The  inclusion  of  fibroblasts  in  the  dermal  compartment  assists 
keratinocyte attachment, growth and differentiation (Krejci et al, 1991).  The models are 
cultured at the air:liquid interface, which causes differentiation of the keratinocytes, 59 
 
resulting  in  stratification  that  resembles  the  physiology  of  human  skin  in  vivo 
(Asselineau et al, 1985).  Due to the formation of a stratum corneum layer, 3D skin 
models have some barrier function to water permeation, which can be altered by varying 
the culturing conditions: humidity, vitamin D and the support matrix composition (Mak 
et  al,  1991).    However,  the  barrier  is  not  as  effective  as  normal  human  skin,  as 
permeation rates through 3D skin models are up to 10-fold greater (Regnier et al, 1993).  
RHE models have been shown to express suprabasal keratins 1 and 10, similar to human 
skin,  however,  they  over-express  keratin  6  and  express  suprabasal  involucrin, 
transglutaminase and filaggrin which are all markers of hyper- proliferative epidermis 
(Ponec et al, 1991). 
 
Due to their physiological approximation to human skin and the ability to dose topically 
with  test  chemicals,  these models  have been adopted for use in  in  vitro toxicology 
assays for irritancy, by measurement of cytotoxicity and IL-1 release (Spielmann et al, 
2007).  Skin models have also been investigated as possible in vitro tools to develop 
assays to predict skin sensitisation potential (dos Santos et al, 2011; Coquette et al, 
2003; Poumay et al, 2004; Spiekstra et al, 2009; Spiekstra et al, 2005; McKim et al, 
2012).    However,  repeat  application  testing  is  not  possible,  due  to  the  lack  of 
desquamation in the models (Ponec et al, 2002).  There are two main commercially 
available  skin  models:  EpiDerm™  (MatTek  Corporation)  and  EpiSkin  (SkinEthic), 
which have been demonstrated to be representative of normal human skin (Monteiro-
Riviere et al, 1997; Rosdy et al, 1993).  Ponec et al (2000) performed a comparision of 
the EpiDerm, EpiSkin and SkinEthic models to human skin, and found them to have 
similar lipid content.  Ceramide 7 was, however, not present in the skin models, and 
ceramides 5 and 6, and free fatty acids were much lower than those detected in human 
skin.    A  comprehensive  comparison  of  the  commercially  available  skin  models  is 
summarised in Ponec et al (2002). 
 
EpiDerm is also available as a full thickness version, EpiDermFT™, with a dermal 
compartment containing human fibroblasts.  Further developments of skin models are in 
progress, to attempt to incorporate immune cells, such as CD34+ LC-like cells (Facy et 
al, 2005), MUTZ derived-LCs (Ouwehand 2011) and  CD4+ T cells (van den Bogaard et 
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1.15 Aims   
CHS is an extensively studied immune response, however, investigations into the roles 
of  different  cell  types  during  CHS  have  focused  mainly  on  LCs,  DCs  and  T  cells.  
Keratinocytes are the most numerous cells in skin and the first cell type to encounter 
chemical  allergen  following  topical  exposure,  and  are  known  to  be  capable  of 
influencing cutaneous immune responses, but their contributions to CHS responses are 
not  well  understood.    For  example,  previous  in  vitro  studies  have  focused  on  the 
response of DCs following direct exposure to chemical allergen, however, few have 
looked at the crosstalk between keratinocytes and DCs or at the molecular response of 
the keratinocyte to chemical allergen.  A commonly expressed hypothesis is that danger 
signals produced by keratinocytes induce the co-stimulatory signal expression on DCs 
required to generate an adaptive immune response.  However, keratinocytes may also 
regulate  cutaneous  immune  responses  in  other  ways,  for  example  by 
influencing/attracting other cell types (T cells, macrophages, granulocytes, fibroblasts) 
through  their  mediator  release.    Investigation  of  which  cytokines,  chemokines  and 
growth factors are generated by keratinocytes may provide clues about which other cells 
are most likely to respond as a result of keratinocyte signalling. 
 
The objective of this project is to characterise keratinocyte-derived epidermal signals in 
the initiation of contact hypersensitivity to chemicals.  We also intend to investigate the 
molecular mechanisms involved in generating intercellular mediator signals in response 
to chemical allergen, to understand how chemicals may interact with keratinocytes to 
trigger CHS responses.  We will first establish which cellular communication mediators 
(such as cytokines, chemokines and growth factors) are released by different in vitro 
keratinocyte models, specifically in response to chemical allergen and distinct from a 
cytotoxic response.  Our next aim is to identify candidate molecular mechanisms for the 
cytokine/chemokine  release  through  a  comprehensive  analysis  of  modulation  of  the 
transcriptome.    Finally,  we  will  ascertain  which  intracellular  signal  transduction 
cascades  are  responsible  for  sensitiser-specific  mediator  expression  using  functional 
assays. 
 
 61 
 
2  MATERIALS AND METHODS 
2.1 Cell culture 
HaCaT cell line 
The  spontaneously  immortalised  human  keratinocyte  cell  line,  HaCaT  (supplied  by 
Professor  N.  Fusenig,  Heidelberg,  Germany)  was  used  for  comparison  with  the  3-
dimensional keratinocyte models.  HaCaT cells (passage 48-52) were cultured in high 
glucose  Dulbecco’s  modified  Eagle  medium  (DMEM)  containing  0.37%  sodium 
bicarbonate, 10% heat inactivated foetal calf serum, 2mM L-glutamine, 1mM sodium 
pyruvate, 100U/ml penicillin and 100g/ml streptomycin (solution prepared in normal 
saline) (all Gibco).  Cells were maintained at 37C in an atmosphere of 5% CO2 and 
passaged (or dosed) when approximately 80% confluent.  To subculture, HaCaT cells 
were  washed  with  phosphate  buffered  saline  (PBS)  and  detached  by  10  minute 
incubation at 37C in 1mM trypsin (0.25%)/ethylenediaminetetraacetic acid (EDTA) 
(Sigma).  Cells were harvested and pelleted by centrifugation at 160 x g for 10 minutes 
and re-suspended in fresh media. 
 
EpiDerm and EpiDermFT models 
Two types of human artificial skin models were used; a keratinocyte only model and a 
keratinocyte and fibroblast model (models and media supplied by MatTek; Ashland, 
MA, USA).  The keratinocyte only models (EpiDermTM) are stratified cultures derived 
from normal human epidermal keratinocytes (NHEK) from neo-natal foreskin (single 
donor).  To form stratified layers, keratinocytes were grown on collagen coated tissue 
culture plate inserts (Millicell™, Millipore) at the air liquid interface.  The keratinocyte 
and fibroblast models (EpiDermFTTM) are stratified cultures of NHEK from neo-natal 
foreskin tissue layered on top of normal human dermal fibroblasts (NHDF) also from 
neo-natal foreskin (multiple donors).  The full thickness (FT) models were produced by 
culturing on tissue culture plate inserts (Millicell, Millipore) at the air liquid interface.  
The culturing conditions for production are proprietary to MatTek.  Upon arrival, both 
models were cultured at 37oC in 5% CO2 in serum free Dulbecco's modified Eagle 
medium (DMEM) containing 5µg/ml gentamicin, 0.25µg/ml amphotericin B, phenol 
red, insulin, epidermal growth factor (EGF) and lipid precursors (MatTek proprietary).  62 
 
The  EpiDerm  media  contained  additional  stimulators  of  epidermal  differentiation 
(MatTek proprietary).  All tissues and media were requested to be hydrocortisone-free 
(removed 3 days prior to shipment) to enable inflammatory signalling to be studied.  
The media were also requested to contain the minimum amount of epidermal growth 
factor  required  for  viability  and  to  be  free  from  all  other  cytokines  present  on  the 
Luminex 30-plex panel (see section on Luminex).  Models derived from three different 
donors were obtained to address inter-individual variability; the same three keratinocyte 
donors were used to prepare the EpiDerm and the EpiDermFT cultures. 
 
2.2 Chemical exposure  
1-Chloro-2,4-dinitrobenzene (DNCB) was selected as an extreme skin sensitiser based 
on its classification in the Local Lymph Node Assay (LLNA) (Loveless et al, 1996).  
Sodium dodecyl sulphate (SDS) was chosen as a representative irritant based on human 
patch test classification (Basketter et al, 2004).  Interestingly, this irritant gives a false 
positive  result  in  the  LLNA  (Loveless  et  al,  1996).    Lipopolysaccharide  (LPS)  and 
Interferon-gamma (IFN) were chosen as positive controls as they are known to activate 
the immune system and hence have the potential to stimulate cytokine release (Pastore 
et al, 1998) (all chemicals, Sigma).   
 
HaCaT cell line  
HaCaT  cells  (passage  49-52)  were  harvested  by  incubation  with  1mM  trypsin 
(0.25%)/EDTA (Sigma) and seeded into 6-well plates (2ml per well of 4x105cells/ml).  
Following overnight culture, maintenance media was removed and the cells exposed to 
DNCB (between 2.5M and 40M), or SDS (between 1M and 500M) diluted in 
0.2% dimethyl sulfoxide (DMSO) (Sigma) in culture media (see section on cell culture).  
HaCaT cells were also exposed to LPS/IFN (1g of each in 1ml culture media) to act 
as a positive control; and culture media, or 0.2% DMSO in culture media to act as 
negative/vehicle  controls.    Following  1,  4  or  24  hour  exposure,  supernatants  were 
removed  and  stored  at  -80oC  (for  cytokine  analysis).    The  cells  were  assessed  for 
viability using the MTT assay (see section on MTT assay below). 
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EpiDerm and EpiDermFT models 
Following  overnight  incubation  in  culture  media  (see  section  on  cell  culture),  the 
models were transferred into 6-well plates containing 2ml of fresh, pre-warmed, culture 
media.  Models were dosed topically with 700l (large models) or 100l (small models) 
of culture media; 0.2%, 0.5% or 1% DMSO in culture media; DNCB (between 62.5M 
and 1000M diluted in 0.2%, 0.5% or 1% DMSO in culture media); SDS (between 
1mM and 40mM) or LPS/IFN (1g of each in 1ml culture media).  The models were 
then incubated at 37C in 5% CO2 and saturated humidity for 1 hour, 4 hours or 24 
hours.  Following incubation with chemical, supernatants were removed and stored at -
80oC (for cytokine analysis/ lactate dehydrogenase (LDH) assay).  Cultures were then 
washed thoroughly with PBS and punched from their housings using a biopsy punch.  
Tissues were divided into three equal parts.  For the histological analysis, sections were 
immersed in 10% (v/v) neutral buffered formalin (NBF) (Sigma).  For mRNA analysis 
tissues were immersed in ‘RNA-Later’ (Applied Biosystems).  The remaining tissue 
sections were lysed in RIPA protein lysis buffer (Sigma).  This procedure was repeated 
for 3 different donors of EpiDerm and EpiDermFT.  All tissue and supernatant samples 
were stored at –80oC.  
 
2.3 Cytotoxicity 
MTT assay 
The MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay was 
used to assess the cytotoxicity of chemicals in the HaCaT cells and the skin models.  
Following treatment, HaCaT cells or skin models were washed with PBS and exposed 
to 0.5mg/ml of MTT (Sigma).  Cultures were incubated in MTT in the dark at 37C in 
5% CO2 for 3 hours.  Following this incubation, HaCaT cells or EpiDerm models were 
washed twice with PBS and incubated (with shaking) in isopropanol for 10 minutes 
(HaCaTs) or 2 hours (models) at room temperature.  The epidermis and dermis of the 
full  thickness  models  were  separated  (using  tweezers)  at  this  stage  and  analysed 
separately.  The absorbance of the isopropanol at a wavelength of 570nm was read 
using a spectrophotometer (Spectramax, Molecular Diagnostics).  Cell viability (%) was 
assessed  by  comparing  the  absorbance  (at  570nm)  of  treated  cells  to  the 
untreated/vehicle controls. 64 
 
LDH assay 
The  LDH  cytotoxicity  assay  was  used  in  place  of  the  MTT  assay  to  estimate  cell 
viability  in  some  of  the  skin  models  (so  that  the  tissue  could  be  utilised  in  other 
endpoints).  The TOX-7 assay kit (Sigma) was used for this assay.  The LDH assay mix 
was prepared by mixing equal amounts of LDH assay Substrate, LDH assay Cofactor 
(re-hydrated in tissue culture grade water) and LDH assay Dye Solution.  Supernatant 
samples (100l) generated from EpiDerm models were aliquoted into a 96 well flat-
bottom plate.  LDH assay mix was added to each well at twice the volume of sample.  
The plate was covered with foil and incubated at room temperature for 30 minutes.  The 
reaction was terminated by the addition of 30l of 1N HCl (Sigma) to each well.  The 
absorbance  of  each  well  was  measured  using  a  spectrophotometer  (Spectramax, 
Molecular  Diagnostics)  at  a  wavelength  of  490nm.    The  background  absorbance  at 
690nm  was  also  measured  and  subtracted  from  the  primary  (490nm)  wavelength 
measurement.    Model  viability  (%)  was  assessed  by  comparing  the  absorbance  of 
treated models to the vehicle controls. 
 
2.4 Histology 
Changes in the morphology of the skin models in response to chemical exposure were 
visualised using histology.   
 
Tissue Processing      
Following 3 hour incubation in 10% (v/v) neutral buffered formalin (NBF), the cultures 
were placed into processing cassettes to maintain the tissue structure.  Tissue processing 
was  performed using the  Leica TP1020 tissue  processor according to the following 
procedure (IMS: Industrial Methylated Spirit): 
Station  Reagent  Temperature  Time 
1  70% IMS   Ambient  30 minutes 
2  80% IMS  Ambient  90 minutes 
3  90% IMS  Ambient  90 minutes 
4  100% IMS  Ambient  90 minutes 
5  100% IMS  Ambient  90 minutes 65 
 
6  100% IMS  Ambient  90 minutes 
7  Xylene  Ambient  30 minutes 
8  Xylene  Ambient  60 minutes 
9  Xylene  Ambient  90 minutes 
10  Wax  60oC  90 minutes 
11  Wax  60 oC  90 minutes 
12  Wax  60 oC  90 minutes 
 
Tissue embedding and sectioning 
Wax infiltrated tissues were embedded in paraffin wax blocks for sectioning using the 
Leica EG1140 HC tissue embedding centre.  Processing cassettes were removed from 
the tissue processor and bathed in molten wax and tissues were then removed from the 
cassette and cut in half to create a flat surface.  Molten wax was poured into a metal 
mould and the tissues were orientated in the wax so that the flat edge lay at the bottom 
of the mould.  Once in position the mould was placed on a cold plate and the wax 
containing the tissue set to give a hardened wax block containing EpiDerm/ EpiDermFT 
tissue.  The wax blocks were trimmed to remove excess wax from around the tissue.  
The block was then placed in a microtome (Leica rotary microtome 2035) and the wax 
shaved until the tissue was exposed.  Sections were cut at 4m and floated in warm 
water onto a clean microscope slide.  The sections were covered with a cover-slip and 
placed in an incubator at 56oC to dry overnight.     
 
H&E staining  
Haematoxylin and Eosin (H&E) staining was carried out using the Leica Autostainer 
according to the following procedure: 
 
Station  Method  Time 
1  Immerse in Xylene  1 minute 
2  Immerse in Xylene  1 minute 
3  Immerse in 100% ethanol   1 minute 
4  Immerse in 100% ethanol   1 minute 66 
 
5  Immerse in 95% ethanol   1 minute 
6  Immerse in 95% ethanol   1 minute 
7  Rinse in water    
8  Haematoxylin  5 minutes 
9  Rinse in water   
10  Differentiate in 1% acid ethanol   
11  Blue in water   10 minutes 
12  Eosin   5 minutes 
13  Rinse in water   
14  Immerse in 95% ethanol   1 minute 
15  Immerse in 95% ethanol   1 minute 
16  Immerse in absolute ethanol   1 minute 
17  Place in fresh absolute ethanol   1 minute 
18  Immerse in Xylene  1 minute 
19  Place in fresh Xylene  1 minute 
20  Mount in DPX   
 
The  slides  were  examined  under  the  microscope  for  histological  changes  and 
photographed  with  both  the  x10  and  x40  zoom  using  a  photomicroscope  (Leica 
DM5500). 
 
2.5 Luminex 
Culture supernatants from HaCaT cells, EpiDerm and EpiDermFT models exposed to 
DNCB, SDS and LPS/IFN were analysed for the presence of cytokines, chemokines 
and growth factors using the Luminex 200IS platform (Luminex).  The human 30-plex 
cytokine/chemokine kit or the human inflammatory 5-plex and the IL-1 single plex kit 
were used to analyse the supernatants (IL1- was analysed separately to IL1- as the 
antibodies for these cytokines cannot be analysed together).  Kits contained all reagents 
unless otherwise stated (Invitrogen).  
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Cytokine/chemokine detection 
Lyophilised standards for 30 cytokines (IL-1RA, IL-1, IL-2, IL-2R, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-10, IL-12, IL-14, IL-15, IL-17, IP-10, MCP-1, MIG, MIP-1, MIP-1, 
RANTES, TNF, VEGF, EGF, EOTAXIN, FGF-basic, GCSF, GM-CSF, HGF, IFN, 
IFN) or 5 cytokines (IL-1, IL-6, IL-8, GM-CSF, TNF)  and a separate batch for IL-
1 were reconstituted in 50% assay diluent and 50% of the relevant culture media.  A 
standard  curve  was  prepared  for  each  cytokine  by  serially  diluting  (1:3)  the 
reconstituted standard in 50% assay diluent plus 50% culture medium.  Following this, a 
96-well filter plate was hydrated with diluted wash solution and aspirated from the wells 
using a vacuum manifold (< 5 inches Hg).  Diluted bead solution containing beads 
coated with antibodies for each cytokine was added to each well (25μl) and the plate 
shielded from light, using a foil coated lid.  The beads were washed by addition of 
0.2ml wash solution to each of the wells.  After 30 seconds the wash solution was 
removed  from  the  wells  by  aspiration  with  the  vacuum  manifold.    This  step  was 
repeated and the filter plate blotted to remove residual liquid.  Incubation buffer (50μl) 
was then added into each well.  100μl of appropriate standard dilution was added to the 
wells  designated  for  the  standard  curve.    Assay  diluent  (50μl)  followed  by  sample 
(50μl) was added to the wells designated for samples.  The plate was incubated for 2 
hours at room temperature on an orbital shaker to keep the beads suspended during the 
incubation (~550 rpm).  Following the 2 hour incubation the liquid was aspirated and 
the wells washed twice with wash solution.  The filter plate was blotted to remove 
residual liquid and 100μl of the diluted biotinylated detector antibody added to each 
well.  The plate was then incubated for 1 hour at room temperature on an orbital shaker 
(~550 rpm).  Following the 1 hour incubation the liquid was aspirated and the wells 
washed twice with wash solution.  The filter plate was blotted to remove residual liquid 
and 100μl diluted Streptavidin-RPE added to each well.  The plate was then incubated 
for a further 30 minutes at room temperature on an orbital shaker.  After 30 minutes, the 
liquid was removed from the wells by aspiration with the vacuum manifold.  The wells 
were washed 3 times in wash solution and the filters blotted to remove residual liquid.  
Wash solution (100μl) was then added to each well and the beads  re-suspended by 
shaking on an orbital shaker (500-600 rpm) for 2-3 minutes.   Plates were analysed 
using the Luminex 200IS platform.  The software was set to read 100 events per bead 
region with a doublet discriminator gate set at 7800-15200.  Data were collected as 68 
 
median relative fluorescence units (RFU) and the concentration of each cytokine was 
determined using the standard curves. 
 
Cytokines and chemokines IL-8, IL-6 and MCP-1 released into the supernatant by the 
EpiDermFT models had concentrations that exceeded the standard curve and so were 
diluted (1:80 for IL-6 and IL-8 or 1:5 for MCP-1) in the corresponding culture medium 
and reanalysed.  
 
2.6 Ribonucleic acid (RNA) extraction: TRIzol method 
Total RNA from HaCaT cells and 3D skin models was extracted using a combination of 
TRIzol  (Invitrogen)  extraction  and  column  purification  using  the  RNeasy  mini  kit 
(Qiagen). 
 
HaCaT cells were lysed directly in 1ml of TRIzol reagent (Invitrogen) and transferred 
into centrifuge tubes.  For the 3D skin models, 50mg of tissue was taken out of RNA 
later and placed in a FastPrep F-matrix tube containing 2 ceramic beads and 1ml of 
TRIzol reagent (Invitrogen).  The tissue was homogenised using the FastPrep-24 (MP 
Biomedicals) 3 times for 20 seconds at 4 macerations/ second each time with 3 min on 
ice between each cycle.  The FastPrep matrix were pelleted by centrifugation at 9,300 x 
g for 2.5 minutes and the TRIzol containing lysed tissue transferred into fresh centrifuge 
tubes.  
 
For both, Chloroform:Isoamyl alcohol mixture (0.2ml) (BioUltra, Sigma) was added 
(into TRIzol lysate) and shaken vigorously to ensure complete mixing.  Following 3 
minutes incubation at room temperature the samples were centrifuged at 10,000 x g for 
15 minutes at 4oC.  The upper aqueous phase of the solution (containing RNA) was 
transferred to a fresh eppendorf tube to which 0.53x volumes of absolute ethanol were 
added.  The aqueous/ethanol mix was added to an RNeasy mini column (Qiagen) and 
centrifuged for 1 minute at 15,700 x g in a bench top centrifuge.  The column was 
washed with 700l of buffer RW1 (Qiagen) and centrifuged for 1 minute at 9,300 x g, 
then rinsed with 500l buffer RPE (Qiagen) and re-centrifuged for 1 minute at 9,300 x 
g.  The rinse with 500l buffer RPE was repeated and the column centrifuged at 9,300 x 69 
 
g for 2 minutes.  RNase free water (50l) was added to the column and incubated for 2 
minutes.  Following this, total RNA was eluted off the column into a fresh RNase free 
eppendorf tube by centrifugation at 15,700 x g for 1 minute.  RNA was stored at -80oC. 
 
2.7 Analysis of RNA quality 
The concentration and purity of the RNA samples were determined using the Agilent 
2100 Bioanalyser.  The RNA 6000 Nano kit (Agilent) was used for this assessment.  
The chip priming station was prepared by attaching a new syringe and adjusting the 
syringe  clip  and  base  plate  to  RNA  chip  specific  positions.    The  gel-dye  mix  was 
prepared by adding RNA 6000 Nano gel matrix to a spin filter and centrifuging at 1500 
x g for 10 minutes at room temperature.  Filtered gel matrix (65l) was transferred to a 
fresh micro-centrifuge tube and 1l of Nano dye concentrate added.  The solution was 
vortexed and centrifuged at 13,000 x g for 10 minutes at room temperature.  The gel-
dye mix (9l) was then loaded onto the RNA 6000 Nano chip and driven through using 
the syringe.  Two additional 9l aliquots of gel-dye mix were also loaded onto the chip 
(see manufactures instructions for loading positions).  RNA 6000 Nano marker (5l) 
was added into each of the remaining wells, to which either 1l RNA ladder or 1l of 
sample RNA was added.  The chip was vortexed for 1 minute and then analysed using 
the Agilent 2100 Bioanalyser.   
 
2.8 cDNA synthesis from total RNA 
Single stranded complementary deoxyribonucleic acid (cDNA) was synthesised from 
total RNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems).  RNA 
(2g total) was added (on ice) to reverse transcription (RT) buffer and RT enzyme mix 
(both Applied Biosystems) and made up to  20l  with  nuclease free water (Applied 
Biosystems).  The reverse transcription was performed using a thermal cycler (Perkin 
Elmer) by heating to 37oC for 60 minutes followed by 95oC for 5 minutes.  The cDNA 
was stored at -20 oC and analysed for quality and concentration before use in qRT-PCR 
measurements using a NanoDrop ND-1000 spectrophotometer (Labtech International 
Ltd).   
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2.9 Quantitative real time polymerase chain reaction  
TaqMan gene expression master-mix (Applied Biosystems) and gene specific TaqMan 
gene expression assays for IL-1 (hs01555410), IL-6 (hs00985641), IL-8 (hs99999034), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  (hs99999905) and hypoxanthine 
phosphoribosyltransferase 1 (HPRT) (hs99999909) containing unlabeled primers (final 
concentration  900nM  per  primer)  and  FAM™  dye-labelled  TaqMan  minor  groove 
binder  (MGB)  probe  (final  concentration  250nM)  (all  Applied  Biosystems)  were 
combined as per manufactures instructions: 
 
Gene  Assay ID  Context Sequence 
IL-1  Hs01555410_m1  AGATGAAGTGCTCCTTCCAGGACCT 
IL-6  Hs00985641_m1  TGCAGAAAAAGGCAAAGAATCTAGA 
IL-8  Hs99999034_m1  GCAGCTCTGTGTGAAGGTGCAGTTT 
GAPDH  Hs99999905_m1  GGGCGCCTGGTCACCAGGGCTGCTT 
HPRT1  Hs99999909_m1  ATGGTCAAGGTCGCAAGCTTGCTGG 
 
TaqMan gene expression master-mix and gene specific TaqMan gene expression assays 
were added to 50ng cDNA diluted in nuclease free water (to total volume 20l) in a fast 
MicroAmp™  optical  96-well  reaction  plate  (Applied  Biosystems).    The  plate  was 
loaded  into  a  7500  fast  real-time  PCR  machine  (Applied  Biosystems)  and  run  in 
standard mode under the following conditions: 
 
Step  Temperature (oC)  Duration  Cycles 
UDG incubation  50  2 min  HOLD 
AmpliTaqGoldUP 
enzyme activation 
95  10 min  HOLD 
Denature  95  15 sec  40 
Anneal/Extend  60  1 min  40 
 
Data were collected for IL-1, IL-6, IL-8, and housekeeping genes GAPDH and HPRT 
for normalisation.   
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2.10 Transcriptomics  
Cell culture and dosing  
HaCaT cells, as previously described (in the section on cell culture), were harvested by 
incubation with 1mM Trypsin (0.25%)/EDTA (Sigma) and seeded into 6-well plates 
(2ml per well of 4x105cells/ml).  Following overnight culture, maintenance media was 
removed and the cells exposed to DNCB (20M, 27.5M or 30M), or SDS (250M); 
both chemicals were diluted in 0.2% Dimethyl Sulfoxide (DMSO) (Sigma) in culture 
media (see section on cell culture).  HaCaT cells were also cultured in 0.2% DMSO in 
culture media to act as a vehicle control.  Following 4 hour exposure, supernatants were 
removed and stored at -80oC (for cytokine/LDH analysis).  Total RNA was immediately 
extracted from the cells using the methods previously described (see Ribonucleic acid 
(RNA) extraction: TRIzol method and Analysis of RNA quality sections). 
 
Preparation and Labelling of cRNA 
The  transcriptomic  analysis  was  performed  using  the  Agilent  human  genome  CGH 
microarray system (4x44k).   
 
Sample RNA diluted in nuclease free water (400ng) was added (6.25ml of 64ng/ml) to 
T7 promoter primer (1.2l) along with one colour spike mix (3.5l of a diluted stock 
solution  at  1:2500  in  dilution  buffer)  (Agilent  RNA  spike-in  kit).    The 
RNA:primer:spike mix was heated to 65oC for 10 minutes in a thermocycler to denature 
both sample and spike-in RNA allowing binding of the promoter primer.  Following 
this, samples were incubated on ice for 5 minutes.  A cDNA master mix was prepared 
containing first strand buffer (pre-warmed to 80oC for 4 minutes), dithiothreitol (DTT), 
deoxynucleotide  (dNTP)  mix,  moloney  murine  leukemia  virus  (MMLV)  reverse 
transcriptase and RNase-out.  The cDNA master mix was added to the primed RNA 
samples and incubated at 40oC for 2 hours, followed by 15 minutes at 65oC and then 5 
minutes  on  ice.    During  this  incubation  a  transcription  mastermix  was  prepared 
containing;  nuclease  free  water,  transcription  buffer,  DTT,  NTP  mix,  polyethylene 
glycol  (PEG;  pre-warmed  to  40oC  for  1  minute),  RNaseOUT,  Inorganic 
pyrophosphatase, T7 RNA polymerase and Cyanine-3 CTP (all Agilent).  Transcription 72 
 
master mix was added to the cDNA samples and incubated at 40oC for 2 hours.  The 
resultant labelled cRNA was purified using a Qiagen RNeasy mini spin column.   
 
Purification and quantification of cRNA (Qiagen mini kit) 
RLT  buffer  (350l)  and  ethanol  (>96%)  (250l)  were  added  to  cRNA  samples 
(previously made up to 100l in nuclease free water). The resultant samples were added 
to RNeasy mini columns in a collection tube (Qiagen) and centrifuged for 30 seconds at 
15,700 x g in a bench top centrifuge.  In a new collection tube, the column was rinsed 
with 500l buffer RPE (containing ethanol) and re-centrifuged for 30 seconds at 15,700 
x g.  The rinse with 500l buffer RPE was repeated and the column centrifuged at 30 
seconds at 15,700 x g.  The dry column was then re-centrifuged at 15,700 x g for 1 
minute to remove all traces of RPE.  cRNA was eluted off the column into a fresh 
RNase-free eppendorf tube by the addition of 50l RNase-free water.  This column was 
incubated with RNase-free water for 1 minute and then centrifuged at 15,700 x g for 30 
seconds. The resultant labelled-cRNA was stored in the dark at -80oC. 
 
cRNA was quantified using a UV-VIS spectrophotometer (measuring at 260 nm and 
550 nm) in an Implen cuvette with a factor 10 LP 1mm cap.  The spectrophotometer 
was blanked using nuclease free water until a constant zero reading could be achieved.   
The RNA absorbance at 260nm and the cyanine-3 dye absorbance at 550nm for each 
eluted  cRNA  sample  were  measured.    From  these  values  the  cRNA  concentrations 
(ngl) (=A260nm x dilution factor (10) x optical density of RNA (40 ngl)) and hence 
yields in g (in 50l total volume) were calculated.  The concentration of Cy3 dye was 
also calculated in each sample (pmol/l) (=A550nm x dilution factor (10) x pmol factor 
(1000) / absorbance co-efficient of Cy3 (0.15)).  The specific activity of the Cy3 dye in 
each sample was calculated as [Cy3 (pmol/l)]/ [cRNA (ng/l) x (1000)].  The values 
were assessed for use in hybridisation reactions. 
 
Preparation of hybridization reaction mixtures  
For each array, a 2μg Cy3-labelled cRNA sample was brought to a final volume of 20μl 
in nuclease-free water.  To this, blocking agent (11μl), fragmentation buffer (2.2μl) and 73 
 
nuclease free water (21.8μl) were added and the tube placed in a thermocycler for 30 
minutes at 60ºC.  The fragmentation process was stopped by the addition of 55μl of 2x 
GEx hybridisation buffer HI-RPM.  The sample was placed on ice until loading onto the 
array. 
 
Loading and hybridization 
The hybridisation chamber was assembled and the samples dispensed into the guides 
(gaskets) on the SureHyb gasket slide (Agilent).  The active array was aligned and 
lowered onto the gasket slide and the slides clamped together.  The assembled slide 
chambers were placed into a rotisserie in a hybridisation oven at 65oC.  Slides were 
rotated at 10rpm at 65oC for 17 hours.   
 
Washing of array slides 
Following incubation the hybridisation camber was disassembled and the array-gasket 
sandwich prised apart whilst submerged in wash buffer 1 (Agilent).  The microarray 
was placed in a slide rack and submerged in a beaker containing wash buffer 1 for 1 min 
at room temperature with constant stirring.  Following this, the array was transferred to 
a beaker containing wash buffer 2 (Agilent) for 1 min at 37oC with constant stirring.  
Following this wash, the array was transferred to a beaker containing acetonitrile at 
room  temperature  for  30  seconds.    The  slide  was  then  transferred  to  a  50ml  tube 
containing  stabilization  and  drying  solution  (Agilent)  for  30  seconds  with  gentle 
rocking.  The array was removed from this solution very slowly, placed on tissue and 
scanned immediately.   
 
Array scanning and analysis 
Arrays were scanned using the Agilent microarray scanner, at both a high (100) and a 
low (10) PMT setting to maximise data from both low and high end signals.  A 5m 
resolution was used, at which each 50m spot was comprised of approximately 100 
pixels.  The array images were visually checked for any obvious artefacts and the data 
was checked for quality using the QC software on the scanner.  Numerical expression 74 
 
data from each image was obtained using the feature extraction software and this data 
was loaded into GeneSpringGx v12.6 software (Agilent) for further analysis.   
 
2.11 Western blotting 
Electrophoresis 
Protein lysates were added to NuPAGE LDS sample buffer (Invitrogen, proprietary) 
and NuPAGE reducing agent (Invitrogen, proprietary), in deionised water.  Samples 
were heated to 70oC for 10 minutes in a block heater and then loaded (10 or 20l/lane of 
the gel) onto duplicate NuPAGE Novex 4-12% or 12% Bis-Tris gels (Invitrogen) in an 
XCell surelock mini cell filled with MOPS NuPAGE SDS running buffer (Invitrogen). 
NuPAGE antioxidant (500l) was added to the upper chamber.  Proteins were separated 
by electrophoresis at 200V constant for 50 minutes with a current of 100-125mA/gel.  
For  larger  proteins,  heated  samples  were  loaded  (10  or  20l/lane  of  the  gel)  onto 
duplicate NuPAGE Novex 3-8% Tris-Acetate gels (Invitrogen) in an XCell surelock 
mini  cell  filled  with  Tris-Acetate  SDS  running  buffer  (Invitrogen).  NuPAGE 
antioxidant  (500l)  was  added  to  the  upper  chamber.    Proteins  were  separated  by 
electrophoresis at 150V constant for 1 hour with a current of 40-55mA/gel. 
 
Total protein loading control  
Following  electrophoresis,  one  gel  was  stained  for  total  protein  to  act  as  a  loading 
control.  The gel was extracted from the casing, micro-waved in ultrapure water for 1 
minute (750watts) and cooled on a shaker for 1 minute.  The water was discarded and 
the process repeated twice.  Simply Blue total protein gel stain (25ml) (Invitrogen) was 
added  to  the  gel  and  micro-waved  for  1  minute  (750watts).    The  stain  was  left  to 
develop on a shaker for 5 minutes and then discarded.  The gel was then washed in 
ultrapure water for 10 minutes on an orbital shaker and the background removed by 
washing with 20ml of 20% NaCl (Sigma) in ultrapure water for 5 minutes.  The gel was 
left to soak in ultrapure water for 1 hour to clear excess background staining. 
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Blot 
The non-loading control gel was transferred by western blotting to a PVDF membrane.  
The Xcell II blot module was constructed to contain the electrophoresed gel and the 
PVDF membrane.  The blotting module was placed in the XCell sure lock mini cell tank 
(Invitrogen).  The upper chamber (covering the gel  and membrane) was  filled with 
NuPAGE  transfer  buffer  (Invitrogen  proprietary  recipe)  supplemented  with  10% 
methanol  and  0.1%  NuPAGE  antioxidant  and  the  outer  chamber  was  filled  with 
deionised water.  The transfer was performed using 30V constant for 1 hour.   
 
Protein visualisation  
To  visualise  proteins,  the  PVDF  membrane  was  first  immersed  in  blocking  buffer 
containing 0.1% TWEEN (Sigma) and 3% dried milk (Marvel) in PBS for 1 hour at 
room temperature.  The membrane was then incubated overnight with primary antibody 
diluted in  antibody dilution buffer (0.03% TWEEN and 1% dried milk  (Marvel) in 
PBS):  
 
  anti-human IL-18, mouse (1.0 mg/ml) (R&D systems) diluted 1:1000  
  anti-phospho p38 MAPK, mouse (2.1mg/ml) (Sigma) diluted 1:10000  
  anti-phospho ERK 1&2 MAPK, mouse (2.0mg/ml) (Sigma) diluted 1:10000  
  anti-phospho JNK MAPK, rabbit (cell signalling) diluted 1:1000  
  anti-phospho HSP27, rabbit (cell signalling) diluted 1:1000  
  anti-IB, mouse (cell signalling) diluted 1:1000  
  anti-phospho tyrosine, mouse (cell signalling) diluted 1:2000  
  anti-phospho EGFR, rabbit (R&D systems) diluted 1:2000  
  anti-actin, mouse (2.0mg/ml) (sigma) diluted 1:10000 
 
Following overnight incubation the membrane was washed three times for 5 minutes in 
PBS containing 0.1% Tween (Sigma).  The membrane was then incubated for 1 hour in 
secondary antibody diluted in antibody dilution buffer (0.03% TWEEN and 1% dried 
milk (Marvel) in PBS): 
  anti-mouse IgG HRP-conjugate (cell signalling) diluted 1:3000  
  anti-rabbit IgG HRP-conjugate (cell signalling) diluted 1:2000  76 
 
  anti-rabbit IgG HRP-conjugate (Invitrogen) diluted 1:3000  
  anti-mouse IgG HRP-conjugate (Dako) diluted 1:1000       
 
Following this, the membrane was washed 3 times for 5 minutes in PBS with 0.1% 
tween  and  rinsed  in  deionised  water  for  2  minutes.    Antibody  probed  bands  were 
visualised using the Sigma-Fast 3,3'-Diaminobenzidine tetrahydrochloride (DAB) and 
urea hydrogen peroxide tablets (Sigma) solubilised in ultrapure water.  Membranes were 
agitated in this solution until the bands became visible (approximately 6 minutes).  The 
membrane was then rinsed in sterile water and left to dry. 
 
2.12 Inhibition experiments 
HaCaT cells were plated out at 4x105cells/ml in 6 well plates (2ml/well). Following 1.5 
days in culture (or when reached 80% confluency) culture media was removed and the 
cells dosed with 2ml of the required concentration of inhibitor or culture media for 1 
hour: 
 
  SB203580 (p38 Inhibitor, Calbiochem) 1M - 25M 
  BAY 11-7082 (NF-B inhibitor, Calbiochem) 1M - 25M 
 
Following 1 hour in culture with inhibitor, 30M DNCB (in 0.15% DMSO) or 0.15% 
DMSO (as vehicle control) were added and cultured for an additional 4 hours.  As 
positive controls, 20ng/ml TNFfor NF-B) or 20ng/ml IL-1 (for p38MAPK) were 
added for 4 hours or 30 minutes respectively.  After incubation the supernatant was 
removed and frozen at -80oC (for cytokine analysis) and the RNA extracted (see section 
on RNA extraction).  
 
2.13 Detection of phosphorylated kinases 
HaCaT cells were plated out at 4x105cells/ml in 6 well plates (2ml/well).  Following 2 
days in culture (or when reached 80% confluency) culture media was removed and the 
cells  dosed with  2ml of 20M -  32.5M  DNCB, 200M - 500M  SDS  or vehicle 
control (0.2% DMSO)  in culture media,  LPS or IFNand  incubated for  30 min, 1, 4, 77 
 
8 or 24hrs.   Following incubation, the supernatant was removed for cytokine analysis.  
The cells and reagents were kept on ice during lysis.  Cells were washed  in ice cold 
wash buffer (2ml) (Bio-Rad), then lysed  in 0.7ml/well lysis solution containing 9.9ml 
cell lysis buffer (BioRad), 40l factor 1, 20l factor 2 and 40l of 500mM PMSF (from 
frozen).  Cells were scraped on ice in lysis buffer using a cell scraper, then agitated at 
300rpm for 20mins at 4oC.  Cell lysates were collected and centrifuged at 4500 x g for 
20  mins  at  at  4oC.    The  supernatants  were  collected  and  the  protein  concentration 
determined using the Bio-Rad DC protein assay.  A standard curve was created using 
BSA (2mg/ml) serially diluted in lysis buffer (described previously).  Samples were also 
prepared neat and diluted 1:2.  5μl of standards or samples were aliquoted into a 96 well 
plate, to which 25μl of reagent A’ (containing 20μl of reagent S to each ml of reagent 
A) was added.  Following this, 200μl of reagent B were added into each well.  After 15 
minutes, absorbance was read at 750 nm and lysate protein concentration determined 
using the standard curve.  
 
Phosphorylated signalling protein assay 
The following proteins from the Bio-Plex phosphoproteins and total target assay (Bio-
Rad) were analysed using the Luminex 200IS (Luminex): 
 
Total protein (10):  Phosphorylated protein (17): 
Akt   Akt 
c-Jun  c-Jun 
CREB  CREB 
ERK1/2  ERK1/2 
HSP27  HSP27 
IB  IB 
JNK  JNK 
MEK-1  MEK-1 
p38 MAPK  p38 MAPK 
p90 RSK  p90RSK 
  p70 
  Histone H3 78 
 
  Src 
  STAT3 (Tyr 705) 
  STAT6 
  TrkA 
  Tyk2 
 
 
The following control lysates were used: 
 
Lysate  Phospho-specific targets 
EGF-treated 
HEK293 
Akt (Ser473), ERK1(Thr202/Tyr204), ERK2 
(Thr185/Tyr187), ERK1/2 (Thr202/Tyr204, 
Thr185/Tyr187), GSK-3/ (Ser21/Ser9), MEK1 
(Ser217/Ser221)  
EGF-treated HeLa  EGFR (Tyr), HSP27 (Ser78), S6 ribosomal protein 
(Ser235/Ser236) 
IFN--treated HeLa  STAT2 (Tyr689), STAT3 (Tyr705), STAT3 (Ser727) 
IL-4-treated HeLa   STAT6 (Tyr641) 
NGF-treated PC12  IRS-1 (Ser636/Ser639), p70 S6 kinase (Thr421/Ser424), 
p90RSK (Thr359/Ser363), TrkA(Tyr490) 
TNF--treated HeLa  IB- (Ser32/Ser36), NF-B p65 (Ser536) 
UV-treated HEK293  ATF-2 (Thr71), c-Jun (Ser63), CREB (Ser133), JNK 
(Thr183/Tyr185), p38MAPK (Thr180/Tyr182), p53(Ser15) 
Phosphotase-treated 
HeLa 
Background control for all phosphoprotein assays 
Untreated HeLa  Positive control for all total target assays except p53 and 
Bcr-Abl 
 
Experimental and control lysates were thawed from –20ºC storage and an equal volume 
of assay buffer added to the experimental lysates.    The 96-well filter plate was washed 
by adding 100l wash buffer to each well.  The buffer was then removed by vacuum 
filtration  and  the  bottom  of  the  plate  blotted  dry.    Coupled  beads  (premixed)  were 
prepared by vortexing and diluting 1:50 in wash buffer.  50µl of diluted beads were 79 
 
added to each well and immediately vacuum filtered.  The beads were then washed 
twice using 100l wash buffer.  The lysates were the vortexed and added (50µl each) to 
the specified well.  The lysates were incubated with the beads overnight (approximately 
18hrs) at room temperature in the dark on a microplate shaker at 300rpm.  Following 
incubation, the liquid was removed by vacuum filtration and the plate washed 3 times 
with 100l wash buffer.  Detection antibodies were diluted 1:25 in detection antibody 
diluent  and  25l  added  to  each  well.    These  were  then  incubated  for  30  minutes 
following which the plate was vacuum filtered and washed a further 3 times with 100l 
wash buffer.  Streptavidin-PE was diluted 1:100 in wash buffer and 50l were added to 
each well.  This was incubated for 10 minutes and then filtered through the plate.  The 
plate was then rinsed 3 times in 100l of re-suspension buffer.  The beads were then re-
suspended  in  125l  of  re-suspension  buffer  and  analysed  using  the  Luminex  200IS 
system.        
 
2.14 Confocal microscopy NF-B  
NF-B  nuclear  translocation  was  measured  using  quantitative  image  analysis 
(Noursadeghi et al, 2008).  HaCaT cells were plated out onto sterile glass cover slips in 
24 well plates at 4x105cells/ml (1ml/well).  Following 1 day in culture (or when reached 
80% confluency) the culture media was removed and the cells dosed with 1ml of the 
required concentration of DNCB, SDS, LPS or vehicle control in culture media.  Cells 
were  incubated  for  1  hour  or  2  hours.    Following  incubation,  culture  media  was 
aspirated  and  the  cells  were  fixed  in  3.7%  wt/v  paraformaldehyde  in  TBS  for  15 
minutes.  Following this, cells were washed 3 times with TBS.  The cells were then 
permeabilised with permeabilisation buffer 0.2% Triton-X100 in TBS for 10 minutes at 
room temperature and washed again 3 times in TBS.  Cells were then incubated with 
blocking buffer (10% normal goat serum in TBS) for 30 minutes at room temperature.  
The blocking buffer was then removed and primary antibody Rabbit anti-NF-κB p65 
(Santa Cruz sc-372) used at 1/50 in blocking buffer added and left overnight at 4°C.  
The following day, antibody was removed and the cells  washed 3 times with TBS.  
Secondary antibody Goat  anti-Rabbit AF-633 (Invitrogen A21072) used at  1/500  in 
blocking buffer was added for 1h at room temperature.  Following 1 hour incubation, 
secondary antibody was removed and the cells washed 3 times with TBS.  Cells were 80 
 
then incubated with DAPI (2 μg/ml in TBS) for 5 minutes followed by 3 washes with 
TBS.  Cover slips were then mounted in mounting solution (Vectashield hard set) and 
stored at 4°C in the dark until analysis by confocal microscopy.  
 
2.15 Detection of Intra-cellular Reactive Oxygen Species (ROS) 
HaCaT  cells  were  plated  in  96-well  collagen-I  coated  microplates  (BD  BioCoat® 
Collagen-I Cellware) at a density of 8x104cells/ml  in  100µl  per well and incubated 
overnight at 37oC with 5% CO2.  Cells were then dosed with between 2.5M and 40M 
DNCB (or positive control between 1.8M and 29M Menadione) for 24 hours.  After 
24 hours, 50μl of pre-warmed Staining Solution (2.8µl of 1mg/ml Hoechst dye and 
86.5µl of 1000µM chloromethyl-dihydrodichlorofluorescein diacetate (cm-H2DCFDA) 
probe (Life Technologies) in 5.5ml of pre-warmed culture media) was added to each 
well  and  incubated  for  30  minutes  in  the  dark  at  room  temperature.    Following 
incubation, 100µl of pre-warmed Fixation Solution (1.6ml 37% Formaldehyde solution 
to 4.4ml PBS) was added.  The plate was then incubated for 30 minutes in the dark at 
room temperature.  Following incubation, the fixation solution was removed and the 
cells washed with 100µl of PBS.  The PBS was then removed and 200l PBS added and 
the plate sealed.  The  plate was analysed using the Cellomics  Array  Scan V using 
Target Activation BioApplication software. 
 
2.16 Peripheral blood mononuclear cell - dendritic cells (PBMC-DC) 
This experiment was conducted under a study approved by the joint University College 
London/University College London Hospitals National Health Service Trust Research 
Ethics Committee and written informed consent obtained from the blood donor.  
 
Human blood (100ml) was diluted in HBSS (60ml), layered onto Lymphoprep (Axis-
Shield) and centrifuged at 800 x g (without brake) for 20 minutes at room temperature.  
Peripheral  blood  mononuclear  cells  (PBMCs) were obtained  from  the interphase by 
pipetting,  and  washed  3  times  in  HBSS  (Gibco).    Monocytes  (CD14+  cells)  were 
isolated from PBMCs by magnetic positive selection with CD14 micro-beads using the 
MACS™  separator  according  to  manufactures  instructions  (Miltenyi  Biotec).    The 
resultant  monocytes  were  maintained  at  1x106  cells/ml  in  RPMI-1640  medium 81 
 
containing 100ng/ml Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) 
and 50ng/ml Interleukin-4 (IL-4) (both gifts from Schering-Plough research institute, 
Kenilworth NJ) at 37oC in 5% CO2.  Following 2 days in culture, the cells were re-fed 
by replacing half the media with fresh media containing GM-CSF and IL-4. After 4 
days  in  culture,  the  PBMC-immature  dendritic  cells  were  exposed  to  either;  0.15% 
DMSO  (vehicle  control),  100ng/ml  LPS  (E.coli  O111:B4,  Invitrogen),  or  filtered 
conditioned  media  (from  HaCaTs  previously  exposed  to  various  concentrations  of 
DNCB, SDS or DMSO).  The conditioned media were diluted 1:2 in RPMI without 
cytokines and the cells cultured for 20hrs.  
  
2.17 Flow Cytometry 
Following incubation, the supernatants were removed by centrifugation and the PBMC-
DCs were blocked for 1hr at 4oC in blocking buffer (HBSS containing 10% goat serum 
and  0.05%  sodium  azide).    Cells  were  then  stained  for  30  minutes  at  4oC  in  50l 
blocking buffer containing:  
  CD83 (FITC) IgG1 (HB15e, BD Biosciences) diluted 1:20  
  CD86 (PE) IgG1 (2331 FUN-1, BD Biosciences) diluted 1:50 
  DC-SIGN (APC) IgG2b (DCN46, BD Biosciences) diluted 1:50 
  or matched isotope controls (IgG1 and IgG2b) (BD Biosciences) diluted 1:50 
 
Following incubation with antibodies, the cells were washed twice with HBSS and re-
suspended in 100l of HBSS containing 1% BSA and 0.05% sodium azide.  Propidium 
iodide (2l) was added and the cells analysed using a FACSCalibur (BD Biosciences).  
The flow cytometery data were analysed using FlowJo 8.0 (Tree Star).   
 
2.18 Statistical analysis 
One way analysis of variance (ANOVA) with Dunnett’s multiple correction post hoc 
test was used to analyse cytokine release data.  One way analysis of variance (ANOVA) 
with Tukey’s multiple correction post hoc test was used for the analysis of real time 
PCR data.  All statistical analysis (with the exception of the microarray data) was done 
using GraphPad Prism v 5.0 software.  
 82 
 
3  KERATINOCYTE MODEL SELECTION AND PRODUCTION OF 
INFLAMMATORY/IMMUNOMODULATORY CYTOKINES 
 
3.1 Introduction  
 
Cytokines and chemokines are small protein mediators critical for the orchestration of 
immune responses through their influence on cellular communication and movement.  
Keratinocytes play a role in the initiation and elicitation of cutaneous immune responses 
by expressing many cytokines, such as IL-1 (Luger et al, 1981; Ansel et al, 1983; 
Phillips et al, 1995), IL-1Kupper et al, 1986; Zepter et al, 1997), IL-1RA (Haskill et 
al, 1991; Phillips et al, 1995; Bigler et al, 1992), IL-6 (Kupper et al, 1989; Khan et al, 
1993; Ishimaru et al, 2013), IL-7 (Ariizumi et al, 1995), IL-8 (Larsen et al, 1989; Li et 
al, 1996; Barker et al, 1990; Andrew et al, 1999), TNF-Kock et al, 1990), IL-10 
(Rivas and Ullrich, 1992), IL-12 (Aragane et al, 1994; Yawalkar et al, 1996), IL-15 
(Blauvelt et al, 1996), IL-18 (Stoll et al, 1997; Naik et al, 1999), IL-23 (Larsen 2009) 
and IL-33 (Meephansan et al, 2012; Taniguchi et al, 2013), IFN(Fujisawa et al, 
1997), chemokines, such as MCP-1 (Barker et al, 1990, 1991) and RANTES (Li et al, 
1996) and growth factors such as TGF (Coffey et al, 1987), TGF (Bascom et al, 
1989), VEGF (Trompezinski, 2004) and GM-CSF (Pastore et al, 1997; Kupper et al, 
1988).   
 
In response to pathogens, the cytokine signature produced by keratinocytes is complex, 
varying between different pathogens, species and strata of the epidermis.  Following 
viral infection, keratinocytes have been shown to produce interferons ,  and as well 
as pro-inflammatory cytokines IL-1, IL-18, TNF and GM-CSF (Surasombatpattana 
et al, 2011; Reinholz et al, 2013; Shao et al, 2010).  Keratinocyte cytokine profiles have 
been shown to differ between different species of fungus  (Shiraki et al, 2006), and 
strains of Malassezia (Donnarumma et al, 2014), indicating that cytokine responses can 
vary  significantly  between  different  pathogens.    The  differentiation  state  of 
keratinocytes  also  appears  to  influence  their  capacity  for  cytokine  production,  as 
bacterial  stimuli  have  been  shown  to  induce  antimicrobial  peptides  and  pro-83 
 
inflammatory cytokines, the levels of which differed between the stratum basale and 
stratum granulosum in human skin (Percoco et al, 2013).   
Cutaneous  immune  responses  to  chemical  allergens  have  also  stimulated  detectable 
levels of cytokines and chemokines in the epidermis: IL-1Enk and Katz 1992a/c., 
Haas  et  al,  1992),  IL-1  (Enk  and  Katz  1992a/c),  IL-6  (Cumberbatch  et  al,  1996; 
Holliday et al, 1996; Flint et al, 1998), IL-10 (Enk and Katz 1992b; Nickoloff et al, 
1994), IL-12 (Muller et al, 1994), IL-18 (Stoll et al 1997), IFN(Enk and Katz 1992a), 
TNF (Piguet et al,1991., Haas et al, 1992; Flint 1998; Enk and Katz 1992a/c), IP-10 
(Enk and Katz 1992a/c),  MIP-2 (Enk and Katz 1992a/c) and GM-CSF (Enk and Katz 
1992a/c).  However, in many studies it was not possible to identify which skin cell type 
is responsible for the production of each cytokine.  In response to chemical allergens, 
keratinocytes specifically have been shown to transcribe or release IL-1Corsini 1998, 
Curtis et al, 2007; Coquette et al, 2003; Newby et al, 2000), IL-1 (Zepter, 1997), IL-8 
(Newby et al, 2000, Coquette et al, 2003; Mohamadzadeh, 1994), IL-18 (Stoll et al 
1997; Naik et al, 1999), IL-23 (Larsen et al, 2009) and TNF (Newby et al, 2000). 
 
Numerous cytokines are involved in orchestrating cutaneous immune responses.  IL-1, 
IL-18 and TNF have been shown to be critical for Langerhans cell (LC) migration in 
contact hypersensitivity (Cumberbatch et al, 1995, 1997, 2001; Shornick et al, 2001), 
while IL-10 inhibits this process (Wang et al, 1999).  The combined effect of these 
signals causes down-regulation of E-cadherin and dissociation of LC from neighbouring 
keratinocytes (Jakob and Udey, 1998).  Following detachment, migration out of the 
epidermis  is  driven  by  a  CXCL12  chemokine  gradient  originating  from  dermal 
fibroblasts and signalling via CXCR4 on LC (Ouwehand et al, 2008).  CCR7 is up-
regulated upon  LC/DC maturation (Saeki et  al, 1999; Forster et al, 1999), allowing 
movement towards CCL19 and CCL21 (Ohl et al, 2004; Saeki et al, 1999; Gunn et al, 
1999; Haessler et al, 2011), which originate from the lymphatics (Gunn et al, 1998).  
During migration, LCs mature to an activated phenotype characterised by a transient 
increase  in  antigen  processing,  and  up-regulation  of  MHCII  and  co-stimulatory 
molecules, for efficient antigen presentation.  Co-stimulatory/adhesion molecules, e.g. 
CD83, CD86 and CD54, have been shown to be up-regulated by cytokines, for example 
IL-1 (Matjeka et al, 2012).   
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In the lymph node, activated DCs release cytokines that influence T cell differentiation 
to determine the type of response, e.g. IL-12 released from DCs has been demonstrated 
to  stimulate  naïve  CD4+  T  cells  to  differentiate  into  Th1  cells  (Hsieh  et  al,  1993; 
Manetti et al, 1993), while TGF, IL-6, IL-21 skewed differentiation to Th17 (Veldhoen 
et al, 2006; Zhou et al, 2007; Korn et al, 2007).  Recently, a skin-homing Th22 cell 
population  has  been identified (Trifari et  al,  2009;  Duhen et  al,  2009), which were 
generated from interactions with DCs expressing IL-6 and TNF (Duhen et al, 2009).  
The T cell polarisation cytokines released by a DC population may be determined by 
the cytokine environment  in  which the DCs encountered antigen, as  well as  by the 
nature of the antigen.   
 
Elicitation of CHS to chemical allergens has been shown to be driven by CD4+ Th1, 
CD8+ type 1 cytotoxic T cells (Wang et al, 2000), CD4+ Th17 (Larsen et al, 2009; 
Pennino et al, 2010), and NK cells (Carbone  et al, 2010), as  well as infiltration of 
macrophages and neutrophils (Goebeler 2001).  T cells home to the skin in response to 
CCL27 (CCR10), CCL17 and CCL22 (CCR4)  (Reiss et al, 2001; Hudak et al, 2002, 
Morales et al, 1999; Homey et al, 2002).  Other immune cells migrate in response to 
chemokines  produced  by  keratinocytes  such  as  MCP-1,  RANTES  (Goebeler  2001), 
CXCL10 (IP-10), CXCL9 (MIG) and CXCL11 (ITAC) (Klunker et al, 2003).  In human 
skin  biopsies  from  patch  test  positive  sites  (during  elicitation)  to  various  allergens, 
IFN, IL4, IL-17 and IL-23 all showed increased expression (Zhao et al, 2009).   
 
In  vitro  systems  have  some  advantages  over  ex  vivo  skin  tissue  for  investigating 
cytokine expression by keratinocytes.  They are based on a single cell type, compared to 
the  mixed  cell  population  in  skin.    It  is  also  technically  more  feasible  to  measure 
cytokines quantitatively in vitro, because in skin they are difficult to extract and short-
lived due to receptor binding.  3D reconstructed human epidermis (RHE) cultures have 
been developed to provide stratified keratinocyte models that are similar to epidermis in 
vivo  (Ponec  et  al,  2003;  Poumay  et  al,  2004).      These  systems  have  been  used  to 
measure irritancy in standard toxicological testing by MTT and IL-1 (Spielmann et al, 
2007), and in assay development for biomarkers to assess skin sensitisation potential, 
such as IL-1 (dos Santos et al, 2011), IL-1 and IL-8 (Coquette et al, 2003; Poumay et 85 
 
al, 2004; Spiekstra et al, 2009), IL-8, CCL20 and CCL27 (Spiekstra et al, 2005), and a 
panel of genes (McKim et al, 2012).   
 
In  this  chapter  we  will  investigate  cytokine  responses  to  DNCB  in  vitro  and  their 
association with death, and characterise the use of 3D skin models for investigating the 
response. 
 
The  aims  of  this  chapter  are  to:  characterise  keratinocyte-derived  inflammatory 
mediator production in response to chemical allergen; understand the kinetics of DNCB 
induced  inflammatory  mediator  release,  its  relationship  with  cytotoxicity  and  the 
kinetics of mediator gene expression; and determine the optimum in vitro model to 
study the response of keratinocytes to chemical allergen  
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3.2 Results 
Morphology of the EpiDermTM and EpiDermFTTM models 
EpiDermTM and EpiDermFTTM models were fixed and stained using haematoxylin and 
eosin  (H&E).    The  EpiDerm  models  (Figure  3-1a  and  3-1b)  comprise  stratified, 
differentiated keratinocytes forming clear stratum: basale; spinosum; granulosum and 
corneum.    Keratohyalin  granules  are  also  evident  in  the  stratum  granulosum.    The 
stratification of the keratinocytes in the EpiDerm model is well defined and represents 
an accurate model of keratinocyte differentiation in human skin.               
 
The EpiDermFT models (Figure 3-2) were also characterised by H&E staining.  These 
models had a very deep dermal fibroblast layer, which appeared viable except at the 
base of the dermis (Figure 3-2a).  The epidermal keratinocytes in these full thickness 
models  did  not  retain  the  viable,  differentiated  strata  (Figure  3-2b)  seen  in  the 
keratinocyte only model (Figure 3-1c).  This model has a much denser stratum corneum 
than  expected,  potentially  over-developed  due  to  a  lack  of  viable  suprabasal 
keratinocytes.  The dermal epidermal junction (DEJ) is also clearly split.  The models 
exposed to 750M DNCB for 24 hours also had split DEJ (Figure 3-2c) and a dense 
stratum  corneum.    In  response  to  DNCB  the  basal  keratinocytes  appear  pyknotic 
indicating these cells are undergoing apoptosis (Figure 3-2d).   
 
A comparative study of cytokine, chemokine and growth factor production by 
HaCaT, EpiDerm and EpiDermFT models 
HaCaT cells, EpiDerm and EpiDermFT models were exposed to DNCB or SDS. 1g/ml 
LPS combined with 1g/ml IFN, a strong pro-inflammatory stimulus, was also tested 
to provide a positive control for cytokine release.  Cells were exposed for 1, 4 (data not 
shown) or 24 hours and the release of 31 different cytokines was measured by multiplex 
ELISA.  Figure 3-3 summarises the cytokines and chemokines that could be detected in 
the supernatant from these models, both constitutively and in response to DNCB or SDS 
or in response to LPS and IFN.  
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a 
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Figure 3-1 Morphology of the EpiDerm models 
The EpiDerm models were stained with H&E and overall structure examined at x10 
magnification (a) and x40 magnification (b).  Stratum corneum, stratum granulosum 
(containing  keratohyalin  granules),  stratum  spinosum  and  stratum  basale  were  all 
evident.     
 
 
 
 
Keratohyalin 
granules 
Stratum  
corneum 
Stratum  
granulosum 
Stratum  
spinosum 
Stratum 
 basale 88 
 
 
Control          DNCB 
a             c 
 
 
 
 
 
 
 
 
 
 
 
b             d 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2 Morphology of EpiDermFT models 
The morphology of the EpiDermFT model was assessed by H&E staining.  Histological 
examination of untreated control models: x10 magnification (a) x40 magnification (b) 
and  models  exposed  to  750M  DNCB  for  24  hours:  x10  magnification  (c)  x40 
magnification (d) show them to be compromised.  Both control and treated models have 
a  deep  dermal  layer,  a  split  dermal-epidermal  junction  (DEJ)  and  dense  stratum 
corneum.  The DNCB treated models have pyknotic basal keratinocytes.  
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It is possible that some of the cytokines that weren’t identified were present but under 
the level of detection of this technology (e.g. TNF).  There is some overlap in the 
cytokines produced in the HaCaT cells and EpiDerm models; however a much larger 
number of cytokines, chemokines and growth factors were detected in the EpiDermFT 
models.    Many  of  the  cytokines  detected  were  also  present  at  much  higher 
concentrations in the media from the EpiDermFT models compared with the EpiDerm 
or HaCaT models.  IL-1 could only be detected in media from HaCaT cells following 
total cell death (e.g. when they were snap frozen – data not shown). 
 
Each of the models was able to respond to LPS and IFN by inducing production and 
release of a number of cytokines.  In the HaCaT cells (Figure 3-4a), FGF-basic, GCSF, 
HGF,  IFN  IL-10,  IL-1ra,  IL-2,  IL-2R,  IL-6,  IL-7,  IP-10,  MCP-1,  MIG,  MIP-1, 
RANTES  and  VEGF  were  all  induced  in  response  LPS  and  IFNcompared  with 
controls.  The levels of IL-8 however decreased slightly in response to LPS and IFN  
 
In  the  EpiDerm  (keratinocyte  only)  models,  13  cytokines  were  induced  following 
exposure to LPS and IFN(Figure 3-4b).  These were FGF-basic, GCSF, IL-17, IL-1ra, 
IL-2R,  IL-7,  IL-8,  IP-10,  MCP-1,  MIG,  RANTES,  VEGF  and  IL-1  In  the 
EpiDermFT (keratinocyte and fibroblast) model, Eotaxin, FGF-basic, IFN, IL-12, IL-
17, IL-1ra IL-2R, IL-7, MIG, MIP-1, RANTES, VEGF, IL-1, IP-10, HGF, MCP-1, 
and GCSF were all induced following exposure to LPS and IFN (Figure 3-4c).  GM-
CSF,  IL-6  and  IL-8  were  also  detectable  in  the  culture  media,  however  the  levels 
appeared unchanged in response to LPS and IFN (compared with vehicle controls).   
 
Figures  3-5  and  3-6  show  overviews  of  the  cytokine  responses  of  HaCaT  cells, 
EpiDerm and EpiDermFT models in response to DNCB and SDS respectively.  The 
cytokine data for HaCaTs and EpiDerm is explored in more detail below.  
 
Figure 3-7 shows how 3 cytokines IL-1ra, IL-6 and IL-8 are expressed in response to 
DNCB, SDS, LPS and LPS and IFN.  DNCB stimulates greater expression of all three 
cytokines compared to the other stimuli. 
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Figure 3-3 Cytokine production in response to stimulation with DNCB, SDS, LPS 
and IFN 
Culture  supernatant  was  collected  from  HaCaT,  EpiDerm  and  EpiDermFT  models 
following 24 hour culture with DMSO vehicle control (a), all concentrations of DNCB 
(b), 1g/ml LPS and IFN (c) or all concentrations of SDS (d).  The supernatants were 
assayed for release of 31 different mediators by ELISA.  The Venn diagram indicates 
mediators that could be detected in each model (EpiDerm cultures were not tested with 
SDS). 
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Figure 3-4 Cytokine production in response to stimulation with LPS and IFN 
HaCaT  cells  (a),  EpiDerm  (b)  and  EpiDermFT  models  (c)  were  exposed  to  culture 
media control (empty bars) or 1g/ml LPS and IFN (filled) for 24 hours.  Supernatants 
were assayed for release of soluble mediators into the media by ELISA.  The graph 
shows mean and SD for three experiments.    
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Figure 3-5  Cytokine production in response to stimulation with DNCB 
HaCaT cells (a), EpiDerm (b) and EpiDermFT models (c) were exposed to 0.2% DMSO 
(empty bars) or DNCB for 24 hours.  Supernatants were assayed for release of soluble 
mediators  into  the  media  by  ELISA.    The  graph  shows  mean  and  SD  for  three 
experiments.   
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Figure 3-6  Cytokine production in response to stimulation with SDS 
HaCaT cells (a and b) and EpiDermFT models (c) were exposed to 0.2% DMSO (empty 
bars) or SDS for 24 hours.  Supernatants were assayed for release of soluble mediators 
into the media by ELISA.  The graph shows mean and SD for three experiments.  IL-6 
and IL-8 levels from EpiDermFT (c) were greater than the limit of detection (LOD). 
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Figure 3-7  Comparison of cytokine production from different stimuli 
HaCaT cells were exposed to meida (control), 0.2% DMSO, DNCB, SDS, 1g/ml LPS 
or 1g/ml LPS and IFN for 24 hours.  Supernatants were assayed for release of IL-6, 
IL-8 or IL-1ra into the media by ELISA.  The graph shows mean and SD for three 
experiments.   
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HaCaT viability in response to DNCB and SDS 
The ability of HaCaT cells to reduce MTT was used as an assessment of viability in 
response to DNCB and SDS.  HaCaTs were exposed to a range of concentrations of 
DNCB or SDS for 24 hours before addition of MTT (Figure 3-8a).  The concentration at 
which 50% cell death occurred was approximately 30M DNCB and between 250 and 
500M SDS. 
 
EpiDerm viability in response to DNCB and SDS 
EpiDerm models from 3 different keratinocyte donors were topically exposed to SDS, 
DNCB or 0.2% DMSO (vehicle control) for 1, 4 (data not shown due to no change in 
cell viability) or 24 hours.  Model viability was measured by LDH leakage (for DNCB) 
in order for the tissue to be utilised in histological examination, or MTT (for SDS) 
(Figure 3-8b).  Following 24 hour exposure to 500M DNCB, the EpiDerm models 
were 60% viable compared with vehicle control treated models.  The concentration at 
which  50%  cell  death  occurred  was  approximately  3.5mM  for  SDS.    The  error 
represented on this graph was intra-donor, as the viability of each chemical exposed 
model was compared to its donor matched control.  Variation was substantially larger 
between donors. 
 
EpiDermFT viability in response to DNCB and SDS 
After exposure of the EpiDermFT models to the same DNCB concentrations as those 
used  for  the  EpiDerm  model,  no  cell  death  could  be  detected  (data  not  shown).  
Following extensive optimisation of the level of DMSO required for adequate model 
penetration, it was speculated that a lack of cell death seen in the EpiDermFT models 
was due to reduction of MTT by the fibroblasts in the dermal layer.  This was confirmed 
by splitting the dermal  and epidermal layers after exposure to chemicals but before 
MTT assay.  In response to DNCB in 0.4% DMSO one donor (Figure 3-8c) showed a 
cytotoxic response to DNCB.  The dose response for cytotoxicity begins at a lower 
concentration in the epidermal layer compared with the dermal layer, perhaps due to 
chemical penetration through the layers.  At low concentrations of chemical there is an 
increase in MTT activity compared with vehicle controls.  However, two subsequent 
donors did not show any signs of cytotoxicity in the epidermis or dermis (data not 96 
 
shown).  EpiDermFT models were also exposed, topically, to 0.04-40mM SDS or 0.2% 
DMSO (vehicle control) for 24 hours.  The ability of the models to reduce MTT was 
measured as an assessment of viability (Figure 3-8c).  For SDS one donor is shown 
which is representative of all three donors.  The concentration at which 50% cell death 
occurs following exposure to SDS was at a concentration between 4 and 10mM.  
 
EpiDerm models show minimal changes in cytokine release in response to DNCB 
The  release  of  cytokines  into  the  culture  supernatant  by  EpiDerm  models  topically 
exposed to DNCB or 0.2% DMSO (vehicle control) for 1, 4 or 24 hours was measured.  
Only 5 out of 31 soluble mediators could be detected from EpiDerm media; these were 
IL-1, IL-1ra, IL-8, MCP-1 and VEGF.  All five were detected even in the absence of 
chemical.  Following exposure to DNCB for 1 or 4 hours the concentrations of these 
factors in the supernatant remained unchanged (data not shown).  Following 24 hour 
exposure  to  DNCB  (Figure  3-9),  there  was  a  tendency  for  IL-1  and  IL-1RA 
concentrations  to  increase  as  concentration  of  chemical  increased,  and  viability 
decreased.   In contrast, the concentrations  of  MCP-1 and  IL-8 increased slightly  at 
250M,  but  decreased  below  background  levels  at  500M.    The  concentrations  of 
VEGF fell sharply and significantly (p<0.01) following exposure to 500M DNCB.  
The inter-donor variability for these cultures was very high, and hence it was difficult to 
demonstrate statistical significance for these changes.   
 
 97 
 
HaCaTs DNCB
0 10 20 30 40 50
0
50
100
150
DNCB [M]
%
 
v
i
a
b
l
e
HaCaTs SDS
0 200 400 600
0
50
100
150
SDS [M]
%
 
v
i
a
b
l
e
EpiDerm DNCB
0 200 400 600
15
40
65
90
115
DNCB [M]
%
 
v
i
a
b
l
e
a
b
c
EpiDermFT DNCB
0 500 1000 1500 2000 2500
0
25
50
75
100
125
150
175
Epidermis
Dermis
DNCB [M]
%
 
v
i
a
b
l
e
EpiDermFT SDS
0 10000 20000 30000 40000 50000
0
25
50
75
100
125
150
Epidermis
Dermis
SDS [M]
%
 
v
i
a
b
l
e
EpiDerm SDS
0 20000 40000 60000 80000
15
40
65
90
115
SDS [M]
%
 
v
i
a
b
l
e
 
Figure 3-8 Cytotoxicity in response to stimulation with DNCB or SDS 
HaCaT cells (a), EpiDerm (b) and EpiDermFT models (c) were cultured in the presence 
of a range of concentrations  of DNCB or SDS for 24 hours  (0M  =  0.2% DMSO 
vehicle control). The ability of the cells to reduce MTT or release LDH (EpiDerm with 
DNCB) was measured as an assessment of viability.  The graph shows mean and SD for 
three experiments.  The EpiDerm SDS graph (b) was generated from data provided by 
Samantha Fletcher.  98 
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Figure 3-9 Cytokine release from EpiDerm following exposure to DNCB 
EpiDerm models were cultured in the presence of a range of concentrations of DNCB 
(0M=  0.2%  DMSO  vehicle  control)  for  24  hours.    Supernatants  were  assayed  for 
release  of  soluble  mediators  by  ELISA.    The  graph  shows  mean  and  SD  for  three 
experiments (3 different donors). Statistical analysis: One way ANOVA with post-test 
Dunnett’s multiple comparison test *p<0.05, **p<0.01, ***p<0.001. 99 
 
Cytokine release is amplified in HaCaT cells following exposure to DNCB 
compared with SDS 
Due to the high donor variability in cytokine production seen in the EpiDerm models 
(and the histological analysis of the EpiDermFT models), the release of cytokine into 
the  culture  supernatant  by  HaCaT  cells,  exposed  to  a  range  of  DNCB  and  SDS 
concentrations for 24 hours, was measured.   
 
Out  of  the  31  cytokines  and  chemokines  measured,  only  7  could  be  consistently 
detected in the HaCaT media in response to vehicle control, DNCB or SDS.  These 
included three cytokines seen in the EpiDerm model (IL-1ra, IL-8 and MCP-1) and 
additionally IL-1, IL-6, GM-CSF and RANTES.  VEGF was detected inconsistently 
and  varied  with  different  batches  of  antibodies  (Invitrogen).    IL-1  could  only  be 
detected following total cell death in response to snap freezing (data not shown).  
 
At  high  (cytotoxic)  concentrations  of  either  DNCB  or  SDS,  there  was  a  strong 
inhibition of release of all mediators except IL-1ra, which was increased in the presence 
of DNCB (Figures 3-10, 3-11 and 3-12).  In contrast, intermediate doses of DNCB, but 
not  SDS  stimulated  significant  increase  in  the  release  of  IL-1ra,  IL-6,  IL-8  and 
RANTES (Figures 3-11 and 3-12).  Interestingly the dose response profiles for each 
mediator were slightly different.   
 
In summary HaCaT cells responded to subtoxic concentrations of the sensitiser DNCB 
by  the  release  of  the  inflammatory  mediators  IL-6,  IL-8  and  RANTES,  and  by  the 
release of the anti-inflammatory mediator IL-1ra.     
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Figure 3-10 MCP-1 production in response to DNCB and SDS 
HaCaT  cells  were  cultured  in  the  presence  of  a  range  of  concentrations  of  DNCB 
(filled)  or  SDS  (empty)  for  24  hours  (0M  =  0.2%  DMSO  vehicle  control).  
Supernatants were assayed for release of MCP-1 by ELISA.  The graph shows mean 
and SD for three experiments.  Statistical analysis: One way ANOVA with post-test 
Dunnett’s multiple comparison test *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3-11 IL-1ra and RANTES production in response to DNCB and SDS 
HaCaT  cells  were  cultured  in  the  presence  of  a  range  of  concentrations  of  DNCB 
(filled)  or  SDS  (empty)  for  24  hours  (0M  =  0.2%  DMSO  vehicle  control).  
Supernatants were assayed for release of IL-1ra (a) and RANTES (b) by ELISA.  The 
graph  shows  mean  and  SD  for  three  experiments.      Statistical  analysis:  One  way 
ANOVA  with  post-test  Dunnett’s  multiple  comparison  test  *p<0.05,  **p<0.01, 
***p<0.001. 
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Figure 3-12 IL-6 and IL-8 production in response to DNCB and SDS 
HaCaT  cells  were  cultured  in  the  presence  of  a  range  of  concentrations  of  DNCB 
(filled)  or  SDS  (empty)  for  24  hours  (0M  =  0.2%  DMSO  vehicle  control).  
Supernatants were assayed for release of IL-6 (a) and IL-8 (b) by ELISA.  The graph 
shows mean and SD for three experiments.  Statistical analysis: One way ANOVA with 
post-test Dunnett’s multiple comparison test *p<0.05, **p<0.01, ***p<0.001 
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IL-1 IL-6, IL-8 and GM-CSF release from HaCaT cells in response to DNCB is 
dependent on time 
 
The release of IL-1, IL-6, IL-8 and GM-CSF by HaCaT cells in response to DNCB 
was investigated further by looking at earlier time points (1, 4 and 24 hours).  IL-1, 
although present at very low levels, was detected in response to both DNCB and SDS 
after 24 hour exposure.  The amount of IL-1 in response to DNCB was double that 
seen in response to SDS (Figure 3-13a).  IL-1 was not detected at earlier time points in 
response to DNCB.  GM-CSF was also detected at very low levels in response to both 
DNCB and SDS after 24 hour exposure.  The response to DNCB was greater and dose-
dependent (Figure 3-13b).  
 
IL-6 could not be detected at 1 hour post exposure to DNCB or SDS (Figure 3-14a). 
There was a small increase at 4 hours with both SDS and DNCB.   Following 24 hour 
DNCB  exposure,  the  level  of  IL-6  was  increased  further,  whereas  there  was  not  a 
significant increase in IL-6 in response to SDS (24 hours). 
 
IL-8 was also only detected at minimal levels at 1 hour post exposure to DNCB or SDS 
(Figure 3-14b).  In response to SDS there was a small increase at both 4 hours and 24 
hours.  After 4 hour exposure to DNCB IL-8 levels were low, however, after 24 hour 
DNCB  exposure,  IL-8  was  markedly  increased  in  response  to  DNCB  compared  to 
vehicle control. 
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Figure 3-13 IL-1 and GM-CSF production in response to DNCB over time  
HaCaT cells were cultured in the presence of a range of concentrations of DNCB or 
SDS  for  1  hour,  4  hours  or  24  hours  (0M  =  0.2%  DMSO  vehicle  control).  
Supernatants were assayed for release of IL-1(a) and GM-CSF (b) by ELISA.  The 
graph shows mean and SD for three experiments.  Statistical analysis: ANOVA with 
post-hoc Dunnett’s modification *p<0.05, **p<0.01, ***p<0.001. 105 
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Figure 3-14 IL-6 and IL-8 production in response to DNCB over time  
HaCaT cells were cultured in the presence of a range of concentrations of DNCB or 
SDS  for  1  hour,  4  hours  or  24  hours  (0M  =  0.2%  DMSO  vehicle  control).  
Supernatants were assayed for release of IL-6 (a) and IL-8 (b) by ELISA.  The graph 
shows mean and SD for three experiments.  Statistical analysis: ANOVA with post-hoc 
Dunnett’s modification *p<0.05, **p<0.01, ***p<0.001. 106 
 
IL-1 IL-6 and IL-8 are actively transcribed following exposure to DNCB  
In order to understand the kinetics of the IL-1, IL-6 and IL-8 protein release, these 
cytokines were analysed at the transcript (mRNA) level.  HaCaT cells were exposed to 
20-32M DNCB or 0.2% DMSO for 1 hour (Figure 3-15) or 4 hours (Figure 3-16) or 
24 hours (Figure 3-17).  Total mRNA was extracted and analysed by qRT-PCR for 
expression of IL-1, IL-6 and IL-8 mRNA.  Following 1 hour exposure to DNCB, IL-
1  IL-6  and  IL-8  appear  to  be  actively  down-regulated  (or  of  lower  expression) 
compared with vehicle control.  IL-1expression was 1.4 fold lower, IL-6 was found to 
be 4 fold lower and IL-8 was 2.2 fold down-regulated compared to vehicle control 
(Figure  3-15).    Following  4  hour  exposure,  there  were  dose-dependent  increases  in 
expression  of  IL-1,  IL-6  and  IL-8  (Figure  3-16).    The  maximum  fold  changes 
compared with vehicle control expression were 1.9 for IL-1, 22.4 for IL-6 and 7.8 for 
IL-8.    Following  24  hour  exposure  to  DNCB  (Figure  3-17),  the  IL-1and  IL-8 
transcripts  remained  upregulated  in  a  dose-dependent  manner  compared  to  vehicle 
control, with maximum fold increases of 11.5 for IL-1and 5.7 for IL-8.  However, IL-
6 was 1.9 fold down-regulated (or of lower expression) compared to vehicle control 
following 24 hour exposure to DNCB.  
 
The relationship between gene expression and protein release for IL-1, IL-6 and 
IL-8 
For  IL-1  a  1.9  fold  increase  in  transcription  of  the  gene  occured  at  4  hours  and 
increased to 11.5 at 24 hours, whereas the protein was only detected at 24 hours, and 
then  at  only  modest  amounts  (maximum  55pg/ml).    Transcription  occurred  more 
quickly for IL-8, with increases in transcription of 7.8 fold at 4 hours and 5.7 fold 
following 24 hours.  This corresponded to a peak IL-8 protein level of 3500pg/ml at 24 
hours.  The IL-6 transcript was up-regulated 22.4 fold at 4 hours and appeared to be 
switched off at 24 hours.  This correlated with a peak IL-6 protein level at 24 hours of 
145pg/ml.   
 
The  EpiDerm  models  treated  with  DNCB  for  24  hours  were  also  assessed  for  the 
expression of IL-1 IL-6 and IL-8 transcripts (Figure 3-18). IL-6 could not be detected, 
and due to large variation in the data, no statistically significant changes were observed.  107 
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Figure 3-15 Transcription of IL-1, IL-6 and IL-8 in response to DNCB  
HaCaT cells were cultured in the presence of a range of concentrations of DNCB for 1 
hour (0M = 0.2% DMSO vehicle control).  Total mRNA was extracted and analysed 
for expression of IL-1a, IL-6 (b) and IL-8 (c) transcripts by qRT-PCR.  Data is 
shown as fold change (relative to vehicle control), normalised to HPRT expression.  The 
graph shows mean and SD for three experiments.  Statistical analysis: ANOVA with 
post-hoc Tukey’s modification *p<0.05, **p<0.01, ***p<0.001. 108 
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Figure 3-16 Transcription of IL-1, IL-6 and IL-8 in response to DNCB  
HaCaT cells were cultured in the presence of a range of concentrations of DNCB for 4 
hours (0M = 0.2% DMSO vehicle control).  Total mRNA was extracted and analysed 
for expression of IL-1a, IL-6 (b) and IL-8 (c) transcripts by qRT-PCR.  Data is 
shown as fold change (relative to vehicle control), normalised to HPRT expression.  The 
graph shows mean and SD for three experiments.  Statistical analysis: ANOVA with 
post-hoc Tukey’s modification *p<0.05, **p<0.01, ***p<0.001. 109 
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Figure 3-17 Transcription of IL-1, IL-6 and IL-8 in response to DNCB  
HaCaT cells were cultured in the presence of a range of concentrations of DNCB for 24 
hours (0M = 0.2% DMSO vehicle control).  Total mRNA was extracted and analysed 
for expression of IL-1a, IL-6 (b) and IL-8 (c) transcripts by qRT-PCR.  Data is 
shown as fold change (relative to vehicle control), normalised to HPRT expression.  The 
graph shows mean and SD for three experiments.  Statistical analysis: ANOVA with 
post-hoc Tukey’s modification *p<0.05, **p<0.01, ***p<0.001. 110 
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Figure 3-18 Transcription of IL-1 and IL-8 in response to DNCB  
EpiDerm models were cultured in the presence of a range of concentrations of DNCB 
for 24 hours (0M = 0.2% DMSO vehicle control).  Total mRNA was extracted and 
analysed for expression of IL-1a and IL-8 (b) transcripts by qRT-PCR.  Data is 
shown as fold change (relative to vehicle control), normalised to HPRT expression.  The 
graph shows mean and SD for three experiments.  Statistical analysis: ANOVA with 
post-hoc Tukey’s modification *p<0.05, **p<0.01, ***p<0.001 111 
 
3.3 Discussion 
 
In this chapter, we evaluated three in vitro models (HaCaT, EpiDerm, EpiDermFT) for 
their use in the investigation of keratinocyte-derived cytokines in response to chemical 
allergen.    The  3D  models  (EpiDerm,  EpiDermFT)  have  been  shown  to  be  more 
representative  of  skin  physiology  than  monolayer  culture,  as  the  keratinocytes 
differentiate into distinct strata (Ponec et al, 2000, 2002; Poumay et al, 2004,).  We have 
confirmed this by histological examination of the EpiDerm cultures, which we found to 
resemble normal human epidermis.  In contrast, the full thickness models did not show 
viable,  differentiated  lower  strata.    This  may  be  due  to  reduced  delivery  of  media 
components  to  the  suprabasal  keratinocytes  through  the  fibroblast  layer  or  a 
consequence  of  lengthy  transport  from  the  supplier.    Other  groups  have  found  full 
thickness type cultures to be a valid model (Spiekstra et al, 2005, Holland et al, 2008, 
2009),  but  these  are  normally  produced  and  studied  in  the  same  laboratory.    The 
cytokine expression from the EpiDermFT models was higher and more diverse than 
from EpiDerm or HaCaT, however the expression profiles from these and the EpiDerm 
models were not reproducible between donors (groups often pool donors to negate this; 
Poumay et al, 2004).  For this reason, we decided that the EpiDerm and EpiDermFT 
models  were  not  suitable  for  mechanistic  investigation  into  cytokine  and  signalling 
responses.  The keratinocyte-only 3D models  (e.g. EpiDerm) are, however, proving 
valuable for toxicity testing of topically applied cosmetics, where cytotoxicity/irritancy 
is the primary end-point (Spielmann et al, 2007). Other groups are trying to improve 
these models by including other cell types such as CD34+ LC-like cells (Facy et al, 
2005), MUTZ derived-LCs (Ouwehand 2011) and  CD4+ T cells (van den Bogaard et al, 
2014).  
 
The HaCaT cells differ from normal human keratinocytes in being immortalised and 
blocked at a single differentiation state (Boukamp et al, 1988).  Nevertheless, the cells 
do share many characteristics with keratinocytes in vivo, and have been widely used as a 
model to study keratinocyte molecular cell biology.  In our context, HaCaT cytokine 
release  showed  the  major  advantage  of  good  reproducibility  between  biological 
replicates.    HaCaT  also  demonstrated  sensitivity  to  different  stimuli,  allowing 112 
 
discrimination between LPS/IFNand DNCB cytokine responses.  For these reasons we 
chose to investigate the HaCaT cells further.  
 
We used LPS with IFN, a combination of an innate and adaptive stimulus, as a positive 
pro-inflammatory control.  The inclusion of IFN also simulates the microenvironment 
during the elicitation phase of CHS where Th1 and Tc1 cells are active.  Indeed, we 
found more chemokines, cytokines and growth factors produced by the HaCaTs and 
EpiDerm  model  (keratinocyte-only  cultures)  in  response  to  IFN/LPS  compared  to 
DNCB or SDS.  In response to IFN/LPS, both of these models released IL-1ra, IL-2R, 
IL-7, IL-8, IP-10, MIG, MCP-1, RANTES, GCSF, VEGF, b-FGF.  In addition to these, 
the HaCaT cells also expressed IL-2, IL-6, IL-10, IFN, MIP1 and HGF, which were 
not seen in the EpiDerm model, while EpiDerm produced IL-1 and IL-17.  A further 
experiment was conducted using EpiDerm with LPS alone (data not shown) where only 
IL-1ra,  IL-8,  MCP-1,  VEGF,  IL-1  were  seen,  indicating  that  the  others  are  IFN 
driven (or a result of combined exposure). 
 
Of the cytokines observed in response to combined innate/adaptive stimulus, IL-1ra, IL-
2,  IL-2R,  IL-6,  IL-7,  IL-10,  IP-10,  MCP-1,  MIG,  MIP-1,  FGF,  GCSF,  IFN, 
RANTES  and  HGF  were  expressed  with  an  average  fold  change  of  more  than  2 
compared to control in either HaCaT or EpiDerm.   
 
A number of pro-inflammatory cytokines and chemokines were induced by LPS/IFN in 
the HaCaT or EpiDerm cultures.  IL-6 up-regulation in response to IFN/LPS has been 
demonstrated by others (Ishimaru et al, 2013; Teunissen et al, 1998).  This cytokine has 
pro-inflammatory  functions  through  stimulation  of  the  acute  phase  response  and 
triggering fever (reviewed in Heinrich et al, 1990).  IL-6 is also a major regulator of the 
Th17/Treg balance (Kimura and Kishimoto, 2010), promoting differentiation of Th17 
cells.  Up-regulation of IFN was also observed in response to IFN/LPS.  IFN is a 
major mediator of antiviral immunity, but also plays an important role in mediating 
macrophage and DC activation.  IFN release has been demonstrated in keratinocytes in 
response to virus (Shao et al, 2010) and at low mRNA levels following LPS stimulation 
(Fujisawa et al, 1997).  
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We detected chemokines for: granulocytes (MIP-1) (and their differentiation factor G-
CSF); monocytes and dendritic cells (IP-10, MCP-1); NK and T cells (IP-10, MCP-1, 
MIG,  RANTES);  and  eosinophils  and  basophils  (RANTES).    IP-10  (Luster  and 
Ravetch,1987,  Kaplan  et  al,  1987;  Klunker  et  al,  2003),  MIG  (Tensen  et  al,  1999; 
Klunker et al, 2003), and MCP-1 (Barker et al, 1990, 1991), are known to be induced by 
IFN, and showed the largest expression levels and fold-increases in our data.  The 
neutrophil/granulocyte  chemoattractant,  IL-8,  was  constitutively  expressed  at  a  high 
level, but was not affected by IFN/LPS in our data.  This is in agreement with Li et al 
(1996) and Barker et al (1990), but IL-8 was found to be activated by others (Teunissen 
et al, 1998; Song 2002). 
 
Growth  factors  HGF  and  b-FGF  were  also  up-regulated.    b-FGF  is  known  to  be 
produced by keratinocytes (Halaban et al, 1988), and is involved in tissue re-modelling 
following infection.  HGF is usually produced by mesenchymal cells, not keratinocytes, 
and  acts  on  epithelial  cells.    It  was  not  seen  in  EpiDerm,  so  it  is  possible  that 
immortalised  HaCaTs  are  capable  of  producing  HGF  as  an  autocrine-proliferation 
signal.   
 
Other mediators induced in response to LPS/IFN IL-1ra, IL-10 and IL-2R are known 
to have immunosuppressive function.  IL-1ra inhibits pro-inflammatory IL-1 signalling 
(reviewed in Arend, 1990), IL-10 down-regulates Th1 cytokine expression (reviewed in 
Moore et al, 2001) and dendritic /Langerhans cell function, and soluble IL-2R (reviewed 
in Caruso, 1993) sequesters IL-2, a cytokine that stimulates T cell survival, proliferation 
and differentiation (reviewed in Boyman and Sprent, 2012).  Interestingly, we also saw 
IL-2 upregulated in response to IFN/LPS (but to a much lower extent than IL-2R), as 
well as IL-7, another T cell survival cytokine.  To our knowledge neither IL-2 nor sIL-
2R expression from keratinocytes has previously been observed.  Yasumura et al (1994) 
were unable to detect sIL-2R in the supernatant of human keratinocytes but did observe 
membrane-bound receptor on a small proportion of the population.  It is possible that 
keratinocytes produce IL-2R as a reaction to IFN to suppress T-cell activity.  IL-7 has 
previously been shown to be transcribed in keratinocytes in response to IFN (Ariizumi 
et al, 1995).  We saw an increase in extracellular IL-1ra, while Phillips et al (1995) saw 
no change in intracellular IL-1ra in response to IFN.  IL-10 has previously been found 114 
 
to  be  induced  by  IFN  in  human  keratinocytes  (Zeitvogel  et  al,  2008),  which  is 
consistent with our result.  Altogether, the combination of IL-1ra, IL-10 and IL-2R may 
reflect  an  active  negative  feedback  loop  to  regulate  the  strong  pro-inflammatory 
stimulus induced by the LPS/IFN combination.   
 
To  characterise  the  keratinocyte-derived  cytokine  profile  in  response  to  a  model 
chemical allergen, we exposed HaCaTs and EpiDerm to DNCB.  In order to distinguish 
the allergen response from chemical-induced cell death, we also investigated responses 
to a model irritant, SDS.  In both keratinocyte models (HaCaT and EpiDerm), IL-1ra, 
IL-8, MCP-1 and VEGF were detected.  Expression of IL-1, IL-6, RANTES and GM-
CSF  was  measured  in  HaCaTs  but  not  EpiDerm,  while  IL-1  was  only  seen  in 
EpiDerm.  Generally, the expression from EpiDerm was lower than that from HaCaTs, 
and much more variable.  The variability observed could potentially be due to slight 
differences in the thickness of the stratum corneum between EpiDerm models.   
 
IL-1 was not detected from HaCaTs in response to DNCB, but was seen following 
snap freezing (data not shown), which suggests release of pre-stored intracellular IL-1 
(Corsini et al, 1998; Coquette et al, 2003).  IL-1 expression from EpiDerm showed a 
tendency  to  increase,  albeit  at  a  low  level  in  response  to  DNCB  (although  highly 
variable between donors).  A low level of IL-1 in response to DNCB compared with 
irritant is consistent with the literature (Poumay et al, 2004; dos Santos et al, 2011; 
Coquette et al, 1999, 2003).  This difference between IL-1 releases might be explained 
by  a  tendency  for  chemical  allergens  to  induce  apoptosis,  compared  with  irritant 
necrotic death and cell rupture (Pastore et al, 1995).  
 
Several  other  cytokines  showed  narrow  dose  responses  to  DNCB,  where  release  of 
cytokine  occurred  at  concentrations  just  under  the  threshold  at  which  the  chemical 
induced cytotoxicity.  This suggests that the cells activate these cytokines when highly 
stressed. 
 
In response to DNCB or SDS, the same cytokines were detected following treatment 
with either chemical, but some of the expression profiles were significantly different.  
Pro-inflammatory cytokines IL-1 and IL-6 were highly up-regulated in response to 115 
 
DNCB but not SDS, which may be part of a sensitiser-specific signature.  Low level IL-
1 release following sensitiser exposure has been seen previously (Zepter et al, 1997), 
but to our knowledge sensitiser-induced IL-6 expression specifically from keratinocytes 
has not been observed before.  IL-6 has been seen in epidermis exposed to chemical-
allergen (Cumberbatch et al, 1996; Holliday et al, 1996; Flint et al, 1998), but cannot be 
assigned to a particular cell type with certainty.    
 
Expression  of  IL-1ra  from  HaCaTs  increases  in  response  to  DNCB  at  similar 
concentrations  to  those  which  induce  IL-1.    IL-1ra  has  been  shown  to  be 
predominantly intracellular, pre-stored in keratinocytes (Haskill et al, 1991), potentially 
as a form of immediate regulation of IL-1 signalling.  The fold increase of IL-1ra was 
lower  than  that  of  IL-1,  and  there  was  no  change  in  the  SDS-induced  IL-1ra 
expression. Spiekstra et al (2009) quote an EC50 value for IL-1ra production from skin 
models  in  response  to  DNCB  which  implies  that  they  have  observed  an  increase, 
however the full data is not disclosed.   
 
The chemokine IL-8 had a similar sensitiser-specific profile to IL-6 and IL-1 IL-8 
expression in response to sensitisers has been observed by others (Newby et al, 2000, 
Coquette et al, 2003; Mohamadzadeh, 1994).  A down-regulation of RANTES was seen 
at  high  concentrations  of  both  DNCB  and  SDS,  however  with  DNCB  there  was  a 
significant release at lower concentrations.  Goebeler et al, 2001 showed RANTES to be 
present in skin during ACD elicitation reactions.  MCP-1 decreased in line with the 
cytotoxicity profile for both chemicals, suggesting it is only produced by unstressed 
cells.   MCP-1 has,  however, been seen in  skin during elicitation of  contact  allergy 
(Goebeler et al, 2001).   It is possible this is due to the effect of IFN on keratinocytes 
(Barker et a, 1991), as we saw a large induction of MCP-1 in our data in response to 
LPS/IFN.   
 
GM-CSF,  a  growth  and  differentiation  factor  for  granulocytes  and  monocytes,  only 
showed low levels of expression, but again displayed a much greater response with 
DNCB compared to SDS.  Terunuma et al (2001) found GM-CSF mRNA to be up-
regulated in response to SDS and Ni, but not with DNCB, although they tested at 3M, 
approximately 10 fold lower than concentrations at which we saw a response.  Enk and 116 
 
Katz  (1992a/c)  also  found  up-regulation  of  GM-CSF  in  skin  following  exposure  to 
sensitiser and irritant.      
 
Having  identified  the  pro-inflammatory  mediators  characteristic  of  a  response  to 
sensitiser (IL-1, IL-6, IL-8), we investigated the kinetics of their transcription. The 
highest fold change of transcription following DNCB exposure was seen in IL-6 at 4 
hours, but it was short-lived and down-regulated by 24 hours.  It is known that IL-6 is 
regulated during CHS responses, as, following exposure to oxazalone, the levels in skin 
peak at 4 hours and decrease by 24 hours (Flint et al, 1998).  These timeframes are 
consistent with our mRNA observations.  Similar protein fold changes are seen with IL-
6 and IL-8 from the high, short transcription activity of IL-6 compared with a lower 
sustained  transcription  for  IL-8.    IL-1  only  increases  in  mRNA  at  24hr,  which  is 
consistent with the slightly lower protein fold change observed. 
 
Only a small number of mediators were produced in response to DNCB.  This could be 
because this highly restricted signal would be sufficient to initiate a priming cascade to 
drive the adaptive response in vivo.  Alternatively, it could be that the keratinocyte 
cytokine  profile  contributes  to  cross-talk  between  skin  resident  cells  including 
macrophages,  fibroblasts,  dendritic  or  Langerhans  cells  that  develops  into  a  more 
diverse set of cytokine/chemokine signals to initiate the response.  In either case, the 
keratinocyte-derived cytokines that we found to be sensitiser specific may play roles at 
key points in the development of ACD.  Due to the vast number of keratinocytes in 
skin,  it  is  likely  that  the  IL-1  and  GM-CSF  they  produce  are  important  factors 
influencing  LC  migration  (Cumberbatch  et  al,  1997;  shornick  et  al.  2001)  and 
maturation (Witmer-pack et al, 1987;Caux et al, 1992; Heufler et al, 1988; Enk et al, 
1993), for presentation of hapten-antigen to T-cells in the lymph node.  The expression 
of RANTES and IL-8 will drive chemotaxis of T cells and granulocytes into the skin.  
The production of IL-1ra demonstrates the capacity of keratinocytes to help regulate the 
inflammatory response.  It has been shown that IL-6 is critical for CHS to DNP-HSA 
(Palm and Medzhitov, 2009), however its function in initiation of the response is less 
clear.   It is possible that the keratinocyte-derived IL-6 might promote the Th17 and Th1 
responses (Serada 2008) known to be important in CHS (Wang et al, 2000; Larsen et al, 
2009; Pennino et al, 2010).  Alternatively, IL-6 could modify the processing of skin-117 
 
protein by cutaneous dendritic cells, leading to presentation of atypical epitopes and 
triggering autoimmune-like responses (Drakesmith et al, 1998).   
 
We would expect to see TNF in these responses (Cumberbatch and Kimber, 1995), 
and indeed we did detect a signal in response to DNCB and not SDS, however the level 
was  below  the  range  of  the  standard  curve  for  the  ELISA  and  only  equated  to  a 
maximum level of 5pg/ml.  It is possible that we missed the peak TNF expression, as 
other groups have found TNF to be released early (Piguet et al, 1992; Haas et al, 
1992).  Low  levels  of  TNF  were  also  seen  in  response  to  IFN  in  PAM212  cells 
(Ariizumi et al, 1995) or LPS in an epidermoid carcinoma cell line (Kock et al, 1990).  
In mouse skin, the expression of TNF (mRNA and protein) following exposure to the 
sensitiser oxazolone are under tight temporal constraints.  This transient and localised 
transcriptional expression peaks and drops within 20 minutes, and protein expression is 
maximal at 2 hours, returning to normal by 4 hours (Flint et al, 1998). 
 
We could not detect active extracellular IL-18 by standard ELISA or western blot (data 
not  shown).    IL-18  has  been  found  at  very  low  levels  in  supernatant  and 
immunoprecipitation was required to concentrate IL-18 enough to measure (Naik et al, 
1999).  Van Och et al (2005) measured a dose response of intracellular IL-18 (but not 
extracellular) in HEL-30 cells exposed to DNCB.  It is possible that active IL-18 is not 
present (Mee et al, 2000) due to the processing required by active caspase-1 (Ghayur et 
al,  1997),  which  is  not  thought  to  be  present  in  keratinocytes  (Akeda  et  al,  2014).   
Recent literature suggests that IL-23 (Larsen 2009) may also  play a role in allergic 
contact dermatitis by enhancing the Th17 response, however we haven’t measured this 
cytokine.  
 
In this chapter, we have compared 3D keratinocyte models to the HaCaT cell line, and 
found HaCaTs to be the most suitable for mechanistic studies.  Combined innate and 
adaptive  stimulus  induced  keratinocyte  release  of  both  pro-inflammatory  and 
immunoregulatory  cytokines.    In  response  to  chemicals,  we  found  a  characteristic 
cytokine  signature  that  differentiates  a  model  sensitiser  from  a  model  irritant,  in 
particular IL-1, IL-6 and IL-8.  In the following chapters we investigate the signalling 
pathways associated with the cytokine changes we identified. 118 
 
4  DIFFERENTIAL GENE EXPRESSION IN THE TRANSCRIPTOME OF 
KERATINOCYTES FOLLOWING EXPOSURE TO DNCB AND SDS  
 
4.1 Introduction  
In the previous chapter, we saw a characteristic cytokine signature related to DNCB 
exposure.  In this chapter, to understand the specificity of this response, we investigated 
the mechanisms behind the cytokine release and associated chemical-induced pathways.  
To achieve this, we studied changes in the keratinocyte transcriptome in response to 
DNCB exposure. 
 
A number of groups have investigated transcriptional changes in response to sensitising 
chemicals.  The majority of these studies have been on dendritic or dendritic-like cells 
(Ryan et al, 2004; Johansson et al, 2011; Miyazawa and Takashima, 2012; Yoshikawa 
et al, 2010; Schoeters et al, 2007; Python et al, 2009; Szameit et al, 2009), with the 
objective of finding a small number of genes to predict sensitisation potential (Gildea et 
al, 2006; Hooyberghs et al, 2008; Lambrechts et al, 2010; Johansson et al, 2013).  Early 
array studies into keratinocyte gene expression analysed the response of 3D skin models 
to irritant chemicals for the identification of irritancy biomarkers (Fletcher et al, 2001; 
Borlon  et  al,  2007).    More  recently,  several  groups  have  performed  array  studies 
focussing on sensitising chemicals and keratinocytes (Yoshikawa et al, 2010; Saito et al, 
2013; Vandebriel et al, 2010; Van der Veen et al, 2013), which have led to development 
of  keratinocyte-based  assays  to  predict  sensitisation  potential  (Emter  et  al,  2013; 
McKim et al, 2010).  Due to the focus on biomarker discovery, the interpretation of 
transcriptomic  changes  in  these  studies  has  been  limited.    However,  differentially 
expressed genes from keratinocyte transcriptomic studies (Saito et al, 2013; Yoshikawa 
et al, 2010; Vandebriel et al, 2010; Van der Veen et al, 2013) seem to be associated with 
four  themes:  transcription  factors  (ATF3,  cFOS);  heat  shock  proteins  (HSPA1B, 
HSPA6,  HSPH1,  DNAJB1,  DNAJB4);  cytokines  and  related  proteins  (IL-1,  IL-8, 
TNFAIP3); and oxidative stress/Nrf2 (HMOX1, NQO1, TXNRD1, GCLC, GCLM). 
Pathway analysis, which highlights the canonical biological processes that are over-
represented in gene expression data, has emerged as a method to help interpret large 
data sets in terms of mechanisms of action.  The pathways within sensitiser-induced 119 
 
gene expression data sets are only now being explored.  Van der Veen et al (2013) have 
recently shown Nrf2, MAPK, Toll like receptor signalling and cytokine pathways to be 
involved in keratinocyte responses to sensitiser. 
 
The  aim  of  this  chapter  is  to  determine  the  differential  gene  expression  in  the 
transcriptome of the keratinocyte cell line HaCaT following exposure to a chemical 
sensitiser, DNCB, and to confirm the specificity of the response through comparison 
with the chemical irritant SDS.  We also aim to identify the ontologies and pathways 
that are significantly over-represented in the data to provide mechanistic interpretation. 
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4.2 Results 
Array data analysis 
The array data files from HaCaT cells exposed to DNCB, SDS or vehicle control were 
analysed using the single colour advanced analysis settings in GeneSpringGX v12.6 
(Agilent).  During loading, flags were assigned as not detected if the data spots were: 
not  positive  and  significant;  or  not  above  background.    Saturated,  non  uniform  or 
population outliers were designated with compromised flags.  Log2 transformation was 
applied to the data (raw signals of 0 were set to 1 before transformation).  The data were 
then normalised by applying the percentile shift algorithm to centre the data from each 
array at the 75th percentile.  Following this, the data were baseline transformed by 
subtracting the median of the vehicle control arrays (0.2% DMSO), entity by entity. 
 
A box whisker plot of the normalised intensities from each array (Figure 4-1a) shows 
that they have similar distributions.  Figure 4-1b shows a profile of 9 feature extraction 
values, representing quality control metrics, for each array.  The profiles are consistent, 
providing confidence in comparisons between arrays. 
 
Principal component analysis (PCA) was performed to check that there is discrimination 
between  treatments  in  the  data,  that  there  are  no  confounding  effects  (e.g.  between 
batches), and to look for potential outliers.  Figure 4-2 shows a clear separation between 
vehicle  control,  DNCB  and  SDS.    It  also  demonstrates  progressively  increasing 
separation from control with increasing doses of DNCB. 
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Figure 4-1 Summary of normalised intensities and quality control metrics 
The quality and consistency of the array data were assessed by comparing the 
normalised intensity values of all probes from each array by box whisker plot (a) and 
comparing profiles of the quality control features for each array (b). 
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Figure 4-2 Principal component analysis plot 
Principal component analysis (PCA) was used to establish the contribution of treatment 
vs. confounding effects to the variance of the data.  The first 3 components are shown: 
x-axis  component  1  (21.64%),  y-axis  component  2  (17.95%),  z-axis  component  3 
(11.35%), % = percentage of total variance.  Each point represents a single array (0M 
= 0.2% DMSO vehicle control).   
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Data filtering 
The data from the arrays were further filtered by flags.  Only probes flagged as detected 
in at least 66 percent of samples (2/3 biological replicates) in any 1 out of 5 treatment 
conditions were accepted for inclusion in the analysis.  This reduced the number of 
probes for analysis from 41093 to 29881. Statistical analysis was performed using this 
filtered list. 
 
Differential gene expression following exposure to DNCB  
The  statistical  significance  of  differentially  expressed  genes  at  each  DNCB 
concentration compared with the DMSO control was calculated.  A one-way ANOVA 
was selected for these data, as only one parameter (dose) was varied, with more than 
two conditions (0, 20, 27.5, 30M DNCB).  The Benjamini Hochberg false discovery 
rate (FDR) multiple testing correction was also applied to reduce chance events being 
highlighted as significant.  8396 genes out of 29881 had a corrected p-value < 0.05 for 
at least one dose of DNCB compared to the DMSO vehicle control.  The data were 
further reduced by application of a fold change cut-off, to select only genes that were 
more than 2-fold differentially expressed (up or down), which resulted in 2147 genes.  
The majority of these were highly significant, with 1869 of these genes also found with 
a  corrected  p-value  <0.01;  70  of  which  had  a  fold  change  of  more  than  10.    The 
normalised intensity values of the 2147 differentially expressed genes with p(corr) < 
0.05 and more than 2-fold change were visualised by line graph (Figure 4-3).  This 
shows that most of the genes follow a dose response (up or down-regulated) following 
exposure  to  DNCB.    Figure  4-4  shows  representative  examples  of  genes  with  dose 
responses to DNCB and highlights the similarity between the biological replicates. 
 
Table 4-1 shows the top 60 genes (of 2147) ranked by absolute fold change at 30M 
DNCB.  The top  60 include cytokines  and chemokines  (such as  IL-1,  IL-6,  IL-8, 
CCL18), heat shock proteins, keratin-associated proteins and transcription factors.     
 124 
 
 
 
 
 
Figure 4-3 Dose response of differentially expressed genes (DNCB vs. control) 
Normalised intensity values of 2147 significantly differentially expressed genes, with 
p(corr) < 0.05 and fold change greater than 2, plotted against dose of DNCB (0M = 
0.2% DMSO vehicle control).  Lines are coloured by expression at 30M (red = up-
regulated, blue = down-regulated). 
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a             IL-1      b                              IL-6 
 
c              IL-8      d                              HSPA6 
 
 
Figure 4-4 Expression of IL-1, IL-6, IL-8 and HSPA6  
Normalised intensity values (log2 fold change – relative to 0.2% DMSO vehicle control) 
for IL-1(a), IL-6 (b), IL-8 (c) and HSPA6 (d) in response to DNCB (concentration in 
M  on  x-axis,  0M  =  0.2%  DMSO  vehicle  control).    Error  bars  show  standard 
deviation of biological replicates (n=3 DNCB, n=4 DMSO). 
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Rank 
Gene 
symbol  Gene name 
Fold 
change   
DNCB 
20M  
Regulation 
DNCB 
20M  
Fold 
change   
DNCB 
27.5M  
Regulation 
DNCB 
27.5M  
Fold 
change   
DNCB 
30M  
Regulation 
DNCB 
30M  
ANOVA 
corrected 
p-value   
1  HSPA6  heat shock 70kDa protein 6 (HSP70B')  10.53  up  301.74  up  611.87  up  4.12E-09 
2  KRTAP1-5  keratin associated protein 1-5  2.90  up  47.97  up  61.85  up  1.18E-07 
3  KRTAP3-2  keratin associated protein 3-2  1.14  down  41.14  up  57.66  up  7.00E-04 
4  SPINK1  serine peptidase inhibitor, Kazal type 1  3.52  up  41.43  up  54.41  up  6.78E-07 
5  MMP3  matrix metallopeptidase 3 (stromelysin 1, progelatinase)  8.11  up  40.95  up  51.00  up  9.17E-04 
6  HTRA3  HtrA serine peptidase 3  12.58  up  35.64  up  50.81  up  9.97E-08 
7  IL1RL1  interleukin 1 receptor-like 1  1.50  up  28.66  up  41.93  up  4.21E-07 
8  KIAA1239  KIAA1239  1.30  up  17.63  up  34.55  up  9.97E-08 
9  HMOX1  heme oxygenase (decycling) 1  31.57  up  37.68  up  33.82  up  2.41E-09 
10  SPANXB2  SPANX family, member B2  2.58  up  18.82  up  33.81  up  3.07E-05 
11  SPANXA1 
sperm protein associated with the nucleus, X-linked, 
family member A1  4.03  up  17.48  up  30.28  up  1.48E-06 
12  SNAI1  snail family zinc finger 1  1.69  down  8.75  up  29.56  up  8.21E-07 
13  TRIM43  tripartite motif containing 43  1.26  up  11.63  up  29.14  up  2.93E-06 
14  KRT34  keratin 34  1.25  down  14.38  up  28.50  up  2.15E-06 
15  C11orf96  chromosome 11 open reading frame 96  1.05  up  15.19  up  28.09  up  3.53E-08 
16  IL1A  interleukin 1, alpha  1.84  up  14.97  up  27.39  up  3.53E-06 
17  NR4A1  nuclear receptor subfamily 4, group A, member 1  1.29  down  12.43  up  23.87  up  1.36E-08 127 
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18  ACTN2  actinin, alpha 2  1.01  down  6.35  up  20.36  up  6.63E-05 
19  KRTAP1-3  keratin associated protein 1-3  1.02  up  3.65  up  18.98  up  3.29E-04 
20  ARC  activity-regulated cytoskeleton-associated protein  1.55  down  8.66  up  18.71  up  8.64E-08 
21  CCL18 
chemokine (C-C motif) ligand 18 (pulmonary and 
activation-regulated)  1.39  down  13.23  up  18.54  up  4.98E-04 
22  USP2  ubiquitin specific peptidase 2  2.28  up  11.15  up  17.84  up  1.67E-05 
23  IL10RA  interleukin 10 receptor, alpha  1.33  down  9.37  up  17.81  up  4.12E-06 
24  DEFB103B  defensin, beta 103B  1.60  up  7.93  up  17.51  up  1.81E-02 
25  ATF3  activating transcription factor 3  1.30  up  10.38  up  17.48  up  1.28E-07 
26  HBG1  hemoglobin, gamma A  1.38  down  6.74  up  17.43  up  6.76E-06 
27  NR4A3  nuclear receptor subfamily 4, group A, member 3  1.72  down  11.14  up  17.30  up  4.21E-07 
28  IL6  interleukin 6 (interferon, beta 2)  1.15  up  7.73  up  16.83  up  3.99E-07 
29  CXCR4  chemokine (C-X-C motif) receptor 4  1.31  down  8.05  up  16.46  up  2.66E-06 
30  LINC00520  long intergenic non-protein coding RNA 520  5.26  up  18.85  up  15.89  up  1.04E-05 
31  CCK  Cholecystokinin  1.26  up  10.26  up  15.66  up  6.48E-06 
32  PIWIL2  piwi-like RNA-mediated gene silencing 2  1.46  up  9.35  up  15.64  up  7.76E-06 
33  HBG1  hemoglobin, gamma A  1.11  up  6.17  up  14.83  up  2.22E-06 
34  VASN  Vasorin  2.50  down  6.80  up  14.66  up  4.27E-08 128 
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35  ZNF280A  zinc finger protein 280A  1.03  up  5.60  up  14.46  up  3.26E-06 
36  MSX1  msh homeobox 1  1.45  down  6.67  up  14.21  up  2.10E-05 
37  ATF3  activating transcription factor 3  1.47  up  9.90  up  13.93  up  3.99E-07 
38  ANKRD1  ankyrin repeat domain 1 (cardiac muscle)  1.06  up  7.64  up  13.44  up  2.53E-05 
39  TRIM53AP  tripartite motif containing 53A, pseudogene  1.02  up  4.69  up  13.17  up  1.28E-07 
40  SPANXD  SPANX family, member D  1.80  up  7.72  up  13.10  up  8.09E-05 
41  PIWIL2  piwi-like RNA-mediated gene silencing 2  1.40  up  8.31  up  12.77  up  1.98E-06 
42  LOC440040  glutamate receptor, metabotropic 5 pseudogene  1.03  up  4.78  up  12.52  up  1.25E-06 
43  IL13RA2  interleukin 13 receptor, alpha 2  5.66  up  16.09  up  12.50  up  5.56E-07 
44  CD55 
CD55 molecule, decay accelerating factor for 
complement (Cromer blood group)  1.46  up  7.86  up  12.31  up  4.27E-08 
45  FOSB  FBJ murine osteosarcoma viral oncogene homolog B  1.11  up  6.70  up  12.24  up  2.16E-07 
46  EGR4  early growth response 4  1.92  down  6.29  up  12.15  up  3.50E-05 
47  GEM  GTP binding protein overexpressed in skeletal muscle  1.08  up  7.41  up  11.82  up  7.55E-07 
48  LYRM9  LYR motif containing 9  3.46  down  13.09  down  11.81  down  2.17E-02 
49  ZNF606  zinc finger protein 606  1.94  down  5.58  down  11.71  down  2.60E-02 
50  DNAJB4  DnaJ (Hsp40) homolog, subfamily B, member 4  4.44  up  9.69  up  11.41  up  3.00E-06 
51  KLF6  Kruppel-like factor 6  2.60  up  9.63  up  11.38  up  2.08E-05 129 
 
Rank 
Gene 
symbol  Gene name 
Fold 
change   
DNCB 
20M  
Regulation 
DNCB 
20M  
Fold 
change   
DNCB 
27.5M  
Regulation 
DNCB 
27.5M  
Fold 
change   
DNCB 
30M  
Regulation 
DNCB 
30M  
ANOVA 
corrected 
p-value   
52  KRTAP4-1  keratin associated protein 4-1  1.10  up  9.05  up  11.35  up  3.37E-04 
53  FOS  FBJ murine osteosarcoma viral oncogene homolog  1.24  down  3.73  up  11.18  up  3.00E-06 
54  DNAJB4  DnaJ (Hsp40) homolog, subfamily B, member 4  4.25  up  9.22  up  10.89  up  1.81E-06 
55  WNK4  WNK lysine deficient protein kinase 4  3.23  down  5.86  down  10.88  down  1.85E-06 
56  IL8  interleukin 8  1.70  up  10.70  up  10.64  up  1.50E-02 
57  ZFAND2A  zinc finger, AN1-type domain 2A  1.70  up  6.89  up  10.32  up  3.53E-08 
58  RGS16  regulator of G-protein signaling 16  1.60  down  3.17  up  10.19  up  2.06E-06 
59  CNN1  calponin 1, basic, smooth muscle  1.14  down  5.48  up  10.15  up  1.12E-04 
60  PPP1R15A  protein phosphatase 1, regulatory subunit 15A  2.20  up  7.50  up  10.10  up  5.65E-06 
 
Table 4-1 Top 60 differentially expressed genes in response to DNCB ranked by fold change  
List of the top 60 (from 2147) differentially expressed genes with p(corr) < 0.05 and  fold change > 2 (relative to control), ranked by fold change (at 
30M DNCB).130 
 
Differential gene expression following exposure to SDS 
The statistical significance of differentially expressed genes from SDS exposed HaCaT 
cells compared with the DMSO control was calculated.  An unpaired t-test was selected 
for this data as there were only 2 conditions (0, 250M SDS), and applied with the 
Benjamini Hochberg FDR multiple testing correction.  In response to SDS, 4264 genes 
out  of  29881  had  a  corrected  p-value  <  0.05.    The  data  were  further  reduced  by 
application of a fold change cut-off, to select only genes that were more than 2-fold 
differentially expressed (up or down), which resulted in 584 genes.  The majority of 
these were highly significant, with 431 of these genes also found with a corrected p-
value of 0.01; only 4 of which had a fold change of more than 10.   
 
The normalised intensity values of the 584 differentially expressed genes with p(corr) < 
0.05 and more than 2-fold change were visualised by line graph (Figure 4-5).  Table 4-2 
shows the top 30 genes (of 584) ranked by absolute fold change.   
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Figure 4-5  Dose response of differentially expressed genes (SDS vs. control) 
Normalised intensity values of 584 significantly differentially expressed genes, with 
p(corr) < 0.05 and   fold change greater than 2, plotted against dose of SDS (0M = 
0.2% DMSO vehicle control).  Lines are coloured by expression at 250M (red = up-
regulated, blue = down-regulated). 
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Rank  Gene symbol  Gene name 
Fold change   
SDS 250M     
vs control 
Regulation 
SDS 250M 
vs control 
T-test 
corrected p-
value 
1  MMP3  matrix metallopeptidase 3 (stromelysin 1, progelatinase)  17.14  up  2.23E-03 
2  CGA  glycoprotein hormones, alpha polypeptide  13.84  up  6.68E-03 
3  IL1RL1  interleukin 1 receptor-like 1  13.49  up  8.50E-04 
4  KIAA1755  KIAA1755  10.20  up  1.57E-03 
5  LINC00659  long intergenic non-protein coding RNA 659  8.57  up  3.19E-03 
6  LPPR5  lipid phosphate phosphatase-related protein type 5  8.52  up  8.48E-03 
7  THBS1  thrombospondin 1  8.33  up  4.74E-03 
8  ENKUR  enkurin, TRPC channel interacting protein  8.04  up  4.47E-02 
9  MIR100HG  mir-100-let-7a-2 cluster host gene (non-protein coding)  7.58  up  1.24E-03 
10  CEP85L  centrosomal protein 85kDa-like  7.53  down  2.26E-02 
11  CREB5  cAMP responsive element binding protein 5  7.12  up  6.39E-04 
12  SEMA6D  sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D  6.85  down  6.54E-04 
13  CHAC1  ChaC, cation transport regulator homolog 1 (E. coli)  6.85  up  1.24E-03 
14  LINC01127  long intergenic non-protein coding RNA 1127  6.63  up  5.45E-04 
15  PHLDA1  pleckstrin homology-like domain, family A, member 1  6.46  up  3.70E-04 
16  IL1A  interleukin 1, alpha  5.96  up  6.54E-04 
17  VAV3  vav 3 guanine nucleotide exchange factor  5.94  down  8.13E-04 133 
 
Rank  Gene symbol  Gene name 
Fold change   
SDS 250M     
vs control 
Regulation 
SDS 250M 
vs control 
T-test 
corrected p-
value 
18  CGA  glycoprotein hormones, alpha polypeptide  5.79  up  1.37E-02 
19  LOC101059954  uncharacterized LOC101059954  5.67  up  8.44E-04 
20  PRUNE2  prune homolog 2 (Drosophila)  5.64  up  5.07E-03 
21  ANO2  anoctamin 2  5.62  up  1.21E-03 
22  CD55  CD55 molecule, decay accelerating factor for complement (Cromer blood group)  5.56  up  4.77E-04 
23  CCK  Cholecystokinin  5.45  up  5.86E-03 
24  DNM3  dynamin 3  5.35  up  6.54E-04 
25  CD55  CD55 molecule, decay accelerating factor for complement (Cromer blood group)  5.26  up  1.10E-03 
26  LOC100507165  uncharacterized LOC100507165  5.19  up  3.19E-03 
27  PHLDA1  pleckstrin homology-like domain, family A, member 1  5.13  up  7.12E-04 
28  IFNE  interferon, epsilon  5.09  up  1.41E-03 
29  INHBA  inhibin, beta A  5.05  up  4.48E-04 
30  CCL2  chemokine (C-C motif) ligand 2  5.01  down  4.72E-04 
 
Table 4-2 Top 30 differentially expressed genes in response to SDS ranked by fold change  
List of the top 30 (from 584) differentially expressed genes with p(corr) < 0.05 and  fold change > 2, ranked by fold change. 
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Overlap between the DNCB and SDS significantly differentially expressed genes 
The overlap between the gene lists for DNCB and SDS with corrected p-values < 0.05 
and fold changes more than 2 (compared with DMSO control) were visualised using a 
Venn  diagram  (Figure  4-6).    Only  263  genes  out  of  a  combined  set  of  2468 
differentially expressed genes were common between the two chemicals. 
 
Gene ontology analysis  
The  database  for  annotation,  visualisation  and  integrated  discovery  (DAVID) 
(http://david.abcc.ncifcrf.gov/tools.jsp) was used to understand the biological functions, 
classified by gene ontology (http://www.geneontology.org), involved in the response of 
HaCaT cells to DNCB and SDS.  The DNCB and SDS final gene-lists resulting from 
normalisation, statistical analysis and 2-fold change cut off (as previously discussed) 
were loaded into DAVID software for enrichment analysis.  Using this software the 
genes were mapped to associated biological functions and the most statistically over-
represented gene ontologies were ranked by modified Fisher exact p-value (Hosack et 
al, 2003).  1553 out of 2147 genes on the DNCB list could be identified in DAVID.  
The most over-represented gene ontologies in response to DNCB generally involved 
regulation of transcription (Table 4-3).  Using the gene-list from SDS exposed HaCaT 
cells,  458 out  of 584 genes  could  be identified in  DAVID.  The enriched terms  in 
response to SDS (Table 4-4) were mainly associated with the regulation of cell death. 
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Figure 4-6 Overlap between the DNCB and SDS differentially expressed genes 
The overlap between the significantly differentially expressed genes following 4 hour 
exposure to DNCB or SDS, represented by Venn diagram.  Differentially expressed 
genes had corrected p-values < 0.05 and fold changes more than 2 at any dose. 
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Gene Ontology Term  Count  Percentage  p-value 
GO:0045449~regulation of transcription  338  26.24224  4.49E-39 
GO:0006350~transcription  287  22.28261  5.36E-36 
GO:0006355~regulation of transcription, DNA-dependent  255  19.79814  4.02E-35 
GO:0051252~regulation of RNA metabolic process  258  20.03106  8.48E-35 
GO:0016481~negative regulation of transcription  65  5.046584  1.80E-08 
GO:0010629~negative regulation of gene expression  69  5.357143  2.44E-08 
GO:0045892~negative regulation of transcription, DNA-dependent  54  4.192547  3.57E-08 
GO:0051253~negative regulation of RNA metabolic process  54  4.192547  6.26E-08 
GO:0051172~negative regulation of nitrogen compound metabolic process  69  5.357143  7.76E-08 
GO:0045934~negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process  68  5.279503  1.02E-07 
GO:0006357~regulation of transcription from RNA polymerase II promoter  86  6.677019  3.07E-07 
GO:0031327~negative regulation of cellular biosynthetic process  71  5.512422  3.34E-07 
GO:0010558~negative regulation of macromolecule biosynthetic process  69  5.357143  5.71E-07 
GO:0009890~negative regulation of biosynthetic process  71  5.512422  7.44E-07 
GO:0000122~negative regulation of transcription from RNA polymerase II promoter  41  3.18323  1.32E-06 
GO:0010033~response to organic substance  83  6.444099  1.59E-06 
GO:0043067~regulation of programmed cell death  89  6.909938  4.81E-06 
GO:0010941~regulation of cell death  89  6.909938  5.57E-06 
GO:0042981~regulation of apoptosis  88  6.832298  5.72E-06 
GO:0009611~response to wounding  64  4.968944  6.65E-06 
GO:0051789~response to protein stimulus  22  1.708075  7.58E-06 137 
 
Gene Ontology Term  Count  Percentage  p-value 
GO:0007243~protein kinase cascade  49  3.804348  8.60E-06 
GO:0045765~regulation of angiogenesis  16  1.242236  1.36E-05 
GO:0032570~response to progesterone stimulus  9  0.698758  2.49E-05 
GO:0045766~positive regulation of angiogenesis  10  0.776398  3.01E-05 
GO:0010605~negative regulation of macromolecule metabolic process  79  6.13354  3.38E-05 
GO:0006954~inflammatory response  43  3.338509  3.42E-05 
GO:0002237~response to molecule of bacterial origin  18  1.397516  4.99E-05 
GO:0031328~positive regulation of cellular biosynthetic process  74  5.745342  5.61E-05 
GO:0010557~positive regulation of macromolecule biosynthetic process  71  5.512422  6.90E-05 
GO:0040012~regulation of locomotion  29  2.251553  8.68E-05 
GO:0009891~positive regulation of biosynthetic process  74  5.745342  8.81E-05 
GO:0032675~regulation of interleukin-6 production  11  0.854037  9.26E-05 
 
 
Table 4-3 Gene ontologies associated with DNCB exposure  
List of over-represented gene ontologies from DAVID ranked by p-value.  Count = number of differentially expressed genes from the data annotated in 
the ontology.  Percentage = count divided by number of genes in the ontology (times 100%). 
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Gene Ontology Term  Count  Percentage  p-value 
GO:0042981~regulation of apoptosis  42  10.74169  2.58E-08 
GO:0043067~regulation of programmed cell death  42  10.74169  3.43E-08 
GO:0010941~regulation of cell death  42  10.74169  3.78E-08 
GO:0009891~positive regulation of biosynthetic process  36  9.207161  4.11E-07 
GO:0031328~positive regulation of cellular biosynthetic process  35  8.951407  8.55E-07 
GO:0043065~positive regulation of apoptosis  25  6.393862  5.60E-06 
GO:0043068~positive regulation of programmed cell death  25  6.393862  6.29E-06 
GO:0010942~positive regulation of cell death  25  6.393862  6.80E-06 
GO:0042127~regulation of cell proliferation  36  9.207161  6.93E-06 
GO:0010557~positive regulation of macromolecule biosynthetic process  31  7.928389  1.86E-05 
GO:0008284~positive regulation of cell proliferation  23  5.882353  2.94E-05 
GO:0010243~response to organic nitrogen  9  2.30179  3.40E-05 
GO:0012501~programmed cell death  29  7.41688  3.63E-05 
GO:0051094~positive regulation of developmental process  18  4.603581  4.37E-05 
GO:0007398~ectoderm development  15  3.836317  4.63E-05 
GO:0008544~epidermis development  14  3.580563  8.25E-05 
GO:0032101~regulation of response to external stimulus  13  3.324808  8.26E-05 
GO:0010604~positive regulation of macromolecule metabolic process  35  8.951407  9.65E-05 
GO:0008219~cell death  31  7.928389  1.05E-04 
GO:0014075~response to amine stimulus  7  1.790281  1.12E-04 
GO:0016265~death  31  7.928389  1.18E-04 139 
 
Gene Ontology Term  Count  Percentage  p-value 
GO:0070482~response to oxygen levels  12  3.069054  1.21E-04 
GO:0040012~regulation of locomotion  14  3.580563  1.27E-04 
GO:0010648~negative regulation of cell communication  16  4.092072  1.39E-04 
GO:0009968~negative regulation of signal transduction  15  3.836317  1.43E-04 
GO:0009611~response to wounding  25  6.393862  1.58E-04 
GO:0002687~positive regulation of leukocyte migration  5  1.278772  1.78E-04 
GO:0006915~apoptosis  27  6.905371  1.82E-04 
GO:0051173~positive regulation of nitrogen compound metabolic process  28  7.161125  2.21E-04 
 
 
 
 
 
Table 4-4 Gene ontologies associated with SDS exposure  
List of over-represented gene ontologies from DAVID ranked by p-value.  Count = number of differentially expressed genes from the data annotated in 
the ontology.  Percentage = count divided by number of genes in the ontology (times 100%). 
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Pathway analysis 
To understand the canonical biological pathways affected in HaCaT cells in response to 
DNCB, the gene expression data were analysed using both Ingenuity pathway analysis 
(IPA)  (Qiagen,  http://www.ingenuity.com)  and  MetaCore  (Thomson  Reuters, 
http://thomsonreuters.com/metacore/).  These software tools were selected due to the 
stringent curation of their biological interaction knowledge databases.  Additionally, the 
MetaCore  software  contains  a  number  of  contact  allergy  specific  pathways.    These 
analyses are, however, limited by the amount of information and number of pathways in 
the databases.     
 
Pathway enrichment analysis was performed to determine the most populated canonical 
pathways  of  the  statistically  significant  (p(corr)  <  0.05  and  fold  change  >  2) 
differentially expressed genes in response to DNCB.  The most represented canonical 
pathways ranked by p-value are shown in Table 4-5 (IPA) and Table 4-6 (MetaCore).  
The ratio (the number of genes differentially expressed, divided by the number of genes 
in the pathway) gives an indication of the proportion of the pathway changing in the 
data.  P-values are calculated as the probability of the number of positive matches on a 
pathway, with a false discovery rate applied.  There is some overlap between the IPA 
and MetaCore analyses, however, often the same core gene network is included under 
different pathway titles in the two tools. 
 
Several  of  the  differentially  expressed  genes  cause  over-representation  of  many 
pathways.  These include cytokines (IL-1, IL-1, IL-6, IL-8, CCL2, CCL3 and CCL4), 
heat  shock  proteins  (Hsp60,  Hsp70)  and  transcription  factors  (c-Jun,  c-Fos,  AP-1, 
EGR1, CEBP, Fra-1, ATF and IB), which appear on numerous canonical pathways.  
Three interesting pathways were selected from each analysis to give examples of visual 
representation of the pathway expression data.  Genes involved in the IL-6 (Figure 4-7), 
IL-10  (Figure  4-8)  and  TLR  (Figure  4-9)  signalling  pathways  were  differentially 
expressed (using IPA).   In MetaCore, the same genes from the data were represented 
in: “Immune response IL-1 signalling” (Figure 4-10), “Immune response HSP60 and 
HSP70 TLR signalling” (Figure 4-11), and “KEAP1/NRF2 as a cellular sensor for skin 
sensitisers” (Figure 4-12) pathways. 
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Rank   Pathway  p-value  Ratio 
1  IL-10 Signaling  5.50E-05  0.224 
2  ILK Signaling  4.07E-04  0.144 
3  Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza  8.91E-04  0.243 
4  Aldosterone Signaling in Epithelial Cells  8.91E-04  0.147 
5  Agranulocyte Adhesion and Diapedesis  1.02E-03  0.14 
6  IL-6 Signaling  1.32E-03  0.155 
7  Cholecystokinin/Gastrin-mediated Signaling  1.74E-03  0.16 
8  Role of IL-17F in Allergic Inflammatory Airway Diseases  1.95E-03  0.22 
9  Granulocyte Adhesion and Diapedesis  2.29E-03  0.137 
10  Hepatic Fibrosis / Hepatic Stellate Cell Activation  2.51E-03  0.13 
11  IL-17A Signaling in Fibroblasts  2.63E-03  0.229 
12  NRF2-mediated Oxidative Stress Response  3.31E-03  0.131 
13  HMGB1 Signaling  3.98E-03  0.144 
14  Glucocorticoid Receptor Signaling  4.17E-03  0.118 
15  Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F  4.47E-03  0.261 
16  IL-17 Signaling  4.47E-03  0.167 
17  Acute Phase Response Signaling  6.92E-03  0.127 
18  Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F  7.08E-03  0.278 
19  PPAR Signaling  1.07E-02  0.144 142 
 
Rank   Pathway  p-value  Ratio 
20  Toll-like Receptor Signaling  1.10E-02  0.155 
21  Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis  1.10E-02  0.109 
22  Role of IL-17A in Arthritis  1.29E-02  0.167 
23  Glutathione Biosynthesis  1.45E-02  0.667 
24  Retinoate Biosynthesis I  1.70E-02  0.2 
25  Transcriptional Regulatory Network in Embryonic Stem Cells  2.09E-02  0.175 
26  LXR/RXR Activation  2.24E-02  0.125 
27  Embryonic Stem Cell Differentiation into Cardiac Lineages  2.95E-02  0.3 
28  Methylglyoxal Degradation III  2.95E-02  0.3 
29  JAK/Stat Signaling  3.02E-02  0.139 
30  CD40 Signaling  3.63E-02  0.141 
 
 
 
Table 4-5 IPA pathway analysis 
List of the top 30 statistically over-represented canonical pathways from the DNCB gene-list using IPA ranked by corrected p-value.  Ratio = number 
of genes differentially expressed, divided by the number of genes in the pathway 
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Rank  Pathway  p-value  FDR   Ratio 
1  Immune response_IL-1 signaling pathway  7.21E-10  5.21E-07  0.3182 
2  Immune response_IL-17 signaling pathways  7.37E-09  2.62E-06  0.2500 
3  Immune response_HMGB1/RAGE signaling pathway  1.09E-08  2.62E-06  0.2642 
4  Immune response_IL-18 signaling  6.10E-08  1.10E-05  0.2333 
5  Role of Endothelin-1 in inflammation and vasoconstriction in Sickle cell disease  1.50E-07  2.17E-05  0.2895 
6  The innate immune response to contact allergens  3.47E-07  3.86E-05  0.3030 
7  Immune response_TREM1 signaling pathway  3.73E-07  3.86E-05  0.2203 
8  Reproduction_GnRH signalling  6.81E-07  6.15E-05  0.1944 
9  Immune response_HMGB1/TLR signaling pathway  8.57E-07  6.89E-05  0.2778 
10  Transcription_Role of AP-1 in regulation of cellular metabolism  1.49E-06  1.07E-04  0.2632 
11  Immune response_IL-3 activation and signaling pathway  2.04E-06  1.34E-04  0.2903 
12  Putative pathways of hormone action in neurofibromatosis type 1  2.38E-06  1.38E-04  0.3333 
13  Immune response_Gastrin in inflammatory response  2.49E-06  1.38E-04  0.1884 
14  Transcription_Role of VDR in regulation of genes involved in osteoporosis  3.78E-06  1.95E-04  0.1967 
15 
Immune response_Substance P-stimulated expression of proinflammatory cytokines via 
MAPKs  5.04E-06  2.43E-04  0.2326 
16  Immune response_HSP60 and HSP70/ TLR signaling   6.75E-06  2.87E-04  0.2037 
17  Immune response_CCL2 signaling  6.75E-06  2.87E-04  0.2037 
18  Signal transduction_PTMs in IL-17-induced CIKS-independent signaling pathways  9.64E-06  3.87E-04  0.2174 144 
 
Rank  Pathway  p-value  FDR   Ratio 
19  Immune response_TLR2 and TLR4 signaling pathways  1.17E-05  4.23E-04  0.1930 
20  Immune response_Role of PKR in stress-induced antiviral cell response  1.17E-05  4.23E-04  0.1930 
21  Expression targets of Tissue factor signaling in cancer  1.48E-05  4.83E-04  0.3182 
22  Immune response_MIF-mediated glucocorticoid regulation  1.48E-05  4.83E-04  0.3182 
23  Immune response_Signaling pathway mediated by IL-6 and IL-1  1.54E-05  4.83E-04  0.2667 
24  Development_ERBB-family signalling  1.62E-05  4.87E-04  0.2308 
25  PDE4 regulation of cyto/chemokine expression in arthritis  1.75E-05  5.05E-04  0.2041 
26  IGF family signaling in colorectal cancer  1.95E-05  5.43E-04  0.1833 
27  The role of KEAP1/NRF2 pathway in skin sensitization  2.58E-05  6.90E-04  0.2500 
28  Immune response_Classical complement pathway  3.03E-05  7.81E-04  0.1923 
29  Development_Regulation of epithelial-to-mesenchymal transition (EMT)  3.67E-05  9.07E-04  0.1719 
30  Role of keratinocytes and Langerhans cells in skin sensitization  3.76E-05  9.07E-04  0.2800 
 
Table 4-6  Metacore pathway analysis  
List of the top 30 statistically over-represented canonical pathways from the DNCB gene-list using Metacore ranked by p-value.  FDR = false 
discovery rate. 
 145 
 
 
Figure 4-7 IL-6 signalling pathway 
Differentially expressed genes involved in the IL-6 signalling pathway from  IPA.  Up-regulated genes (red) and down-regulated genes (green), 
intensity of colour indicates level of fold change.   146 
 
 
Figure 4-8 IL-10 signalling pathway  
Differentially expressed genes involved in the IL-10 signalling pathway from IPA.  Up-regulated genes (red) and down-regulated genes (green), 
intensity of colour indicates level of fold change.   147 
 
 
Figure 4-9 Toll-like receptor signalling pathway  
Differentially expressed genes involved in the TLR signalling pathway from  IPA.  Up-regulated genes (red) and down-regulated genes (green), 
intensity of colour indicates level of fold change.   148 
 
 
Figure 4-10 Immune response IL-1 signalling pathway 
Differentially  expressed genes  involved in  the IL-1 signalling pathway from  MetaCore.  The  thermometers  show up-regulated (red) and down-
regulated (blue) gene changes at 20M (1), 27.5M (2) and 30M (3).   149 
 
 
Figure 4-11 Immune response HSP60 and HSP70 TLR signalling pathway  
Differentially expressed genes involved in the Hsp/TLR signalling pathway from MetaCore.  The thermometers show up-regulated (red) and down-
regulated (blue) gene changes at 20M (1), 27.5M (2) and 30M (3).   150 
 
 
Figure 4-12 KEAP1/NRF2 pathway as a cellular sensor for skin sensitisers  
Differentially expressed genes involved in the Nrf2 signalling pathway from MetaCore.  The thermometers show up-regulated (red) and down-
regulated (blue) gene changes at 20M (1), 27.5M (2) and 30M (3).   151 
 
Upstream regulator analysis  
In order to identify potential triggers of the differential gene expression, the data were 
analysed in IPA to find upstream regulators that drive similar gene expression profiles.  
A  closer  match  of  up-  and  down-regulation  leads  to  greater  statistical  significance.  
Upstream regulators include drugs, chemicals and endogenous molecules.   
 
From  this  analysis,  TNF,  MEK/ERK,  JNK,  p38MAPK,  NF-B,  TLR,  and  EGFR 
signalling (or their chemical inhibitors) were highlighted (Table 4-7).  Three of these 
upstream regulators (p38MAPK, JNK and NF-B) are shown as examples, alongside 
the corresponding gene profiles from our data (Figure 4-13 and 4-14). 
 
Transcription factor target analysis 
Another  analysis  method  to  investigate  which  factors  control  the  differentially 
expressed genes in the data is to detect over-represented transcription factor:promoter 
binding  sites.    The  open  access,  web-based  oPOSSUM  software 
(http://opossum.cisreg.ca/oPOSSUM3)  was  used  for  this  purpose.    The  standard 
JASPAR  CORE  profile  database  was  used  with  the  following  default  settings:  a 
minimum specificity of 8 bits, and a matrix match threshold of 85% with 5000/5000 
upstream/downstream sequence were chosen.   The top 30 transcription factors (sorted 
by z-score) are listed (Table 4-8).   
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Rank   Upstream regulator  Molecule type  Predicted activation state  Activation    z-score  p-value of overlap 
1  TNF  Cytokine  Activated  3.303  2.51E-16 
2  PDGF BB  Complex  Activated  3.216  6.81E-15 
3  SB203580  chemical - kinase inhibitor  Inhibited  -2.446  3.13E-13 
4  IL1B  Cytokine  Activated  3.411  1.11E-12 
5  25-hydroxycholesterol  chemical reagent  Activated  2.157  2.44E-12 
6  P38 MAPK  Group  Activated  2.809  2.49E-12 
7  CREB1  transcription regulator  Activated  3.066  5.28E-12 
8  PD98059  chemical - kinase inhibitor  Inhibited  -3.773  1.29E-11 
9  IRAK4  Kinase        1.87E-11 
10  NFkB (complex)  Complex  Activated  2.909  2.02E-11 
11  poly rI:rC-RNA  chemical reagent  Activated  3.449  2.68E-11 
12  LDL  Complex     1.88  2.82E-11 
13  IKBKB  Kinase     1.088  3.12E-11 
14  lipopolysaccharide  chemical drug  Activated  3.999  3.36E-11 
15  IL10  Cytokine     -0.671  4.70E-11 
16  SP600125  chemical - kinase inhibitor  Inhibited  -3.097  2.45E-10 
17  prostaglandin E2  chemical - endogenous mammalian  Activated  2.285  2.48E-10 
18  TREM1  transmembrane receptor  Activated  2.25  2.58E-10 
19  U0126  chemical - kinase inhibitor  Inhibited  -3.541  3.67E-10 
20  thapsigargin  chemical toxicant  Activated  2.93  6.58E-10 
21  cholesterol  chemical - endogenous mammalian     0.747  9.33E-10 153 
 
Rank   Upstream regulator  Molecule type  Predicted activation state  Activation    z-score  p-value of overlap 
22  Jnk  Group  Activated  2.278  1.04E-09 
23  TAC1  Other  Activated  2.376  1.66E-09 
24  SFTPA1  transporter  Inhibited  -2.646  1.66E-09 
25  Pka  complex     1.664  1.82E-09 
26  BAPTA-AM  chemical reagent  Inhibited  -2.401  2.10E-09 
27  cycloheximide  chemical reagent     1.142  2.88E-09 
28  PPRC1  transcription regulator  Activated  2.401  3.82E-09 
29  EGF  growth factor  Activated  3.197  3.84E-09 
30  IL4  cytokine     1.876  4.25E-09 
 
 
 
Table 4-7 Upstream regulator analysis 
List of top 30 upstream regulators matching the gene expression profile induced by DNCB, ranked by p-value, from IPA. 
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b 
                 
Figure 4-13 p38MAPK and JNK as upstream regulators 
Upstream regulators consistent with modulation of many of the differentially expressed 
genes  include  p38MAPK  (a)  and  JNK  (b),  from  IPA.    Orange  arrows  =  predicted 
activation, yellow arrows = inconsistent effect compared to upstream regulator, grey 
arrow = association with unknown direction.  Red nodes = up-regulated gene in our 
data.  155 
 
 
 
 
 
 
 
Figure 4-14 NF-B as an upstream regulator  
NF-B was highlighted as a potential upstream regulator consistent with modulation of 
many  of  the  differentially  expressed  genes,  from  IPA.    Orange  arrows  =  predicted 
activation, yellow arrows = inconsistent effect compared to upstream regulator, grey 
arrow = association with unknown direction; solid lines = direct interaction.  Red nodes 
= up-regulated gene in our data.  
 
 
 
 
 
 156 
 
Transcription 
factor  Family  z-score 
Fisher 
score 
SP1  BetaBetaAlpha-zinc finger  26.086  41.418 
Klf4  BetaBetaAlpha-zinc finger  22.166  52.038 
Egr1  BetaBetaAlpha-zinc finger  19.959  30.373 
MZF1_1-4  BetaBetaAlpha-zinc finger  17.869  30.006 
MZF1_5-13  BetaBetaAlpha-zinc finger  16.712  35.152 
SRF  MADS  16.529  16.963 
NF-kappaB  Rel  15.382  33.832 
NFYA  NFY CCAAT-binding  15.038  18.468 
HIF1A::ARNT  Helix-Loop-Helix  14.034  32.222 
REL  Rel  14.024  26.299 
Arnt  Helix-Loop-Helix  13.735  25.797 
ELK1  Ets  13.571  26.699 
Arnt::Ahr  Helix-Loop-Helix  11.314  25.139 
SPI1  Ets  11.178  27.077 
ELF5  Ets  10.609  30.924 
Mycn  Helix-Loop-Helix  10.498  18.287 
NFKB1  Rel  9.844  18.248 
SPIB  Ets  9.844  37.179 
IRF1  IRF  9.539  16.336 
FOXO3  Forkhead  9.531  18.689 
USF1  Helix-Loop-Helix  9.301  24.834 
FEV  Ets  9.264  25.244 
Stat3  Stat  9.16  28.072 
RELA  Rel  8.843  24.486 
ZNF354C  BetaBetaAlpha-zinc finger  8.819  40.238 
TEAD1  Homeo  8.745  12.536 
Myc  Helix-Loop-Helix  8.66  18.038 
INSM1  BetaBetaAlpha-zinc finger  8.613  22.643 
E2F1  E2F  8.452  18.353 
Table 4-8 Transcription factor target analysis 
List of the top 30 transcription factors controlling the differential gene expression 
induced by DNCB, ranked by z-score, from oPOSSUM.  Fisher score = negative natural 
logarithm of the p-values.   157 
 
Network analysis  
In order to gain a less restricted view of the data, network analysis was performed.  
Pathway analysis is restricted to known canonical pathways, whereas network analysis 
allows overlaying of data onto all known protein:protein interactions.   
 
A human interactome database (http://wiki.cytoscape.org/Data_Sets, Annotated human 
interactome  2007,  courtesy  of  Andrew  Garrow)  was  loaded  into  the  Cytoscape  3.1 
platform (http://www.cytoscape.org/).  This database contains information about which 
proteins  are  known  from  literature  to  interact  with  each  other.    In  Cytoscape,  the 
proteins are designated nodes and the interactions edges, which allows the formation of 
a network diagram.  A DNCB gene-list (p(corr) < 0.05 and fold change > 1.5) was 
overlaid onto this network and the non-changing proteins in the network filtered out, 
leaving only the differentially expressed genes (Figure 4-15).  Detailed views focused 
on individual hubs are shown in Figures 4-16 and 4-17.     
 
Gene expression of cytokines, chemokines, heat shock and keratin-related proteins 
We  searched  for  interleukins  (Table  4-9)  and  chemokines  (Table  4-10)  in  the  gene 
expression data to obtain a general view of cytokine and chemokine transcription in 
response  to  DNCB.    Also,  many  of  the  top  fold  change  genes  were  heat-shock  or 
keratin-related proteins, therefore we specifically searched for these families in the data 
(Table 4-11 and 4-12).    
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Figure 4-15 Network analysis: full network  
The significantly differentially expressed genes in response to DNCB (p(corr) < 0.05 
and  fold  change  >  1.5)  were  overlaid  onto  a  human  interactome  network.    Nodes 
coloured by fold change (red = up-regulated, green = down-regulated).  Nodes sized by 
p(corr), largest = most significant. 
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Figure 4-16 Network analysis: sub-networks - Heat shock proteins and JUN 
Detailed view of the network focussing on heat shock proteins (a) and JUN (b) sub-
networks.    Nodes  coloured  by  fold  change  (red  =  up-regulated,  green  =  down-
regulated).  Nodes sized by p(corr), largest = most significant. 
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Figure 4-17 Network analysis: sub-networks – MAPK and AhR 
Detailed  view  of  the  network  focussing  on  MAPK  (a)  and  AhR  (b)  sub-networks.  
Nodes coloured by fold change (red = up-regulated, green = down-regulated).  Nodes 
sized by p(corr), largest = most significant. 
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Gene symbol  Gene name 
FC (abs) 
DNCB 30M 
Regulation 
DNCB 
p (Corr)  
DNCB 
FC (abs) 
SDS 250M 
Regulation 
SDS 
p (Corr) 
SDS  
IL1RL1  interleukin 1 receptor-like 1  41.927  up  5.073E-05  13.491  Up  9.811E-05 
IL1A  interleukin 1, alpha  27.385  up  7.639E-06  5.961  Up  7.224E-05 
IL10RA  interleukin 10 receptor, alpha  17.810  up  6.836E-04  1.127  Up  8.716E-01 
IL6  interleukin 6 (interferon, beta 2)  16.827  up  5.301E-06  1.315  Up  1.894E-02 
IL13RA2  interleukin 13 receptor, alpha 2  12.498  up  5.766E-05  4.554  Up  7.224E-05 
IL8  interleukin 8  10.644  up  4.512E-02  2.348  Up  2.768E-01 
IL16  interleukin 16  3.263  down  3.512E-03  1.433  Up  8.478E-02 
IL1R2  interleukin 1 receptor, type II  2.441  up  4.514E-04  3.855  Up  7.224E-05 
IL1RN  interleukin 1 receptor antagonist  2.095  up  4.037E-03  1.000  down  9.970E-01 
IL1B  interleukin 1, beta  2.002  up  1.676E-05  1.609  Up  2.708E-04 
IL7R  interleukin 7 receptor  1.979  up  4.158E-02  2.303  Up  1.310E-02 
IL7R  interleukin 7 receptor  1.945  up  6.966E-02  2.562  Up  2.294E-02 
IL33  interleukin 33  1.937  up  3.899E-01  1.115  down  4.747E-01 
IL17RA  interleukin 17 receptor A  1.812  down  5.073E-05  1.154  down  2.198E-02 
IL1R2  interleukin 1 receptor, type II  1.785  up  4.967E-02  3.632  Up  1.018E-03 
IL11  interleukin 11  1.633  down  2.123E-03  1.810  Up  7.832E-03 
Table 4-9 Gene expression of interleukins  
A list of interleukins that have a fold change greater than 1.5 in response to DNCB (at 30M). 162 
 
Gene 
symbol  Gene name 
FC (abs) 
DNCB 
30M 
Regulation 
DNCB 
p (Corr)  
DNCB 
FC (abs) 
SDS 
250M 
Regulation 
SDS 
p (Corr)  
SDS 
CCL18 
chemokine (C-C motif) ligand 18 (pulmonary and 
activation-regulated)  18.544  up  1.67E-03  1.079  down  8.96E-01 
CXCR4  chemokine (C-X-C motif) receptor 4  16.464  up  1.57E-04  1.366  up  2.32E-01 
CCL3  chemokine (C-C motif) ligand 3  6.770  up  2.59E-03  1.610  up  3.25E-01 
CX3CL1  chemokine (C-X3-C motif) ligand 1  4.707  up  2.27E-03  1.229  down  3.30E-01 
CCL3L3  chemokine (C-C motif) ligand 3-like 3  4.490  up  2.27E-03  1.077  up  8.67E-01 
CCR7  chemokine (C-C motif) receptor 7  4.105  up  7.28E-04  1.459  up  1.33E-01 
CCL4  chemokine (C-C motif) ligand 4  3.141  up  5.21E-03  1.684  up  2.32E-01 
CCL26  chemokine (C-C motif) ligand 26  3.009  up  4.10E-04  1.022  down  8.66E-01 
CCL26  chemokine (C-C motif) ligand 26  2.959  up  1.05E-04  1.078  down  3.16E-01 
CCL3L3  chemokine (C-C motif) ligand 3-like 3  2.772  up  7.98E-03  1.183  up  5.03E-01 
CCR2  chemokine (C-C motif) receptor 2  2.613  up  2.72E-02  1.978  up  6.64E-02 
CCL2  chemokine (C-C motif) ligand 2  2.553  down  7.35E-05  5.008  down  6.63E-05 
CX3CL1  chemokine (C-X3-C motif) ligand 1  2.191  up  1.71E-01  1.310  down  5.68E-01 
CCL7  chemokine (C-C motif) ligand 7  2.069  down  7.05E-03  2.098  down  8.27E-03 
CCL25  chemokine (C-C motif) ligand 25  2.039  up  5.52E-02  1.194  up  4.62E-01 
CXCR5  chemokine (C-X-C motif) receptor 5  2.033  up  4.85E-01  1.072  down  8.60E-01 163 
 
Gene 
symbol  Gene name 
FC (abs) 
DNCB 
30M 
Regulation 
DNCB 
p (Corr)  
DNCB 
FC (abs) 
SDS 
250M 
Regulation 
SDS 
p (Corr)  
SDS 
ACKR3  atypical chemokine receptor 3  1.866  up  2.27E-03  1.537  down  2.09E-02 
CXCR2P1  chemokine (C-X-C motif) receptor 2 pseudogene 1  1.730  down  7.98E-03  1.178  up  8.67E-01 
CCR3  chemokine (C-C motif) receptor 3  1.681  up  4.28E-01  1.046  up  9.14E-01 
CCR4  chemokine (C-C motif) receptor 4  1.574  up  4.29E-01  3.995  up  3.25E-01 
 
 
 
 
Table 4-10 Gene expression of chemokines   
A list of chemokines that have a fold change greater than 1.5 in response to DNCB (at 30M). 
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Gene 
symbol  Gene name 
FC (abs)  
DNCB 30M 
Regulation 
DNCB 
p (Corr) 
DNCB 
FC (abs) 
SDS 250M 
Regulation 
SDS 
p (Corr) 
SDS 
HSPA6  heat shock 70kDa protein 6 (HSP70B')  611.867  up  3.31E-07  1.840  down  7.17E-03 
HSPA1L  heat shock 70kDa protein 1-like  9.920  up  4.83E-06  2.037  down  1.57E-03 
HSPA1A  heat shock 70kDa protein 1A  8.479  up  4.83E-06  1.417  down  1.97E-02 
HSPA1A  heat shock 70kDa protein 1A  7.477  up  1.72E-06  1.419  down  7.17E-03 
HSPB8  heat shock 22kDa protein 8  3.754  up  6.91E-04  1.897  up  7.45E-02 
HSPH1  heat shock 105kDa/110kDa protein 1  3.619  up  1.36E-06  1.159  up  7.38E-02 
HSPA12A  heat shock 70kDa protein 12A  3.574  down  2.14E-02  1.414  down  4.72E-01 
HSPA1A  heat shock 70kDa protein 1A  3.502  up  4.83E-06  1.335  down  7.17E-03 
HSPB3  heat shock 27kDa protein 3  2.926  down  9.59E-05  1.167  down  2.12E-01 
HSPH1  heat shock 105kDa/110kDa protein 1  2.842  up  6.77E-07  1.106  up  1.68E-01 
HSPD1  heat shock 60kDa protein 1 (chaperonin)  2.655  up  1.04E-03  1.096  down  6.10E-01 
HSP90AA1  heat shock protein 90kDa alpha (cytosolic), class A 1  1.978  up  8.72E-04  1.115  up  3.00E-01 
HSP90AA1  heat shock protein 90kDa alpha (cytosolic), class A 1  1.962  up  1.48E-02  1.257  down  4.52E-01 
HSPA4  heat shock 70kDa protein 4  1.866  up  1.08E-03  1.003  up  9.60E-01 
HSPB9  heat shock protein, alpha-crystallin-related, B9  1.813  down  1.96E-03  1.240  up  1.54E-01 
AHSA1  AHA1, activator of heat shock 90kDa protein ATPase 
homolog 1 (yeast) 
1.811  up  1.08E-03  1.009  up  9.31E-01 
HSPA8  heat shock 70kDa protein 8  1.753  up  1.96E-03  1.095  up  4.60E-01 165 
 
Gene 
symbol  Gene name 
FC (abs)  
DNCB 30M 
Regulation 
DNCB 
p (Corr) 
DNCB 
FC (abs) 
SDS 250M 
Regulation 
SDS 
p (Corr) 
SDS 
HSP90AB6P  heat shock protein 90kDa alpha (cytosolic), class B 
member 6, pseudogene 
1.723  up  4.87E-01  1.133  down  8.76E-01 
HSP90AA1  heat shock protein 90kDa alpha (cytosolic), class A 1  1.701  up  2.17E-02  1.039  down  8.48E-01 
HSP90AB1  heat shock protein 90kDa alpha (cytosolic), class B 1  1.687  up  1.36E-04  1.012  up  8.48E-01 
HSPA13  heat shock protein 70kDa family, member 13  1.647  up  1.51E-03  1.203  up  1.54E-01 
HSPD1  heat shock 60kDa protein 1 (chaperonin)  1.616  up  1.56E-04  1.074  up  1.68E-01 
 
 
 
 
Table 4-11 Gene expression of heat shock proteins  
A list of heat shock proteins that have a fold change greater than 1.6 in response to DNCB (at 30M). 
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Gene symbol  Gene name 
FC (abs) 
DNCB 
30M 
Regulation 
DNCB 
p (Corr) 
DNCB 
FC (abs) 
SDS 
250M 
Regulation 
SDS 
p (Corr) 
SDS 
KRTAP1-5  keratin associated protein 1-5  61.849  up  9.15E-05  1.558  Up  1.39E-01 
KRTAP3-2  keratin associated protein 3-2  57.664  up  2.16E-02  1.294  down  8.54E-01 
KRT34  keratin 34  28.499  up  1.69E-04  2.179  Up  3.70E-02 
KRTAP1-3  keratin associated protein 1-3  18.977  up  8.84E-03  1.939  Up  3.09E-01 
KRTAP4-1  keratin associated protein 4-1  11.352  up  5.25E-03  1.000  Up  1.00E+00 
KRTAP4-6  keratin associated protein 4-6  7.793  up  8.84E-03  1.074  Up  8.65E-01 
KRTAP1-1  keratin associated protein 1-1  5.818  up  1.77E-04  1.240  Up  3.25E-01 
KRTAP3-1  keratin associated protein 3-1  4.609  up  3.82E-03  1.018  down  9.47E-01 
KRT27  keratin 27  4.027  up  7.19E-02  2.980  Up  1.55E-01 
KRTAP2-3  keratin associated protein 2-3  3.897  up  2.50E-03  1.920  Up  4.09E-02 
KRTAP9-2  keratin associated protein 9-2  2.737  up  4.77E-01  1.865  down  6.13E-01 
KRT6B  keratin 6B  2.138  down  2.15E-03  2.382  Up  6.03E-04 
KRTAP1-1  keratin associated protein 1-1  2.051  up  2.05E-02  1.477  down  3.10E-01 
KRT23  keratin 23 (histone deacetylase 
inducible) 
1.856  down  2.23E-03  1.645  Up  1.65E-02 167 
 
Gene symbol  Gene name 
FC (abs) 
DNCB 
30M 
Regulation 
DNCB 
p (Corr) 
DNCB 
FC (abs) 
SDS 
250M 
Regulation 
SDS 
p (Corr) 
SDS 
KRTAP19-1  keratin associated protein 19-1  1.825  up  3.32E-01  2.002  Up  2.88E-01 
KRTAP4-12  keratin associated protein 4-12  1.710  up  2.17E-01  1.145  Down  6.22E-01 
KGFLP2  keratinocyte growth factor-like protein 
2 
1.675  down  5.66E-01  1.440  Down  6.22E-01 
KRT33B  keratin 33B  1.624  up  1.74E-01  1.017  up  9.58E-01 
KRTAP2-3  keratin associated protein 2-3  1.567  up  4.19E-01  1.036  up  9.31E-01 
 
 
 
 
Table 4-12 Gene expression of keratins and keratin associated proteins  
A list of keratins and keratin associated proteins that have a fold change greater than 1.5 in response to DNCB (at 30M). 
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4.3 Discussion 
 
In this chapter, we investigated the transcriptional response of HaCaT cells to a model 
sensitiser (DNCB) and a model irritant (SDS).  We observed large differences in gene 
expression  between  the  two  chemicals,  as  was  initially  evident  from  our  principal 
component analysis of the raw signal intensities from the arrays.  The overlap between 
significantly  differentially  expressed  genes  was  small,  and  gene  ontology  analysis 
showed  that  different  processes  were  being  affected.    In  general,  the  most  over-
represented  gene  ontologies  in  response  to  DNCB  were  regulation  of  transcription, 
whereas  in  response  to  SDS  they  were  mainly  regulation  of  cell  death.    These 
differences  might  be  caused  by  the  different  chemistries  of  DNCB  and  SDS.    The 
electrophilic  nature  of  DNCB  makes  it  likely  to  covalently  modify  any  exposed 
nucleophilic amino acids on proteins (Aleksic et al, 2007), and it is possible that this 
could change their functional state and lead to changes in transcription.  Conversely, 
SDS is an amphiphilic anionic surfactant that can cause membrane disruption leading to 
necrotic cell death (Pastore et al, 1995).   
 
From  the  transcriptomic  analysis,  we  see  differential  expression  of  cytokines, 
chemokines and growth factors, which are consistent with the cytokine release seen 
from HaCaT cells in the previous chapter.  For example, IL-1, IL-6 and IL-8 were 2, 
17 and 10.6-fold up-regulated (respectively) on the arrays, which correspond to 2, 15 
and 8-fold seen in chapter 3 by qRT-PCR.  Also, the increase in IL-1RA and decrease in 
MCP-1 seen at the protein level in chapter 3 were mirrored in the array data (IL-1RA 
2.1-fold up, MCP-1 2.6-fold down).  IL-1, although not found to be released by the 
cells  in  the  previous  chapter,  was  27-fold  up-regulated  at  the  transcriptional  level, 
indicating  that  it  is  actively  synthesised  but  remains  pre-stored  (Cohen  et  al,  2010; 
Corsini et al, 1998; Coquette et al, 2003).  TNF was only 1.37-fold increased at 4 
hours,  however,  it  was  the  most  significant  upstream  regulator  found  in  pathway 
analysis, and also, TNF induced protein 3 (TNFAIP3) was up to 5-fold upregulated, 
indicating that TNF may have been present at an earlier time.   
 169 
 
In response to DNCB, transcription of IL-1 family cytokines and receptors included 
both stimulatory and inhibitory components, suggesting activation of IL-1 signalling in 
a tightly regulated manner.  For instance, we saw up-regulation of agonists IL-1 and 
IL-1 as well as the antagonist IL-1RA and the inhibitory decoy receptor interleukin-1 
receptor type 2 (IL-1R2).  Keratinocytes have been shown by others to express IL-1R2 
(Lukiw et al, 1999; Yamaki et al, 2010), which inhibits local inflammation induced by 
IL-1  (Rauschmayr  et  al,  1997),  since  it  binds  IL-1  but  lacks  a  signal  transmission 
domain, preventing a response to the ligand.  IL-1R2 also binds to intracellular IL-1 
and protects it from cleavage to its active form (Zheng et al, 2013).  This may contribute 
to the lack of IL-1 release we observed in response to DNCB. 
 
Another  gene  from  the  IL-1  family,  interleukin-1  receptor-like  1  (IL-1RL1)  was 
significantly up-regulated in response to DNCB, with the highest fold change of all 
interleukin-related genes (42-fold).  Its ligand, IL-33, was also up-regulated although 
just under 2-fold, and has been shown to be expressed in the nucleus of keratinocytes 
(Moussion et al, 2008).  IL-33 signalling is known to drive Th2 responses (Schmitz et 
al, 2005), and more recently CD8+ responses (Bonilla et al, 2012).  Recent evidence has 
shown  that  IL-33  plays  an  important  role  in  responses  to  contact  allergens.    The 
abrogation of IL-33 has been shown to reduce ear swelling in mouse CHS (Taniguchi et 
al, 2013), and it has been found to be expressed in human skin during ACD (Mattii et al, 
2013).  Our data indicate that these in vivo responses may be driven by keratinocyte-
derived IL-33. 
 
In addition to pro-inflammatory cytokines, we saw transcription of genes that suggest 
anti-inflammatory components of the response.  For example, the receptor for the anti-
inflammatory cytokine IL-10 (IL-10RA) and the decoy receptor for IL-13 (IL-13RA2; 
Kawakami et al, 2001) were strongly up-regulated in HaCaT cells.  Also, unexpectedly, 
the IL-17 receptor (IL-17RA) was slightly down-regulated (1.8-fold), which would act 
to reduce the effect of Th17 cells known to be involved in ACD (Larsen et al, 2009; 
Pennino et al, 2010).   
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We also saw down-regulation of IL-11 in response to DNCB.  It is possible that down-
regulation  of  IL-11  may  increase  the  CHS  response,  since  administration  of 
recombinant human IL-11 decreases CHS reactions (Peterson et al, 2000). 
 
Many chemokines that drive the infiltration of both innate and adaptive immune cells 
into the epidermis were found to be modulated in response to DNCB.  In addition to IL-
8  and  MCP-1  (previously  discussed),  several  of  the  other  differentially  expressed 
chemokines  are  known  to  be  involved  in  ACD.    CCL3,  a  chemotractant  for 
granulocytes, and CCL4, a chemoattractant for T cells, NK cells and monocytes, were 
both  up-regulated in  our data and have been shown to  be expressed in  skin  during 
elicitation to contact allergens (Goebeler et al, 2001).  CCL18, which is known to attract 
naïve T cells (Adema et al, 1997) and cause maturation of macrophages (Schraufstatter 
et al, 2012), has been seen in vivo during elicitation to contact sensitisers (Goebeler et 
al, 2001; Pivarcsi et al, 2004).  The CD4+ T cell chemoattractant IL-16 (reviewed in 
Center et al, 1996) is also known to be involved in CHS (Yoshimoto et al, 2000).  It is 
expressed in the epidermis during sensitisation and elicitation to TNCB and oxazolone 
(Masuda et al, 2005), and polymorphisms in its promoter have been associated with 
increased susceptibility to ACD (Reich et al, 2003).  In contrast to this, we observed a 
decrease in IL-16 in response to DNCB, therefore it is possible that a different cell type 
is the source of IL-16 during CHS.   
 
The other differentially expressed chemokines have not previously been associated with 
CHS.  However, given their ability to attract granulocytes (CCL26), T cells (CCL25, 
CX3CL1),  monocytes  (CCL7),  macrophages  and  dendritic  cells  (CCL25),  their  up-
regulation is likely to assist cutaneous immune responses to chemical exposure.  For 
example, CX3CL1 is a T cell chemoattractant that also facilitates adhesion to T cells 
(Bazan et al, 1997), and is expressed in human skin and keratinocyte cell lines (Sugaya 
et al, 2003).  Therefore, it is plausible that it may be involved in elicitation of CHS.  
Further  study  would  be  required  to  determine  which  of  the  differentially  expressed 
chemokines have essential roles in CHS. 
 
In addition to the chemokine expression, transcription of several chemokine receptors 
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been found to be expressed in keratinocytes in response to IL-4 (Kagami et al,  2005); 
CCR4 and CXCR4 have been shown to be expressed by keratinocytes (Kroeze et al, 
2012);  and  CXCR4  is  also  involved  in  the  regulation  of  keratinocyte  proliferation 
(Takekoshi et al, 2013).     Differentially expressed chemokine receptors CCR2 and 
CCR7, from our study, were not previously detected in skin (Kroeze et al, 2012), and 
CXCR5 has, to our knowledge, not been reported to be expressed on keratinocytes.  
We  saw  a  striking  up-regulation  of  many  heat  shock  proteins  (Hsp)  in  response  to 
DNCB, which was not seen in response to SDS.  Many of these had gene expression 
fold-changes greater than 10 that were highly significant.  The differentially expressed 
Hsp clustered together in network analysis, alongside DnaJ proteins, also known as 
Hsp40.  Hsp are essential for protein folding and degradation, and the DnaJ family 
regulate the activity of Hsp70 by stimulating ATP hydrolysis, enabling Hsp70 to bind to 
unfolded  polypeptides  (Qiu  et  al,  2006).    The  Hsp  response  to  DNCB  was  also 
highlighted in pathway  analysis, where the Hsp60/70 pathway was one of the most 
significant found.   In common with our observation, others have seen transcription of 
Hsp  in  keratinocytes  in  response  to  sensitisers:  HSPA1B  (Vandebriel  et  al,  2010); 
HSPA6, HSPH1, DNAJB4 (Saito et al, 2013); DNAJB1 and DNAJB4 (Yoshikawa et 
al, 2010).  Keratinocytes have been shown to produce Hsp70 and Hsp27 in response to 
osmotic stress (Garmyn et al, 2001).  Yusuf et al (2009) saw reduced CHS responses to 
DNFB with inhibition of Hsp27 or Hsp70.  There is also some evidence that peptides 
chaperoned by Hsp70 are presented more efficiently (Binder et al, 2001; Ishii et al, 
1999) and result in larger DTH elicitation responses (Roman and Moreno, 1997).   Hsp 
are thought to act as endogenous danger signals, since they are released from necrotic 
cells and are able to stimulate DC maturation (Basu et al, 2000), potentially through 
TLR4 (Ohashi et al, 2000).   
 
It  is  possible  that  we  saw  such  a  large  up-regulation  of  Hsp  to  process  mis-folded 
protein caused by covalent modification by DNCB.  DnaJ/Hsp40 has been shown to be 
important  for  ubiqutination  processing  of  keratin  in  keratinocytes  (Yamazaki  et  al, 
2012).    In  our  data,  as  well  as  the  Hsp,  we  also  saw  many  other  genes  from  the 
ubiquitination pathway, including USP2, SPINK1, HTRA3 (all more than 10-fold up-
regulated) and NEDD4L, UBE2B, UBE2D3,  UCHL1, USP36 more than 2-fold  up-
regulated in response to DNCB.  172 
 
 
We saw a large number of keratins and keratin associated proteins (KRTAP) highly up-
regulated.    These  are  known  to  contain  a  high  percentage  of  nucleophilic  residues 
(Rogers  et  al,  2006).    It  is  possible  that  sensitisers  haptenate  these  keratin  proteins 
(Aleksic et al, 2008; Simonsson et al, 2011) and lead to loss of function, meaning that 
transcription is necessary to restore the cellular architecture.  
 
Several of the gene expression analysis methods suggest the involvement of NF-B in 
the  response  to  DNCB.    In  the  pathway  analysis,  NF-B  itself  was  not  seen  to  be 
differentially expressed, however, its negative regulator IB was down-regulated, and 
NF-B inducing kinase (NIK) was up-regulated.  NF-B was also highlighted as an 
important  upstream  regulator  due  to  the  up-regulation  of  IL-1,  IL-6,  IL-8  and  -
defensin.  Transcriptional activity of NF-B and its sub-components REL and RELA 
was inferred to be highly significant, based on up-regulation of their transcriptional 
targets in transcription factor analysis.    
 
There is substantial evidence for involvement of MAPK pathways in the response to 
DNCB.    Many  of  the  significant  pathways  included  up-regulation  of  transcription 
factors that are downstream of MAP kinases, e.g. ATF3, c-Jun, c-Fos, C/EBP (NF-IL6).  
The most striking evidence was from the upstream regulator analysis, which, due to the 
expression of related genes, highlighted p38MAPK, JNK, CREB (downstream of ERK) 
and inverse relationships  with  chemical  inhibitors of p38MAPK,  JNK and MEK1,2 
(upstream  of  ERK).    Transcription  factor  analysis  showed  the  relevance  of  MAPK 
activated transcription factors Myc, ELK1 and other ETS family transcription factors.  
JNK  was  also  found  as  a  central  hub  in  network  analysis,  connected  to  modulated 
DUSP 4, 6, 7, 10 and 16 which are MAPK phosphatases (reviewed in Jeffrey et al, 
2007).  p38MAPK and JNK phosphorylation has previously been seen in skin explants 
and  reconstituted  human  epidermis  exposed  to  DNFB  or  oxazolone  (Koeper  et  al, 
2007), and inhibition of p38MAPK, but not JNK or ERK, reduced CHS reactions to 
DNFB in mice (Ayush et al, 2013).  In contrast, inhibition of JNK, but not p38MAPK 
or ERK, decreased TNCB-induced IL-18 expression from PAM212 keratinocytes (Yun 
et al, 2010). 
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We saw some evidence for Nrf2/ARE activity from pathway analysis, where pathways 
related to Nrf2 and glutathione synthesis were found to be significantly modulated in 
our data.  The Nrf2 pathway featured in the pathway analysis due to up-regulation of 
MafF and MafG (which bind Nrf2 to form a transcription factor complex), and HMOX-
1, TXNRD1, IL-8, GCLC and GCLM.  DNCB has been shown to inhibit thioredoxin 
reductase  (TXNRD1)  and  increased  transcription  maybe  acting  to  recover  function 
(Arner et al, 1995).  Others have seen transcription of Nrf2-dependent genes, including 
HMOX-1, TXNRD1, IL-8, GCLC, GCLM, NQO1 and AKR1C2, in keratinocytes in 
response to sensitisers (Vandebriel et al, 2010; Saito et al, 2013; Yoshikawa et al, 2010; 
Van der Veen et al, 2013; Emter et al, 2013).  Several  groups have observed Nrf2 
activation following exposure to sensitisers in DC or DC-like cells (Ade et al, 2009; 
Lewis et al, 2006; Megherbi et al, 2009; Migdal et al, 2013), which could be due to 
direct binding to Keap-1 (Kobayashi et al, 2009) or generation of sufficient reactive 
oxygen species (ROS) to activate Keap-1, causing release and translocation of Nrf2.  In 
vitro keratinocyte assays are being developed that aim to predict sensitisation potential 
based on this hypothesis.  KeratinoSens is based on a luciferase reporter gene under the 
control of the ARE of AKR1C2 in HaCaT cells (Emter et al, 2010), and SenCeeTox 
measures  Nrf2-related  genes  AKR1C2,  NQO1,  TXN,  IL-8,  HMOX-1,  ALDH3A1, 
MAFF and GCLC among 11 genes used in the prediction (McKim et al, 2010, 2012).  
In  addition  to  the  ARE,  involvement  of  the  xenobiotic  response  element  (XRE)  is 
implied  by  our  data,  since  the  aryl  hydrocarbon  receptor  (AhR)  and  its  nuclear 
translocator (ARNT) were highly ranked in the transcription factor analysis, and AhR 
was also the hub of a small cluster in the network analysis.  This receptor is activated by 
planar aromatic hydrocarbons, and binds the XRE triggering the expression of genes 
related to chemical metabolism.   
 
The pathway and transcription factor analyses of the data have given us insight into the 
signalling cascades that might be triggered by DNCB (MAPK, NF-B and Nrf2).  We 
can also use the data to speculate about potential receptor-mediated initiation of these 
signalling cascades.  For example, NF-B and MAPK are downstream of the IL-1R and 
TLRs, and we see modulation of other genes on these cascades (such as IL-1RL1, IL-
1R2, TRAF6, TIRAP, TICAM1 and agonists IL-1, IL-33), as well as the TLR ligands 
LPS  and  PolyIC  appearing  in  the  list  of  upstream  regulators.    These  observations 174 
 
suggest the possibility that DNCB could initiate IL-1 or TLR signalling, either directly 
or via production of danger signals.  Another possibility is the EGFR/ErbB receptors, 
which are upstream of MAPK.  We saw the ErbB pathway amongst the highest ranked 
pathways, and EGF in the list of significant upstream regulators.  We also saw ErbB4 
and the ErbB feedback inhibitor 5-fold modulated in the data.  Both EGFR and ErbB 
have cysteine rich extracellular domains that DNCB could bind.  Alternatively, HB-
EGF, a ligand for both EGFR and ErbB4, was also upregulated (4-fold).   
 
In this  chapter, we have investigated the transcriptional  changes  in  keratinocytes  in 
response to DNCB (summarised in Figure 4-18), and have generated some potential 
mechanisms by which DNCB triggers cytokine release based on mRNA profiles.  In the 
next  chapter,  we  will  investigate  the  functional  protein  responses  of  some  of  the 
candidate  mechanisms,  including  the  intracellular  signalling  cascades  NF-B  and 
p38MAPK,  their  involvement  with  cytokine  release  and  potential  triggering 
mechanisms (ROS generation and EGFR signalling).   
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Figure 4-18 Summary of the interpretation of the transcriptomics data  
The schematic includes directly modulated genes, and pathways, upstream regulators 
and transcription factors highlighted in analysis of the transcriptomics data. 
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5  ACTIVATION  OF  INTRACELLULAR  SIGNALLING  CASCADES  IN 
HACAT CELLS FOLLOWING EXPOSURE TO DNCB  
 
5.1 Introduction  
In the previous chapter, we investigated the transcriptional response of keratinocytes to 
DNCB, and saw changes in the expression of genes driven by the p38MAPK, ERK, 
JNK, NF-B and Nrf2 signalling cascades.  In this chapter, we will investigate these 
mRNA findings at the functional protein level and determine if any are responsible for 
the sensitiser-specific cytokine profile (IL-1, IL-6, IL-8) seen in chapter 3. 
 
It is known that IL-1, IL-6 and IL-8 have promoter binding sites for NF-B (Kunsch 
and Rosen, 1993; Libermann and Baltimore, 1990; Hiscott et al, 1993) and for MAPK-
activated  transcription  factors  such  as  c-Jun  and  Fos  (AP-1)  (Faggioli  et  al,  2004; 
Cucinotta et al, 2008; Roman et al, 2000).  Therefore, it is possible that one or more of 
these  signalling  pathways  is  driving  the  release  of  these  cytokines  in  response  to 
sensitiser. 
 
Sensitiser-induced  MAPK  and  NF-B  intracellular  signalling  have  mostly  been 
investigated in dendritic cells (DC)  (Ade et al, 2007; Aiba et al, 2003; Antonios et al, 
2009; Arrighi et al, 2001; Boisleve et al 2004; Boisleve et al 2005; Bruchhausen et al, 
2003; Mizuashi et al, 2005; Trompezinski 2008) or DC-like cells (Cruz et al, 2002; 
Hirota  et  al,  2009;  Suzuki  et  al,  2009;  Matos  et  al,  2005a/b;  Mitjans  et  al  2008; 
Miyazawa et al, 2008; Megherbi et al, 2009; Nukada et al, 2008; Iijima et al, 2003).   In 
most cases, p38MAPK is activated in response to sensitisers, while the data are less 
consistent  for  ERK,  JNK  and  NF-B,  and  depend  on  the  chemical  or  time-point 
investigated.  The objective of several of these studies was to characterise the role of 
MAPK and NF-B signalling cascades in DC maturation, measured by expression of 
CD83, CD86, CCR7 or HLA-DR (Ade et al, 2007; Antonios et al, 2009; Boisleve et al, 
2004).  
  
More  recently,  p38MAPK,  ERK  and  JNK  were  also  shown  to  be  activated  in 
keratinocytes in response to DNFB, PPD and oxazolone (Frankart et al, 2012; Galbiati 177 
 
et al, 2011; Koeper et al, 2007), and NF-B activation was observed in response to 
TNBS, DNBS and PPD (Galbiati et al, 2011; Miyazaki et al, 2000).  MAPK signalling 
has been shown to be activated in skin (in vivo) during DNFB-induced CHS (Ayush et 
al, 2013), and inhibition of p38MAPK reduced the CHS ear swelling response (Ayush 
et al, 2013; Pastore et al, 2005).   
 
In addition to evidence for MAPK and NF-B activation, in the previous chapter we 
also found indications that sensitiser-induced cytokine gene expression changes may be 
triggered by EGFR/ErbB or ROS.  Both of these triggers are known to stimulate the 
MAPK  pathways  (Teng  et  al,  2007;  EGFR  signalling  reviewed  in  Lemmon  and 
Schlessinger,  2010),  and  therefore  represent  possible  mechanisms  to  initiate  the 
response.  
 
As one of the sensitiser-specific cytokines, IL-1 has been shown to induce DCs to 
migrate and mature in CHS (Cumberbatch et al, 1997; Shornick et al, 2001), in addition 
to  establishing  which  pathways  drive  the  sensitiser-specific  cytokine  release  from 
keratinocytes, it would be interesting to know if they have a functional effect on DCs. 
 
The objectives of this chapter are therefore to: identify which signalling pathways are 
activated  in  response  to  DNCB  (including  the  likely  candidates  from  the  previous 
chapter); determine which signalling cascades have a role in DNCB-driven IL-1, IL-6 
and  IL-8  expression;  investigate  likely  triggering  mechanisms  of  these  signalling 
pathways (receptor or ROS mediated); and test if the sensitiser-specific cytokine release 
has a functional effect on DC maturation. 
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5.2 Results 
Activation of p38MAPK signalling pathway in response to DNCB 
HaCaT cells were cultured in the presence of DNCB, LPS or IFN over a time course of 
30 minutes to 24 hours.  Cell lysate proteins were separated by SDS-PAGE, and di- 
phosphorylated (Thr180/Tyr182) p38MAPK (Figure 5-1a and c) and-actin as a loading 
control  (Figure  5-1b)  were  measured  by  western  blot.    One  of  two  representative 
experiments is shown.  In response to DNCB, p38MAPK was phosphorylated at 30 
minutes,  1,  4  and  8  hours,  but  not  at  24  hours.    The  phospho-p38MAPK  response 
peaked at 1 hour and then decreased.  LPS and IFNdid not give a detectable phospho-
p38MAPK signal by western blotting.  
 
A similar experiment was performed with a reduced range of time points (30 minutes, 1 
and 4 hours) and  single concentrations of 30M DNCB and 300M SDS.  Protein was 
extracted,  and  total  and  phosphorylated  p38MAPK  measured  by  Luminex  ELISA 
(Figure  5-2).    Data  are  shown  as  total  and  phosphorylated  raw  fluorescence 
measurements (a and b) and the ratio of phosphorylated:total (c and d).  The graphs 
show mean and standard deviation  (SD) from three  experiments.   The  total  protein 
levels of p38MAPK were relatively constant in the DNCB and SDS treated HaCaT 
cells.    The  phosphorylated:total  p38MAPK  ratios  were  significantly  increased  with 
DNCB  and  SDS  compared  with  control.    The  increase  in  the  phosphorylated:total 
p38MAPK ratio seen in response to DNCB peaked at 1 hour, which is consistent with 
the western blot data.   
 
Activation of Hsp27 in response to DNCB 
Heat  shock  protein  27  (Hsp27)  is  downstream  from  p38MAPK  in  the  signalling 
cascade.    In  an  identical  experiment  to  that  previously  described,  total  and 
phosphorylated (Ser82) Hsp27 were measured by Luminex ELISA (Figure 5-3).  The 
total  protein  levels  of  Hsp27  are  constant  across  all  treatments.    The 
phosphorylated:total Hsp27 ratio increased in response to DNCB at all time-points, and 
at  the  early  time-points  (30  minutes,  1  hour)  in  response  to  SDS.    All  treatments, 
including vehicle control, show a time-dependent decrease in phospho-Hsp27. 
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Figure 5-1 phospho-p38MAPK in response to DNCB, LPS or IFN 
HaCaT cells were cultured in the presence of 0.2% DMSO (VC), 27.5M or 30M 
DNCB (a and b), 1g/ml LPS or IFN (c) over a time-course.  Cell lysate proteins were 
separated by SDS-PAGE, and di-phosphorylated (Thr180/Tyr182) p38MAPK (a and c) 
and-actin (b) were measured by western blot.  One of two representative experiments 
is shown.  L = molecular weight ladder. 
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Figure 5-2 p38MAPK response to stimulation with DNCB, SDS, LPS and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (a and 
c), or 1g/ml LPS or IFN (b and d) over a time-course.  Protein was extracted, and 
total  and  phosphorylated  p38MAPK  were  measured  by  Luminex  ELISA.    Data  are 
shown as total and phosphorylated raw fluorescence measurements (a and b) and the 
ratio  of  phosphorylated:total  (c  and  d).    DMSO  control  data  (in  b  and  d)  from 
DNCB/SDS  experiments.    The  graphs  show  mean  and  SD  from  three  experiments. 
Statistical analysis (c only): Two-way ANOVA with Bonferroni post-test (* p < 0.05, 
** p < 0.01, *** p < 0.001).   181 
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Figure 5-3 Hsp27 response to stimulation with DNCB, SDS, LPS and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (a and 
c), or 1g/ml LPS or IFN (b and d) over a time-course.  Protein was extracted, and 
total and phosphorylated Hsp27 were measured by Luminex ELISA.  Data are shown as 
total  and phosphorylated raw fluorescence measurements  (a and b) and the ratio of 
phosphorylated:total (c and d).  DMSO  control data (in b and d) from DNCB/SDS 
experiments.    The  graphs  show  mean  and  SD  from  three  experiments.  Statistical 
analysis (c only): Two-way ANOVA with Bonferroni post-test (* p < 0.05, ** p < 0.01, 
*** p < 0.001).   
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Inhibition of p38MAPK signalling  
HaCaT  cells  were  exposed  to  increasing  concentrations  of  the  p38MAPK  inhibitor 
SB203580 (Cuenda et al, 1995) in the presence or absence of 30M DNCB.  The MTT 
assay was used to assess cell viability (Figure 5-4).  There was minimal effect on cell 
viability  at  all  inhibitor  concentrations  up  to  25M.  IL-1  was  used  as  a  positive 
control to check the efficacy of the p38MAPK inhibitor SB203580.  Cells exposed to 
IL-1  without  inhibitor  showed  increased  phospho-p38MAPK,  by  western  blotting 
(Figure 5-5).  The level of phospho-p38MAPK decreased with increasing concentration 
of  inhibitor,  indicating  that  the  inhibitor  was  working  to  suppress  p38MAPK 
phosphorylation. A similar reduction in phosphorylation of p38MAPK has been seen 
previously  in  THP-1  cells  (Frantz  et  al,  1998).    We  also  measured  phosphorylated 
Hsp27  by  western  blot  (Figure  5-6).    The  level  of  IL-1  induced  phopho-Hsp27 
decreased with increasing concentration of the p38MAPK inhibitor.   
 
IL-1, IL-6 and IL-8 transcription in response to DNCB +/- p38MAPK inhibition  
HaCaT cells were exposed to DNCB for 4 hours with increasing concentrations of the 
p38MAPK inhibitor SB203580.  IL-1, IL-6 and IL-8 mRNA expression were analysed 
by  qRT-PCR  (Figure  5-7).      The  data  were  plotted  as  fold  change  normalised  to 
uninhibited vehicle control (0M p38MAPK inhibitor, DMSO 0.15%).  In the absence 
of DNCB, the vehicle control combined with low concentrations of inhibitor caused 
transcription of all three cytokines (peaking at 1-3M SB203580).  This increase was 
more apparent in IL-1 expression due to the lack of DNCB-induced response at 4 
hours (Figure 5-7a).  It is not clear what is driving the IL-1 difference with and without 
DNCB, it is possible that it could be due to  an interaction between DNCB and the 
SB203580 inhibitor.  The expression of IL-1 (Figure 5-7a) was unchanged in response 
to DNCB, and with inhibitor concentrations up to 5M.  Above this concentration of 
inhibitor,  IL-1  message  was  down-regulated  both  in  the  presence  and  absence  of 
DNCB.  DNCB induced a strong up-regulation of IL-6 mRNA, which was significantly 
inhibited in response to p38MAPK inhibitor at concentrations above 5M (Figure 5-
7b).    DNCB-  mediated  IL-8  mRNA  expression  was  also  significantly  inhibited  in 
response to p38MAPK inhibitor at concentrations of 1M or above (Figure 5-7c). 
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Figure 5-4 Cytotoxicity of the p38MAPK inhibitor SB203580 
HaCaT cells were exposed to 0.15% DMSO (VC) or 30M DNCB with increasing 
concentrations of the p38MAPK inhibitor SB203580.  The MTT assay was used to 
assess cell viability.  The graphs show mean and SD from three experiments.  
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Figure 5-5 phospho-p38MAPK in response to IL-1 +/- p38MAPK inhibitor  
HaCaT cells were cultured in the presence of 20ng/ml recombinant human IL-1 for 30 
minutes  +/-  p38MAPK  inhibitor  SB203580  (0-25M).    Cell  lysate  proteins  were 
separated by SDS-PAGE, and di-phosphorylated (Thr180/Tyr182) p38MAPK measured 
by western blot.  L = molecular weight ladder. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-6 phospho-Hsp27 in response to IL-1 +/- p38MAPK inhibitor  
HaCaT cells were cultured in the presence of 20ng/ml recombinant human IL-1 for 30 
minutes  +/-  p38MAPK  inhibitor  SB203580  (0-25M).    Cell  lysate  proteins  were 
separated by SDS-PAGE, and phosphorylated (Ser82) Hsp27 measured by western blot.  
L = molecular weight ladder. 
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Figure 5-7 IL-1, IL-6 and IL-8 transcription in response to DNCB +/- p38MAPK 
inhibition  
HaCaT cells were exposed to 0.15% DMSO (VC) or 30M DNCB, with increasing 
concentrations of the p38MAPK inhibitor SB203580.  IL-1, IL-6 and IL-8 mRNA 
expression was analysed by qRT-PCR.  Data are fold change normalised to uninhibited 
vehicle control.  The graphs show mean and SD from three experiments. Statistical 
analysis: One-way ANOVA with post-hoc Tukey’s multiple comparison test * p < 0.05, 
** p < 0.01, *** p < 0.001. 
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Activation of the ERK1/2 signalling pathway in response to DNCB 
HaCaT cells were cultured in the presence of DNCB over a time-course of 30 minutes 
to 24 hours.  Cell lysate proteins were separated by SDS-PAGE, and di-phosphorylated 
(Thr183/Tyr185)  Erk1/2  (Figure  5-8a)  and-actin  (Figure  5-8b)  were  measured  by 
western blot.  One of two representative experiments is shown.  At 30 minutes, there 
was no change in the phosphorylation level of ERK1/2 with DNCB exposure compared 
to vehicle control.  There was a decrease in phospho-ERK1/2 at 1 hour, followed by an 
increase at all later time-points in response to DNCB.   
 
A similar experiment was performed with a reduced range of time points (30 minutes, 1 
and 4 hours) and  single concentrations of 30M DNCB and 300M SDS.  Protein was 
extracted, and total and phosphorylated ERK1/2 measured by Luminex ELISA (Figure 
5-9).    Data  are  shown  as  total  and  phosphorylated  raw  fluorescence  measurements 
(Figure 5-9a and b) and the ratio of phosphorylated:total (Figure 5-9c and d).  The 
graphs show mean and SD from three experiments.  The total protein levels of ERK1/2 
were relatively constant with all treatments.  The phosphorylated:total ERK1/2 ratio 
with vehicle control was much lower at 4 hours than at 30 minutes or 1 hour.  DNCB 
induced a significant decrease in the ratio at 30 minutes and 1 hour, followed by a 
significant increase at 4 hours, consistent with the western blot.  In contrast, following 
exposure to SDS, the phosphorylated:total ERK1/2 ratio was significantly increased at 
30 minutes and 4 hours, but unchanged at 1 hour. 
Activation of MEK and p90RSK in response to DNCB 
MEK, the upstream signalling kinase to ERK1/2, and p90RSK, a downstream target of 
ERK1/2,  were  also  investigated  to  further  understand  the  modulation  of  the  ERK 
signalling pathway.  In an identical experiment to that previously described, total and 
phosphorylated MEK and p90RSK were measured by Luminex ELISA (Figures 5-10 
and 5-11).  The total protein levels of both were relatively constant in all treatments.  
The  ratio  of  phosphorylated:total  MEK  decreased  over  time  with  vehicle  control.  
Following  exposure  to  DNCB,  there  were  significant  decreases  in  the 
phosphorylated:total ratios of MEK and p90RSK at 30 minutes and 1 hour.  In contrast, 
SDS treatment led to significant increases in the phosphorylated:total ratios of MEK at 
all time points and p90RSK at 30 minutes and 4 hours. 187 
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Figure 5-8 phospho-ERK1/2 in response to DNCB 
HaCaT cells were cultured in the presence of 0.2% DMSO (VC), 27.5M or 30M 
DNCB (a and b) over  a time-course.  Cell lysate proteins  were separated by SDS-
PAGE,  and  di-phosphorylated  (Thr183/Tyr185)  ERK1/2  (a)  and-actin  (b)  were 
measured  by  western  blot.    One  of  two  representative  experiments  is  shown.    L  = 
molecular weight ladder. 
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Figure 5-9 ERK1/2 response to stimulation with DNCB, SDS, LPS and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (a and 
c), or 1g/ml LPS or IFN (b and d) over a time-course.  Protein was extracted, and 
total and phosphorylated ERK1/2 were measured by Luminex ELISA.  Data are shown 
as total and phosphorylated raw fluorescence measurements (a and b), and the ratio of 
phosphorylated:total (c and d).  DMSO  control data (in b and d) from DNCB/SDS 
experiments.    The  graphs  show  mean  and  SD  from  three  experiments.  Statistical 
analysis (c only): Two-way ANOVA with Bonferroni post-test (* p < 0.05, ** p < 0.01, 
*** p < 0.001).   189 
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Figure 5-10 MEK response to stimulation with DNCB, SDS, LPS and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (a and 
c), or 1g/ml LPS or IFN (b and d) over a time-course.  Protein was extracted, and 
total and phosphorylated MEK were measured by Luminex ELISA.  Data are shown as 
total and phosphorylated raw fluorescence measurements (a and b), and the ratio of 
phosphorylated:total (c and d).  DMSO  control data (in b and d) from DNCB/SDS 
experiments.    The  graphs  show  mean  and  SD  from  three  experiments.  Statistical 
analysis (c only): Two-way ANOVA with Bonferroni post-test (* p < 0.05, ** p < 0.01, 
*** p < 0.001).   190 
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Figure 5-11 p90RSK response to stimulation with DNCB, SDS, LPS and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (a and 
c), or 1g/ml LPS or IFN (b and d) over a time-course.  Protein was extracted, and 
total and phosphorylated p90RSK were measured by Luminex ELISA.  Data are shown 
as total and phosphorylated raw fluorescence measurements (a and b), and the ratio of 
phosphorylated:total (c and d).  DMSO  control data (in b and d) from DNCB/SDS 
experiments.    The  graphs  show  mean  and  SD  from  three  experiments.  Statistical 
analysis (c only): Two-way ANOVA with Bonferroni post-test (* p < 0.05, ** p < 0.01, 
*** p < 0.001).   191 
 
Activation of the JNK signalling pathway in response to DNCB 
HaCaT cells were cultured in the presence of DNCB over a time-course of 30 minutes 
to 24 hours.  Cell lysate proteins were separated by SDS-PAGE, and di-phosphorylated 
(Thr183/Tyr185) p46 and p54 JNK (Figure 5-12) were measured by western blot.  In 
response to DNCB, weak phospho-JNK signals were seen at 1 and 4 hours.  Phospho-
JNK could not be detected with vehicle control. 
 
A similar experiment was performed with a reduced range of time points (30 minutes, 1 
and 4 hours), and single concentrations of 30M DNCB and 300M SDS.  Protein was 
extracted, and total and phosphorylated JNK measured by Luminex ELISA (Figure 5-
13).  Data are shown as total and phosphorylated raw fluorescence measurements (a and 
b) and the ratio of phosphorylated:total (c and d).  The graphs show mean and standard 
deviation (SD) from three experiments.  The total protein levels of JNK were relatively 
constant in the DNCB and SDS treated HaCaT cells.  The phosphorylated:total JNK 
ratios were significantly increased with DNCB at 1 and 4 hours compared with control, 
consistent with the western blot data.  The ratio was also increased from control at 30 
minutes following exposure to SDS. 
 
Activation of c-Jun and CREB in response to DNCB 
c-Jun and CREB are transcription factors activated by MAP kinases.  In an identical 
experiment to that previously described, total and phosphorylated c-Jun and CREB were 
measured by Luminex ELISA (Figures 5-14 and 5-15).  The total protein levels of c-Jun 
increased over time with  vehicle control,  while total  CREB was  constant  across all 
treatments.  The phosphorylated:total c-Jun ratio increased at 1 and 4 hours in response 
to DNCB compared to control.  SDS exposure produced much smaller changes in c-Jun 
phosphorylation.  The ratio of phosphorylated:total CREB decreased over time with 
vehicle  control.    There  were  significant  increases  in  the  ratio  at  all  time-points  in 
response to DNCB, and at 30 minutes and 1 hour in response to SDS, compared to 
control. 
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Figure 5-12  phospho-JNK in response to DNCB 
HaCaT cells were cultured in the presence of 0.2% DMSO (VC), 27.5M or 30M 
DNCB over a time-course.  Cell lysate proteins were separated by SDS-PAGE, and di-
phosphorylated (Thr183/Tyr185) p46 and p54 JNK were measured by western blot.  L = 
molecular weight ladder.  
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Figure 5-13 JNK response to stimulation with DNCB, SDS, LPS and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (a and 
c), or 1g/ml LPS or IFN (b and d) over a time-course.  Protein was extracted, and 
total and phosphorylated JNK were measured by Luminex ELISA.  Data are shown as 
total and phosphorylated raw fluorescence measurements (a and b), and the ratio of 
phosphorylated:total (c and d).  DMSO  control data (in b and d) from DNCB/SDS 
experiments.    The  graphs  show  mean  and  SD  from  three  experiments.  Statistical 
analysis (c only): Two-way ANOVA with Bonferroni post-test (* p < 0.05, ** p < 0.01, 
*** p < 0.001).   
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Figure 5-14 c-Jun response to stimulation with DNCB, SDS, LPS and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (a and 
c), or 1g/ml LPS or IFN (b and d) over a time-course.  Protein was extracted, and 
total and phosphorylated c-Jun were measured by Luminex ELISA.  Data are shown as 
total and phosphorylated raw fluorescence measurements (a and b), and the ratio of 
phosphorylated:total (c and d).  DMSO  control data (in b and d) from DNCB/SDS 
experiments.    The  graphs  show  mean  and  SD  from  three  experiments.  Statistical 
analysis (c only): Two-way ANOVA with Bonferroni post-test (* p < 0.05, ** p < 0.01, 
*** p < 0.001).   
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Figure 5-15 CREB response to stimulation with DNCB, SDS, LPS and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (a and 
c), or 1g/ml LPS or IFN (b and d) over a time-course.  Protein was extracted, and 
total and phosphorylated CREB were measured by Luminex ELISA.  Data are shown as 
total and phosphorylated raw fluorescence measurements (a and b), and the ratio of 
phosphorylated:total (c and d).  DMSO  control data (in b and d) from DNCB/SDS 
experiments.    The  graphs  show  mean  and  SD  from  three  experiments.  Statistical 
analysis (c only): Two-way ANOVA with Bonferroni post-test (* p < 0.05, ** p < 0.01, 
*** p < 0.001).   196 
 
Investigation of the NF-B signalling pathway in response to DNCB 
HaCaT cells were cultured in the presence of DNCB over a time-course of 30 minutes 
to 24 hours.  Cell lysate proteins were separated by SDS-PAGE, and IB (Figure 5-
16a) and -actin as a loading control (Figure 5-16b) were measured by western blot.  In 
response to DNCB, IBlevels did not change at any dose or time-point. 
 
A similar experiment was performed with a reduced range of time points (30 minutes, 1 
and 4 hours) and  single concentrations of 30M DNCB and 300M SDS.  Protein was 
extracted, and total and phosphorylated IB measured by Luminex ELISA (Figure 5-
17).  Data are shown as total and phosphorylated raw fluorescence measurements (a and 
b) and the ratio of phosphorylated:total (c and d).  The graphs show mean and standard 
deviation  (SD)  from  three  experiments.    The  total  protein  levels  of  IB  were 
approximately  constant  in  the  DNCB  and  SDS  treated  HaCaT  cells.    The 
phosphorylated:total IB ratios were significantly decreased with DNCB and SDS at 
all time-points, compared with control.  
 
HaCaT cells were exposed to 0.2% DMSO (VC), 20-32.5M DNCB, 200-300M SDS, 
or 1-2g/ml  LPS for 2 hours.  NF-B RelA was  observed by confocal microscopy 
(Figure 5-18).  Data shown are the confocal images (Figure 5-18a) for NF-B RelA 
(red),  DAPI (blue) for  cells  exposed to  DMSO  (VC) or 32M  DNCB for 2 hours.  
Figure 5-18b shows the ratio of NF-B RelA inside the nucleus:outside the nucleus for 
each condition.  Based on the assumption that measurements on individual cells are 
independent  variables,  there  was  a  significant  increase  in  nuclear  NF-B  RelA 
translocation with all treatments compared to DMSO vehicle control.  
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Figure 5-16 IB in response to DNCB 
HaCaT cells were cultured in the presence of 0.2% DMSO (VC), 27.5M or 30M 
DNCB over a time-course.  Cell lysate proteins were separated by SDS-PAGE, and 
IB(a) and-actin (b) were measured by western blot.   
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Figure 5-17 IB response to stimulation with DNCB, SDS, LPS and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (a and 
c), or 1g/ml LPS or IFN (b and d) over a time-course.  Protein was extracted, and 
total and phosphorylated IB were measured by Luminex ELISA.  Data are shown as 
total and phosphorylated raw fluorescence measurements (a and b), and the ratio of 
phosphorylated:total (c and d).  DMSO  control data (in b and d) from DNCB/SDS 
experiments.    The  graphs  show  mean  and  SD  from  three  experiments.  Statistical 
analysis (c only): Two-way ANOVA with Bonferroni post-test (* p < 0.05, ** p < 0.01, 
*** p < 0.001).   199 
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Figure 5-18 NF-B translocation in response to DNCB, SDS and LPS  
HaCaT cells were exposed to 0.2% DMSO (VC), 20-32.5M DNCB, 200-300M SDS, 
or 1-2g/ml LPS for 2 hours.  NF-B RelA was observed by confocal microscopy.  
Data  shown  are  the  confocal  images  for  NF-B  RelA  (red),  DAPI  (blue)  for  cells 
exposed to DMSO (VC) or 32.5M DNCB for 2 hours (3 replicates) (a).  Ratio of NF-
B RelA inside the nucleus:outside the nucleus (each data point represents an individual 
cell)  for  each  condition  (b).  Statistical  analysis:  One-way  ANOVA  with  post-hoc 
Dunnett’s  multiple  comparison  test  *  p  <  0.05,  **  p  <  0.01,  ***  p  <  0.001.  All 
treatments were significant compared to DMSO vehicle control with p < 0.001 (***). 
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Inhibition of NF-B signalling  
HaCaT cells were exposed to increasing concentrations of the NF-B inhibitor BAY11-
7082 (Pierce et al, 1997).  TNF was used as a positive control to check the efficacy of 
the NF-B inhibitor BAY11-7082.  Cells exposed to TNF without inhibitor show large 
increases in IL-1, IL-6 and IL-8 mRNA expression (Figure 5-19, n=1).  The levels of 
each cytokine decrease with increasing concentration of inhibitor, indicating that the 
inhibitor was working to suppress NF-B signalling.  
 
HaCaT cells were exposed to 30M DNCB with increasing concentrations of the NF-
B inhibitor.  IL-1, IL-6 and  IL-8 mRNA expression were analysed by  qRT-PCR 
(Figure 5-20).  Data shown are fold change normalised to uninhibited vehicle control 
(0M inhibitor, 0.15%DMSO).  The NF-B inhibitor caused a concentration dependent 
decrease in the vehicle induced expression of IL-1 IL-6 and IL-8.  DNCB-induced IL-
1 and IL-8 showed a small increase in expression with increasing concentrations of 
inhibitor up to 3M (although not significant), followed by a significant decrease at 
25M.  DNCB-induced IL-6 expression was unchanged by inhibitor concentration up to 
10M, followed by a decrease at 25M.    
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Figure 5-19 IL-1, IL-6 and IL-8 transcription in response to TNF +/- NF-B 
inhibition  
HaCaT cells were exposed to vehicle control (culture media) or 20ng/ml TNF with 
increasing concentrations of the NF-B inhibitor BAY11-7082.  IL-1(a), IL-6 (b) and 
IL-8  (c)  mRNA  expression  were  analysed  by  qRT-PCR.    Data  are  fold  change 
normalised to uninhibited vehicle control.  No statistical analysis as n=1. 
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Figure 5-20 IL-1, IL-6 and IL-8 transcription in response to DNCB +/- NF-B 
inhibition  
HaCaT cells were exposed to 0.15% DMSO (VC) or 30M DNCB with increasing 
concentrations of the NF-B inhibitor BAY11-7082.  IL-1(a), IL-6 (b) and IL-8 (c) 
mRNA expression were analysed by qRT-PCR.  Data are fold change normalised to 
uninhibited vehicle control.  The graphs show mean and SD from three experiments.  
Statistical analysis: one-way ANOVA with Tukey’s multiple comparison test.  
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Activation of STAT3 and STAT6 in response to DNCB, SDS, LPS and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (Figure 
5-21a and c), or 1g/ml LPS or IFN (Figure 5-21b and d) over a time-course.  Protein 
was extracted, and phosphorylated STAT3 (Figure 5-21a and b) and phosphorylated 
STAT6  (Figure  5-21c  and  d)  (not  total)  was  measured  by  Luminex  ELISA.    The 
phosphorylated STAT3 responses to DNCB, SDS and vehicle control showed the same 
decrease with time.  No significant changes in phosphorylated STAT3 or STAT6 were 
seen with any of the treatments.  
 
Activation of Tyk2 in response to DNCB, SDS, LPS and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (Figure 
5-22a),  or  1g/ml  LPS  or  IFN  (Figure  5-22b)  over  a  time-course.    Protein  was 
extracted,  and  phosphorylated  Tyk2  (not  total)  was  measured  by  Luminex  ELISA.  
Phosphorylated Tyk2 significantly increased at 1 and 4 hours in response to DNCB 
compared to control.  No changes were seen following exposure to SDS. 
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Figure 5-21 phospho-STAT3 and phospho-STAT6 response to DNCB, SDS, LPS 
and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (a and 
c), or 1g/ml LPS or IFN (b and d) over a time-course.  Protein was extracted, and 
phosphorylated STAT3 (a and b) and phosphorylated STAT6 (c and d) (not total) were 
measured by Luminex ELISA.  Data are shown as phosphorylated raw fluorescence 
measurements.  DMSO control data (in b and d) from DNCB/SDS experiments.  The 
graphs show mean and SD from three experiments.  Statistical analysis (a and c only): 
Two-way ANOVA with Bonferroni post-test (* p < 0.05, ** p < 0.01, *** p < 0.001).   205 
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Figure 5-22 phospho-Tyk2 and phospho-Histone H3 response to DNCB, SDS, LPS 
and IFN 
HaCaT cells were exposed to 0.2% DMSO (VC), 30M DNCB or 300M SDS (a), or 
1g/ml LPS or IFN (b) over a time-course.  Protein was extracted, and phosphorylated 
Tyk2 (not total) was measured by Luminex ELISA.  Data are shown as phosphorylated 
raw  fluorescence  measurements.    DMSO  control  data  (in  b)  from  DNCB/SDS 
experiments.    The  graphs  show  mean  and  SD  from  three  experiments.    Statistical 
analysis (a only): Two-way ANOVA with Bonferroni post-test (* p < 0.05, ** p < 0.01, 
*** p < 0.001).   
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Activation of phospho-tyrosine in response to DNCB  
HaCaT cells were cultured in the presence of 0.2% DMSO (VC) or 30M DNCB for 8 
hours.  Cell lysate proteins were separated by SDS-PAGE, and total phospho-tyrosine 
measured  by  western  blot  (Figure  5-23).    The  lysate  from  the  DNCB  treated  cells 
showed a large molecular weight band just above 171kDa (referenced by the ladder), 
that was not present in the vehicle control.  There was also a band at approximately 
117kDa (referenced by the ladder) that was present in the control but not the DNCB 
exposed cells. 
 
Investigation of EGFR activation in response to DNCB 
To  determine  if  the  tyrosine-phosphorylated  large  molecular  weight  protein  seen  in 
response  to  DNCB  (Figure  5-23)  was  phosphorylated  EGFR  (MW  approximately 
185kDa), HaCaT cells were cultured in the presence of 0.2% DMSO (VC) or 20-30M 
DNCB  for  8  hours.    Cell  lysates  were  separated  by  SDS-PAGE,  and  phospho-
EGFR/ErbB1 (Tyr1173) measured by western blot (Figure 5-24).  Phospho-EGFR/ErbB1 
(Tyr1173) was detected at a similar intensity in all samples (control and DNCB treated). 
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Figure 5-23 phospho-tyrosine in response to DNCB 
HaCaT cells were cultured in the presence of 0.2% DMSO (VC) or 30M DNCB for 8 
hours.  Cell lysate proteins were separated by SDS-PAGE, and total phospho-tyrosine 
measured by western blot (4 replicates loaded).  One of two representative experiments 
is shown.   
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Figure 5-24 phospho-EGFR in response to DNCB 
HaCaT cells were cultured in the presence of 0.2% DMSO (VC) or 20-30M DNCB for 
8 hours.  Cell lysate proteins were separated by SDS-PAGE, and phospho-EGFR/ErbB1 
(Tyr1173) measured by western blot.   
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Generation of reactive oxygen species (ROS) in response to DNCB 
HaCaT cells were cultured in the presence of 0.2% DMSO (VC), 2.5-40M DNCB or 
menadione as a positive control (Loor et al, 2010) for 24 hours.  Cells were incubated 
with  ROS  detection  probe  (CM-H2DCFDA),  which  can  detect  hydrogen  peroxide 
(H2O2),  hydroxyl  radical  (HO•),  peroxyl  radical  (ROO•)  and  peroxynitrite  anion 
(ONOO-).  Intracellular probe fluorescence was measured by high throughput imaging 
using  the  Cellomics  Array  scan  (by  Samantha  Windebank).  The  percentage  of 
responding cells represents the percentage of cells with an average fluorescence over a 
threshold defined so that 15% of control treated cells are included (Figure 5-25a and b).  
There was a significant dose-dependent increase in the percentage of responding cells 
following exposure to DNCB, which was similar to the positive control menadione.  
Mean cellular total intensity represents the mean of the total intensities measured from 
each  cell.    The  mean  cellular  average  intensity  represents  the  mean  of  the  average 
intensities measured from each cell. The mean intensity SD represents the mean of the 
standard deviations of the intensities measured from each cell.  All three of these data 
metrics showed a significant dose-dependent increase in response to DNCB, up to a fold 
change  of  approximately  3  times  control.    Altogether,  these  results  demonstrate 
substantial generation of reactive oxygen species triggered by exposure to DNCB.    
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Figure 5-25 ROS generation in response to DNCB and menadione 
HaCaT cells were cultured in the presence of 2.5-40M DNCB or 1.8-29M menadione 
for 24 hours (0M = 0.2% DMSO vehicle control).  Cells were incubated with ROS 
detection  probe  (CM-H2DCFDA),  and  intracellular  probe  fluorescence  measured  by 
high throughput imaging using the Cellomics Array scan.  Statistical analysis: one-way 
ANOVA with Tukey’s multiple comparison test: (* p < 0.05, ** p < 0.01, *** p < 
0.001).  a and c, 10M DNCB or above p < 0.001 (***).  Measurement of ROS by 
Samantha Windebank.  
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Response of PBMC-DC to HaCaT conditioned media  
Peripheral  blood  mononuclear  cells  (PBMCs)  were  obtained  from  human  blood. 
Monocytes (CD14+ cells) were isolated from PBMCs and cultured with GM-CSF and 
IL-4 to stimulate differentiation into immature dendritic cells.  These PBMC derived 
DC were exposed for 20 hours to either: 0.15% DMSO (control); 100ng/ml LPS; or 
filtered  conditioned  media  from  HaCaT  cells  previously  exposed  to  various 
concentrations of DNCB, SDS or DMSO.  Expression of DC-SIGN, CD83 and CD86 
were analysed by flow cytometry.  To ensure analysis of the live DC population, cells 
were gated by FSC and SSC, then for DC-SIGN positive cells and for live cells by 
propidium iodine stain (Figure 5-26).    
 
In response to DMSO (directly not as conditioned media), PBMC-DC had a slightly 
greater  expression  of  CD83  and  CD86,  while  LPS  exposed  cells  showed  a  marked 
increase in expression of both compared to untreated cells (Figure 5-27).   
 
Following exposure to supernatant from HaCaT cells exposed to 27.5- 40M DNCB, 
PBMC-DC showed a small dose-dependent increase in CD83 and CD86 expression 
(Figure 5-28), although the magnitude was much less than that produced by LPS.   
 
A similar experiment was performed with a range of concentrations of DNCB and SDS, 
with biological replicates for each treatment (Figure 5-29).  In all cases only a small 
increase in CD83 or CD86 was seen, which was much lower than the increase observed 
with LPS-stimulated PBMC-DC.   
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Figure 5-26 Gating of PBMC-DC 
The PBMC-derived DC population were first gated by FSC and SSC (a), then for DC-
SIGN positive cells (FL4-H) (b), followed by live/dead propidium iodine stain (FL3-H) 
(c).  This gating was applied to all DC analyses. 
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Figure 5-27 PBMC-DC CD83 and CD86 expression in response to LPS 
PBMC-derived DC were untreated (a and b), or exposed directly to DMSO (c and d) or 
100ng/ml  LPS  (e  and  f)  for  20  hours.    CD83  (a,  c  and  e)  and  CD86  (b,  d  and  f) 
expression were measured by flow cytometry.  Graphs show isotype control (grey), 
unstimulated DC (red), DMSO or LPS exposed (green).  
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Figure 5-28 PBMC-DC CD83 and CD86 expression in response to supernatant 
from DNCB-treated HaCaT cells 
PBMC-derived DC were exposed to supernatant from HaCaT cells exposed to 27.5M 
DNCB (a and b), 32.5M DNCB (c and d) or 40M DNCB (e and f).  CD83 (a, c and e) 
and CD86 (b, d and f) expression were measured by flow cytometry.  Graphs show 
unstimulated DC (red), supernatant-exposed (green). 
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Figure 5-29 PBMC-DC CD83 and CD86 expression in response to supernatant 
from DNCB and SDS-treated HaCaT cells  
PBMC-derived  DC  were  exposed  for  20  hours  to  supernatant  from  HaCaT  cells 
exposed to 0.15% DMSO, or a range of concentrations of SDS or DNCB, or directly to 
LPS.  CD83 (a) and CD86 (b) expression were measured by flow cytometry.  BR = 
biological replicate.  
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5.3 Discussion  
 
In this chapter, we have investigated the signalling cascades and triggers highlighted at 
the mRNA level in chapter 4, and their functional link to the sensitiser-specific cytokine 
profile seen in chapter 3.  We first investigated the MAPK pathways, p38MAPK, ERK 
and  JNK,  as  well  as  some  of  their  downstream  targets:  c-Jun,  CREB,  Hsp27  and 
p90RSK.   
 
We found that p38MAPK was phosphorylated in response to DNCB, with a peak of 
about 5 times the control level at 1 hour, and sustained phosphorylation until at least 8 
hours.  In response to SDS, p38MAPK phosphorylation also increased, but to a much 
lesser extent, and was not sustained.  Several authors have reported phosphorylation of 
p38MAPK  in  response  to  sensitiser,  at  time  points  from  15  minutes  to  8  hours, 
specifically: DNFB in reconstructed human epidermis (RHE) models (Frankart et al, 
2012);  p-phenylenediamine  (PPD)  in  the  NCTC2544  human  keratinocyte  cell  line 
(Galbiati 2011); DNFB and oxazolone in (mouse and human) skin extracts and human 
RHE models (Koeper et al, 2007); and DNFB in mouse ear skin (Ayush et al, 2013).  In 
contrast  to  these  and  our  results,  Yun  et  al  (2010)  did  not  see  phosphorylation  of 
p38MAPK  in  response  to  TNCB  at  30  minutes  in  a  mouse  keratinocyte  cell  line, 
Pam212.  The in vivo relevance of p38MAPK in CHS was demonstrated by a reduction 
of the ear swelling response to DNFB during p38MAPK inhibition (Ayush et al, 2013). 
 
Following inhibition of p38MAPK, we saw decreases in DNCB-induced transcription 
of  IL-1,  IL-6  and  IL-8.    These  observations  demonstrate  a  role  for  p38MAPK  in 
driving the sensitiser-specific cytokine response in keratinocytes.  Following p38MAPK 
inhibition in keratinocytes and other cell types, other groups have also seen reduced 
cytokine expression: IL-1 levels were decreased in vivo in mouse skin (Ayush et al, 
2013); DNFB-driven IL-8 was inhibited in RHE (Frankart et al, 2012); DNCB-induced 
IL-1 and IL-8 expression were suppressed in PBMC-DC (Aiba et al, 2003); DNCB-
induced IL-8 release was inhibited in THP-1 cells (Mitjans et al 2008; Nukada et al, 
2008); LPS-induced IL-6 decreased in rat lung alveolar epithelial cells (Haddad, 2002); 
and IL-1-induced IL-6 was reduced in mouse skeletal muscle cells (Luo et al, 2003).  217 
 
Similarly, inhibition of Mnk1 (which is downstream of ERK and p38MAPK) inhibited 
anicomycin-induced IL-1 and IL-6 expression in keratinocytes (Kjellerup et al, 2007).   
 
A reduced DNFB-stimulated CHS response (Yusuf et al, 2009) was also seen following 
inhibition of Hsp27, which is directly downstream of p38MAPK (Garmyn et al, 2001).  
In our data, Hsp27 was phosphorylated over at least 4 hours and to a similar extent to 
p38MAPK, adding to the evidence that the p38MAPK pathway is being activated in 
response  to  DNCB.    The  phospho-Hsp27  response  to  SDS  was  short-lived  in 
comparison and similar to the SDS-induced p38MAPK profile.    
 
We  also  investigated  phosphorylation  of  ERK  in  response  to  DNCB.    The  ratio  of 
phosphorylated:total ERK was a maximum of 4-fold down-regulated in DNCB-treated 
cells compared to control at 30 minutes and 1 hour, however, at 4 hours the phospho-
ERK response to DNCB switched to about 4-fold up-regulated, acting slightly later than 
the p38MAPK response.  The upstream kinase for ERK, MEK, was also reduced at 30 
minutes and 1 hour, and was unchanged compared to control at 4 hours.  The same 
profile was  also  seen with the downstream  ERK target  p90RSK.  The reduction in 
activation of the ERK signalling cascade could be explained by previous observations 
of p38MAPK mediated inhibition of ERK (Zhang et al, 2001; Numazawa et al, 2003; 
Boisleve et al, 2005).  Our data are consistent with this proposed mechanism, in that the 
maximum suppression of ERK, MEK and p90RSK occurred at the same time as peak 
p38MAPK phosphorylation.   
 
In  contrast  to  DNCB,  phosphorylation  of  ERK,  MEK  and  p90RSK  were  highly 
upregulated at 30 minutes and 4 hours in response to SDS.  Overall, this indicates that 
activation of the ERK signalling cascade is responsive to SDS.   
 
Other published data on ERK phosphorylation in response to sensitiser exposure show 
conflicting results, which may be partly due to the interaction with p38MAPK.  ERK 
phosphorylation was found to be increased between 1 and 8 hours in response to: DNFB 
in  RHE  (Frankart  et  al,  2012);  DNFB  and  oxazolone  in  (mouse  and  human)  skin 
extracts  (Koeper  et  al,  2007);  and  DNFB  in  mouse  ear  skin  (Ayush  et  al,  2013).  
However, no changes in ERK phosphorylation were seen in human RHE models in 218 
 
response to DNFB and oxazolone (Koeper et al, 2007); or in response to TNCB in 
Pam212 (Yun et al, 2010). 
 
Several  authors  have  investigated  the  effect  of  ERK  signalling  on  cytokine  release 
through inhibition of MEK, leading to reductions in: DNFB-induced IL-8 release in 
RHE (Frankart et al, 2012); DNCB-induced IL-1 expression in PBMC-DC (Aiba et al, 
2003); DNCB-induced IL-8 release in THP-1 cells (Nukada et al, 2008);  and IL-1-
induced IL-6 in mouse skeletal muscle cells (Luo et al, 2003).  
 
 
We found that JNK was also phosphorylated in response to DNCB, at 1 and 4 hours, 
whereas  very  little  change  was  detected  with  SDS.    Several  authors  have  reported 
phosphorylation of JNK at time points from 30 minutes to 3 hours, in response to: 
DNFB and oxazolone in (mouse and human) skin extracts and human RHE models 
(Koeper et al, 2007); TNCB in Pam212 cells (Yun et al, 2010); and DNFB in mouse ear 
skin (Ayush et al, 2013).   
 
In  addition  to  p38MAPK,  ERK  and  JNK,  we  investigated  activation  of  c-Jun  and 
CREB, which are downstream targets of multiple MAPK pathways.  In response  to 
DNCB, we detected significant phosphorylation of both transcription factors; the ratios 
of phosphorylated:total c-Jun and CREB were 4-fold and 10-fold greater than control at 
4 hours, respectively.  In contrast, c-Jun was only slightly activated at 1 hour following 
exposure to SDS, and CREB was phosphorylated at early timepoints but not sustained 
at 4 hours.    
 
In summary, our data demonstrate an important contribution of the MAPK signalling 
cascades in sensitiser induced cytokine release from keratinocytes.  In general, DNCB 
appears to activate the oxidative stress-induced kinases p38MAPK and JNK, whereas 
SDS has a greater effect on the ERK pathway, more associated with cell proliferation.   
 
In the gene expression changes in the previous chapter, we found evidence of NF-B 
activation,  as  well  as  MAPK  signalling,  in  response  to  DNCB.    Therefore,  we 
investigated the NF-B response at the protein level.  We measured total IB, which 219 
 
inhibits NF-B translocation, therefore a decrease in IB would correspond to NF-B 
activation.    However,  we  saw  no  change  in  total  IB  levels  following  exposure  to 
DNCB  or  SDS.    In  contrast,  phosphorylated  IB  was  found  to  be  down-regulated 
between 30 minutes and 4 hours, which was more pronounced with DNCB than SDS.  
IB is ubiquitinated and degraded following phosphorylation (reviewed in Pasparakis, 
2009),  and  therefore  the  decrease  in  phosphorylated  IB  we  observed  might  be 
explained by an increase in the rate of proteasomal degradation, leading to a decrease in 
phospho-IB levels.  This would be consistent with the observed increase in expression 
of  proteins  associated  with  the  ubiquitination  pathways  in  response  to  DNCB  (see 
chapter  4).    We  also  studied  the  translocation  of  NF-B  from  the  cytosol  into  the 
nucleus and found a small, but dose-dependent increase in nuclear NF-B in response to 
DNCB, and when we inhibited NF-B, we found reduced expression of DNCB-induced 
IL-1, IL-6 and IL-8.  The inhibitor dose-dependence was, however, not as pronounced 
as the inhibition of TNF-induced IL-1, IL-6 and IL-8.  This difference could be due 
to the additional influence of MAPK driving DNCB-induced cytokine expression as 
well as NF-B.  HaCaT cells have been reported to have unusual NF-B signalling 
compared to primary keratinocytes (Chaturvedi et al, 2001; Lewis et al, 2006) which 
may contribute to our conflicting results.  However, in agreement with our results, Aiba 
et al (2003) saw a decrease in phospho-IB and no change in total IB in PBMC-DC in 
response to DNCB.  In a different human keratinocyte cell line (NCTC-2544), total IB 
was  found  to  be  reduced  in  response  to  p-phenylenediamine  (PPD)  (Galbiati  et  al, 
2011), and NF-B was activated in response to TNBS and DNBS in murine Pam212 
keratinocytes  (Miyazaki  et  al  2000).    Also,  NF-B  inhibition  reduced  poly(I:C)- 
induced IL-8 expression in HaCaT cells (Voss et al, 2012).  Although our results are not 
all consistent with an activated NF-B phenotype, on balance there is evidence of a role 
for NF-B signalling in DNCB-induced cytokine release. 
 
We found no changes in phosphorylation levels of STAT3 and STAT6 in response to 
DNCB or SDS, while phosphorylated Tyk2 (a member of the JAK family) increased by 
just 1.4-fold at 30 minutes and 1 hour following exposure to DNCB.  In agreement with 
this, Valk et al (2002) saw no activation of STAT3 or STAT6 in PBMC-DC following 220 
 
exposure to TNCB.  These results suggest little involvement of JAK/STAT signalling, 
which is also consistent with the transcriptomics data from chapter 4. 
 
In  order  to  understand  the  possible  upstream  triggers  for  the  activated  signalling 
cascades, we have investigated the potential for ROS generation, or phosphorylation of 
receptor tyrosine kinases (RTK).  We probed for total phosphotyrosine, and observed a 
strong band at just over 171kDa in response to DNCB, which was absent for control.  
This  represented  a  large  molecular  weight  protein  with  phosphorylated  tyrosine 
residues, which we hypothesised to be a RTK.  Exposure of PBMC-DC to sensitisers 
for  just  15  minutes  has  been  found  by  others  to  trigger  increased  phosphorylated 
tyrosine residues (proteins up to 135kDa measured) (Kuhn et al, 1998; Becker et al, 
2003).  We investigated whether the RTK could be EGFR, as EGFR/ErbB signalling is 
upstream of the MAPK cascades (reviewed in Lemmon and Schlessinger, 2010), and 
was highlighted in the analysis of the transcriptomics data in chapter 4.  This receptor 
has a molecular weight of 185kDa, in the right range for the phosphotyrosine band, and 
a cysteine rich extracellular domain (reviewed in Lemmon and Schlessinger, 2010) that 
could undergo covalent modification by DNCB.  To test this hypothesis, we probed for 
phosphorylated (Tyr1173) EGFR.  We found constitutive activation of this receptor with 
control,  and no change following exposure to  DNCB.  Following our investigation, 
Frankart et al (2012) saw phospho-EGFR in RHE in response to DNFB between 1 and 4 
hours, but not at 8 hours.  It is possible that the time point we chose (8 hours) was too 
late to detect increased phosphorylated EGFR.  Alternatively, the difference in results 
may be due to differences between RHE and HaCaT cells, since Frankart et al (2012) 
did not observe phospho-EGFR in their control samples.  Other studies also provide 
evidence  for  involvement  of  EGFR  activation  in  CHS.    EGFRs  were  found  to  be 
internalised in normal human keratinocytes in vitro following DNFB exposure (Lambert 
et al, 2010), and in vivo, an EGFR inhibitor caused increased ear swelling during a CHS 
response to DNFB (Pastore et al, 2005).  In common with Frankart et al (2012), we also 
detected increased transcription of HB-EGF (chapter 4), which is a ligand for both the 
EGFR and ErbB4.  Given the constitutive activation of EGFR we observed in HaCaT 
cells, it is possible that the ErbB4 receptor has a more dynamic role in responding to 
chemical stress.  ErbB4 has  a molecular weight of 180kDa, and is therefore also a 221 
 
plausible candidate for the phospho-tyrosine band; however, further investigation would 
be required to test this new hypothesis.  
 
In addition to the possibility of DNCB binding directly to RTKs, DNCB could have an 
indirect  effect  through  generation  of  ROS,  which  could  modulate  intra-cellular 
signalling.  For example, it has been shown that ROS can trigger MAPK signalling 
cascades  (Teng  et  al,  2007).    To  investigate  the  ROS  hypothesis,  we  measured 
production of ROS in HaCaT cells following DNCB exposure, and found a significant 
dose-dependent response.   In agreement with our data, other groups have shown that 
ROS are produced by sensitisers in DC-like cell lines (Miyazawa et al, 2012; Saito et al, 
2013), and more recently in keratinocytes (Kim et al, 2012; Esser et al, 2012; Galbiati et 
al, 2014; Onami et al, 2014).  Sensitisers have also been shown to decrease detectable 
free thiols on the surface of DC or DC-like cells (Hirota et al, 2009; Suzuki et al, 2009; 
Kagatani et al, 2010).  This could be due to binding by the sensitiser or sensitiser-
induced ROS.  In either case, application of glutathione (GSH) or N-acetylcysteine have 
been found to reduce effects of sensitiser exposure including: tyrosine phosphorylation 
(Bruchhausen et al, 2003); MAPK activation (Bruchhausen et al, 2003; Matos et al, 
2005 (2)); GSH depletion (Mizuashi et al, 2005); and DC maturation (CD80, CD86) 
(Iijima et al, 2003).  Given the extent of ROS production, the hypothesis that DNCB-
generated ROS initiate the intracellular signalling cascades remains plausible.  Further 
investigation would be required to determine the relative contributions of ROS vs. direct 
DNCB binding in triggering the sensitiser-specific cytokine profile. 
 
We hypothesise that the MAPK and NF-B signalling cascades could be initiated by 
DNCB via two main routes: production of oxidative stress, or triggering of RTKs.  Both 
of these mechanisms are likely to depend on the electrophilic nature of DNCB, either by 
direct binding to free cysteine residues or via increasing intracellular ROS, directly or 
by sequestering of antioxidant defences (e.g. glutathione, thioredoxin).  In the oxidative 
stress case, Nrf2 signalling could be triggered following binding of ROS or DNCB to 
Keap1, allowing nuclear translocation of Nrf2 (Itoh et al, 1998).  The contributions of 
direct DNCB binding or ROS to Nrf2 activation could be determined by measuring 
DNP-haptenated  Keap1,  or  by  observing  the  effect  of  reducing  ROS  levels  on 
signalling, for example by over-expressing SOD and catalase.  Oxidative stress is also 222 
 
known  to  trigger  MAPK  pathways  (p38MAPK,  JNK),  via  effects  on  the  upstream 
kinase ASK1 and PTP phosphatases.  ASK1 kinase activity is inhibited by constitutive 
interaction  with  reduced  thioredoxin  (Saitoh  et  al,  1998).    Following  exposure  to 
DNCB,  depletion  of  reduced  thioredoxin,  combined  with  irreversible  inhibition  of 
thioredoxin reductase, may remove ASK1 inhibition and cause activation of p38MAPK 
and JNK (Ichijo et al, 1997).  ROS have also been shown to cause reversible oxidation 
of cysteine residues at the catalytic site of MAPK phosphatases (MKP; cysteine-based 
PTP  /  DUSP),  rendering  them  unable  to  de-phosphorylate  activated  MAPK  and 
therefore potentiating signal transduction (Kamata et al, 2005; Robinson et al, 1999).  It 
is possible that DNCB could also inhibit phosphatases, by irreversibly modifying the 
same free cysteine residue (or via increasing intracellular ROS).  In order to assess these 
mechanisms, we could measure the effect of DNCB on ASK1 or MKP activity; or test 
whether DNCB can bind directly to MKP. 
 
Independently of oxidative stress, DNCB could bind to extracellular cysteine residues 
on  RTKs  (e.g.  ErbB,  InsR,  Ret),  causing  phosphorylation  and  activating  the 
downstream cascades, MAPK and NF-B.  We could test this hypothesis by looking for 
DNCB bound to cysteine-rich RTKs and/or receptor phosphorylation in response to 
DNCB.  Blocking / mutating these receptors would give us an idea of the contribution 
of receptor-mediated vs. ROS-mediated activation of MAPK signalling.  A second stage 
in the response, caused by DNCB-induced transcription of ligands (e.g IL-1, DAMPs, 
growth factors) could  be activation of  IL-1R,  TLR or RTK signalling.   To test  the 
impact of this on cytokine release, we could block IL-1R / TLRs, e.g. by knocking out 
MyD88.  As these hypothesised mechanisms only depend on electrophilic reactivity, it 
is  likely  that  other  sensitising  chemicals  would  follow  the  same  mechanism,  which 
could be easily tested with more chemicals. 
 
To investigate if the functional effect of the sensitiser-specific cytokines was to induce 
DC  maturation,  we  exposed  PBMC-DC  to  conditioned  media  from  HaCaT  cells 
previously exposed to DNCB.  We saw a small dose-dependent increase in CD83 and 
CD86, however, the magnitude was much lower than that produced by exposure to LPS, 
and not significant.  Matjeka et al (2012) carried out a similar experiment, but used 
much higher, cytotoxic concentrations of sensitiser to generate keratinocyte-conditioned 223 
 
media,  and  saw  DC  maturation,  partly  driven  by  IL-1  and  other  danger  signals 
released  after  cell  death.    Therefore,  it  is  unlikely  that  cytokines  derived  from 
keratinocytes exposed to sub-cytotoxic concentrations of sensitiser are influencing DC 
to mature during the induction of ACD.   
 
Given that keratinocyte conditioned media did not activate DC maturation, we speculate 
that  epidermal  keratinocytes  may  be  performing  an  alternative  role  in  CHS.    For 
example, they may contribute more to DC migration than maturation (e.g. via IL-1).  
Keratinocyte cytokine release may affect other cells to increase production of cytokines 
that trigger DC maturation or migration.  The keratinocytes could be more involved in 
chemotaxis (e.g. via IL-8, and other chemokines), recruiting immune cells to site of 
chemical exposure.  It may be that the main role of the keratinocyte is to sequester 
harmful  chemicals,  especially  in  the  thiol-rich  outer  skin  layers,  and  produce 
chemokines and DAMPs on death (IL-1, IL-33, HMGB1) which activate DC.  The 
keratinocytes are also likely to be the main source of modified protein to act as antigen 
external to DCs for presentation on MHC. 
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6  GENERAL DISCUSSION 
 
Contact hypersensitivity (CHS) is a well known adaptive immune response.  However, 
although keratinocytes are the first cell type to encounter chemical allergen, their role in 
the  induction  of  CHS  has  not  been  fully  characterised.    We  have  investigated  the 
molecular mechanisms activated in keratinocytes in response to chemical allergen.  In 
particular, we have studied sensitiser-induced transcriptional changes and activation of 
intracellular  signalling  cascades,  and  the  resultant  cytokine  release,  which  may  be 
important in the orchestration of skin cells to initiate an adaptive immune response.  
 
To find a suitable in vitro model to characterise the role of keratinocytes in contact 
hypersensitivity,  we  evaluated  the  HaCaT  cell  line  and  3-dimensional  human  skin 
models  (EpiDerm,  EpiDermFT).    The  3D  models  offer  significant  advantages  over 
monolayer culture, in that they are more representative of the physiology of human skin 
(Ponec  et  al,  2000,  2002;  Poumay  et  al,  2004).    In  our  experiments,  histological 
examination of the EpiDerm model confirmed a fully differentiated and stratified tissue 
structure, representative of keratinocyte differentiation in human epidermis; however, 
we  did  not  find  that  the  full  thickness  models  (EpiDermFT)  had  normal  tissue 
physiology.  Cytokine gene expression and protein release from the 3D models were 
found to be highly variable between donors.  This was potentially due to variation in the 
thickness of the stratum corneum between models leading to differences in chemical 
exposure of the viable keratinocyte layers (Regnier et al, 1993).   The variability in 
cytokine  measurements  excluded  further  use  of  these  models  to  investigate  the 
mechanisms behind sensitiser-induced mediator release. 
 
In  order  to  reduce  variability  and  uncover  mechanistic  detail,  we  investigated  the 
HaCaT  cell  line  as  a  potential  in  vitro  model.    These  cells  are  derived  from 
spontaneously immortalised (but non-tumorigenic) human keratinocytes, first isolated 
from  the  distant  periphery  of  an  adult  skin  melanoma.    They  retain  the  ability  to 
differentiate normally (unlike other keratinocyte cell lines) and can produce stratified 
epidermal  tissue  (Boukamp  et  al,  1988).    Despite  this,  HaCaT  cells  do  differ  from 
normal  human  keratinocytes  in  being  immortalised  and  cytogenetically  abnormal 
(Boukamp et al, 1988).  They contain mutations in both alleles of the p53 gene, which 225 
 
results in a mutant p53 protein with an extended half life (Lehman et al, 1993).  HaCaT 
cells have also been reported to have high constitutive NF-B activity compared to 
primary  keratinocytes  (Chaturvedi  et  al,  1999;  Qin  et  al,  1999;  Lewis  et  al,  2006), 
however,  we  observed  increased  activation  compared  to  this  baseline,  following 
exposure to DNCB.  Although there are some differences between the HaCaT cell line 
and primary keratinocytes, they have many features in common, and HaCaT cells are 
frequently  used  as  a  model  for  human  keratinocytes.    Critically,  for  investigating 
molecular mechanisms in our studies, the measurements in HaCaT cells were extremely 
consistent, and sensitive to different stimuli.  We have used HaCaT cells throughout our 
research;  however,  it  would  be  interesting  to  verify  our  key  results  in  primary 
keratinocytes.  
 
Using HaCaT cells, we investigated the release of keratinocyte-derived mediators that 
may play a role in intercellular communication during the initiation of CHS.  Following 
exposure to the chemical allergen DNCB, we saw increased release of cytokines (IL-1, 
IL-1ra,  IL-6),  chemokines  (IL-8,  RANTES)  and  the  growth  factor  GM-CSF.    We 
compared this response to HaCaT cells exposed to the irritant SDS, to distinguish the 
allergen response from cell death, and found a sensitiser-specific signature of amplified 
release of IL-1, IL-6 and IL-8.  The transcription kinetics of these three cytokines were 
different.  IL-6 expression, as well as being dose-dependent, was high but short lived, 
whereas  IL-1  and  IL-8  were  sustained  for  longer,  and  increased  after  peak  IL-6 
expression, indicating that there might be feedback mechanisms operating between the 
cytokines.  Expression of IL-1 and IL-8 has been seen previously from keratinocytes in 
response to sensitisers (Zepter et al, 1997; Newby et al, 2000, Coquette et al, 2003; 
Mohamadzadeh, 1994), whereas sensitiser-induced IL-6 expression has been observed 
in skin in vivo (Cumberbatch et al, 1996; Holliday et al, 1996; Flint et al, 1998), but not 
specifically  from  keratinocytes.    Our  results  demonstrate  that  keratinocytes  are  a 
potential source of IL-6 in skin during CHS responses.  In our study, the sensitiser-
specific cytokine responses were closely linked to the level of chemical-induced stress 
on the cells, and were maximally activated at concentrations just below the cytotoxicity 
threshold.  This led us to study a very narrow range of concentrations of DNCB, with 
careful consideration of the amount of cell death caused in each experiment.   226 
 
After observing the sensitiser-specific cytokine release, we investigated changes in the 
HaCaT  transcriptome  in  response  to  DNCB  and  SDS,  to  understand  the  pathways 
driving this response.  We saw many DNCB-specific changes in gene expression that 
were not seen in response to SDS.  In general, genes involved in the regulation of 
transcription  were  modulated  with  DNCB,  suggesting  an  active  cellular  response, 
whereas for SDS the changes were mainly linked to cell death. 
 
In the transcriptome response to DNCB, we observed up-regulation of IL-1, IL-6 and 
IL-8, and also IL-1 family cytokines and receptors (IL-1, antagonist IL-1ra, inhibitory 
decoy receptor IL-1R2, IL-1RL1 and its ligand IL-33), suggesting activation of IL-1 
signalling in a tightly regulated manner.  The transcription of IL-1 was 27-fold up-
regulated,  but  we  found  that  the  IL-1  protein  was  only  released  by  HaCaT  cells 
following total cell death (snap freezing or extremely high concentrations of DNCB).  
This indicates that IL-1 is pre-stored in keratinocytes in response to sensitiser.   
 
In addition to inflammatory cytokines, we found strong transcriptional up-regulation of 
many chemokines, suggesting that keratinocytes may have a role in attracting immune 
cells in response to sensitiser.  The chemokines specifically up-regulated in response to 
DNCB and not SDS included: CCL18, CCL3, CX3CL1, CCL3L3, CCL4, CCL26 and 
CCL25.    Collectively,  these  chemokines  attract  a  range  of  cell  types  previously 
described at sites of CHS, including granulocytes, monocytes, dendritic cells, NK cells 
and T cells.  Many of these chemokines have not previously been described as being 
expressed by keratinocytes in response to sensitisers. 
 
As well as cytokine and chemokine mediators, we saw large increases in the expression 
of  keratins,  keratin  associated  proteins,  and  heat  shock  proteins  that  have  a  role  in 
protein  folding  and  degradation.    We  also  observed  modulation  of  proteases  and 
ubiquitin-related genes.  Together, these changes are indicative of increased turnover of 
proteins in the cell, which could be attributed to protein mis-folding caused by DNCB 
haptenation, or keratinocyte hyperplasia leading to tissue re-modelling. 
 
To assist biological interpretation of the large number of gene expression changes, we 
performed  pathway,  transcription  factor  and  upstream  regulator  analyses.    In  these 227 
 
investigations, we found consistent evidence for the involvement of MAPK and NF-B 
signalling in response to DNCB.  In addition to the NF-B and MAPK pathways, Nrf2 
and  AhR  signalling,  which  trigger  the  ARE  and  XRE  respectively,  were  also 
highlighted in transcription factor and pathway analysis.   
 
Having  identified  potential  signalling  cascades  from  bioinformatics  analysis  of  the 
transcriptomics  experiments,  we  confirmed  the  functional  involvement  of  these 
pathways in response to DNCB.  We found that DNCB activated the oxidative stress-
induced kinases JNK and p38MAPK, and transcription factors downstream of MAPK, 
c-Jun and CREB.  In contrast, the SDS response was more associated with activation of 
the ERK pathway.  We also saw involvement of NF-B signalling in the keratinocyte 
response to DNCB, by direct measurement of NF-B translocation.  Using inhibitors, 
we demonstrated that the DNCB-specific IL-1, IL-6 and IL-8 release required both 
p38MAPK and NF-B signalling (independently).   
 
In order to initiate a T cell-mediated response to chemical allergen, DCs migrate from 
skin  to  the  local  draining  lymph  nodes  and  express  co-stimulatory  molecules.    The 
mechanism by which skin cells influence DCs to up-regulate these molecules has not 
been fully characterised.  In an immune response to chemical allergen, in the absence of 
pathogen, endogenous danger signals (DAMPs) including cytokines are likely to be the 
trigger for  DC  migration and maturation, but  the identity and cellular origin  of the 
DAMPs involved is not clear.  A successful CHS response also relies on presentation of 
chemical-derived antigen, and the source and route of processing and presentation of 
this  antigen  is  uncertain.    Hypotheses  for  antigen  include:  haptenation  of  protein 
followed by presentation of peptides containing the hapten; or presentation of atypical 
self-peptides due to mis-processing of haptenated protein or modification of the MHC 
groove by the chemical.  Understanding more about these critical mechanisms for the 
initiation of CHS would help to establish why some chemicals are more effective at 
triggering  CHS  than  others.    These  key  challenges  surrounding  DC  maturation  and 
chemical-derived  antigen  are  both  dependent  on  events  that  occur  in  the  skin,  and 
understanding the mechanisms of the keratinocyte response to chemical allergen is an 
important step towards addressing these questions. 
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An important question is whether the restricted set of mediators, which were observed 
to be up-regulated in reponse to DNCB in this study, is sufficient to initiate priming of 
an adaptive immune response, or if cross-talk with other cell types is required.  We 
hypothesised that the function of the sensitiser-induced keratinocyte-derived mediators 
could be to induce DC maturation.  We exposed PBMC-DC to conditioned media from 
DNCB-stimulated  keratinocytes  (at  sub-cytotoxic  concentrations),  and  saw  a  small 
dose-dependent  increase  in  DC  maturation  markers  CD83  and  CD86,  although  this 
increase was much smaller than that produced by LPS.  It is likely that the limited 
amount  of  DC  maturation  we  observed  was  due  to  the  dose-dependent  increase  in 
keratinocyte-derived IL-1, which has been shown to enhance antigen presentation by 
DCs (Enk et al, 1993).  However, our data suggests it is unlikely that keratinocytes 
alone  are  able  to  incite  DCs  to  fully  mature  following  exposure  to  sub-cytotoxic 
concentrations of sensitiser; and DC maturation may require a degree of keratinocyte 
cell death in exposed tissue.  IL-1 and IL-33, which we found to be up-regulated in 
response to DNCB, are released from intracellular stores following cell death, and are 
known  to  act  as  danger-associated  molecular  patterns  (DAMPs,  Cohen  et  al,  2010; 
Cayrol and Girard, 2009).  IL-1 has been shown to be capable of activating dendritic 
cells to express co-stimulatory molecules (Matjeka et al, 2012), and IL-33 promotes 
Treg function (Schiering et al, 2014; Matta et al, 2014).  As well as cytokine signalling 
mediators,  we  saw  a  large  increase  in  transcription  of  heat  shock  proteins  and  -
defensin 103b, which may provide additional danger signalling to neighbouring cells in 
the  epidermis,  causing  DC  maturation  (Basu  et  al,  2000;  Funderberg  et  al,  2007) 
following keratinocyte cell death.   
 
An alternative hypothesis, if a substantial level of cell death is not required, is that the 
keratinocyte-derived mediators we detected are part of communication with other skin 
cells to produce amplified or more diverse stimuli that can initiate an immune response.  
In  vivo  cutaneous  immune  responses  to  chemical  allergens  involve  cytokines  and 
chemokines (discussed previously) generated in the epidermis: IL-1, IL-1, IL-6, IL-
10,  IL-12,  IL-18,  IFN,  TNF,  IP-10,  MIP-2  and  GM-CSF.    It  is  not  possible  to 
accurately  identify  which  skin  cell  type  is  responsible  for  the  production  of  each 
cytokine, but the keratinocyte-derived cytokines we have observed could be directly 
contributing  to  this  milieu  or  stimulating  other  cell  types  to  create  the  correct 229 
 
environment.  For example, high levels of IL-6 and IL-8 can be induced in fibroblasts 
with keratinocyte-derived IL-1 (Boxman et al, 1996).  The keratinocyte mediators may 
also  trigger  LCs  to  produce  additional  IL-1  and  IL-6,  or  TNF  production  from 
macrophages.  
 
It is also possible that the main effect caused by intercellular mediators released from 
keratinocytes at sub-cytotoxic concentrations is to attract immune cellular infiltrate to 
the site of chemical exposure.  This suggestion is supported by the large increase in 
expression of many chemokines in response to DNCB, and high levels of IL-8 release, 
known to be a chemoattractant for granulocytes and T cells (Harada et al, 1994).  If the 
main role of keratinocytes in CHS is the production of chemokines, then keratinocytes 
may have a larger role in the elicitation, rather than the initiation of CHS responses.  In 
support of an elicitation role, we saw release of a large number of mediators in response 
to a combined innate/adaptive immune stimulus, LPS/IFN, which is representative of 
the skin microenvironment during an active elicitation response.  LPS/IFN-induced 
mediator  release  included  pro-inflammatory  cytokines  (IL-2,  IL-6,  IL-7,  IFN), 
chemokines  (MIP-1,  IP-10,  MCP-1,  MIG,  RANTES),  growth  factors  (HGF,  FGF, 
GCSF), and immuno-suppressive mediators (IL-1ra, IL-10, IL-2R).  These data suggest 
that keratinocytes could help to regulate elicitation responses through both stimulatory 
and inhibitory mechanisms.  The role of keratinocytes in elicitation of CHS has not been 
well studied and warrants further investigation. 
 
One intriguing aspect of the sensitiser-specific cytokine signature from keratinocytes, 
the high and short-lived expression of IL-6, may be connected to the question of the 
mechanism  of  antigen  generation  in  CHS.    IL-6  has  previously  been  linked  with 
autoimmune responses, by causing mis-processing in the endosome, resulting in the 
presentation of atypical epitopes (Drakesmith et al, 1998).  Blocking the IL-6 receptor 
was also shown to inhibit experimental autoimmune encephalomyelitis, and suppress 
antigen-specific T cells (Serada et al, 2008).  These data contribute to the hypothesis 
that keratinocyte-derived IL-6 might stimulate a sensitiser-induced ‘autoimmune-like’ 
reaction.    This  idea  is  supported  by  the  increase  in  proteinase  and  proteasome 
expression  indicated  in  our  transcriptomics  data.    In  addition  to  IL-6  driven  mis-
processing,  it  is  possible  that  DNCB  haptenates  and  causes  mis-folding  of  many 230 
 
proteins,  which  are  processed  to  present  peptides  that  appear  non-self.    This  is 
consistent with the strong up-regulation of Hsps observed following exposure to DNCB, 
which may be transcribed as a response to mis-folded protein in order to accelerate their 
delivery to the proteasome. 
 
Based on our observations, we can propose the molecular mechanisms that lead to the 
keratinocyte-derived  cytokine  release  (Figure  6-1).    DNCB  is  a  highly  reactive 
electrophilic  chemical,  and  is  therefore  likely  to  covalently  modify  any  exposed 
nucleophilic amino acids on protein (Aleksic et al, 2007, 2008).  We found evidence to 
support  non-specific  protein  modification,  in  that  many  of  the  changes  seen  in  the 
transcriptome relate to proteins containing a high proportion of cysteine, or cysteine 
residues in critical functional domains e.g. KRTAPs, chemokines, phosphatases, and 
proteins involved in glutathione/thioredoxin and redox sensitive Keap1/Nrf2 pathways.   
 
Direct binding of DNCB to cysteine residues on Keap1 may trigger activation of Nrf2 
signalling (Kobayashi et al, 2009).  DNCB is also known to sequester glutathione (Chia 
et  al,  2010)  and  thioredoxin  by  direct  binding,  and  irreversibly  inhibit  thioredoxin 
reductase (Nordberg et al, 1998).  These reactions alter the redox balance of the cell, 
and allow endogenous ROS levels to rise.  We found that DNCB produced a significant 
increase in intracellular ROS; it is possible that once the amount of ROS overwhelms 
antioxidant defences, the ROS will also contribute to the activation of redox-sensitive 
signalling cascades such as Nrf2 and stress-activated MAPK (p38MAPK, JNK).  ASK1, 
a kinase upstream of p38MAPK and JNK, is inactivated by interaction with reduced 
thioredoxin, therefore a decrease in the level of thioredoxin can trigger p38MAPK and 
JNK  signalling.    Also,  oxidation  of  functionally-critical  cysteine  residues  on  MKP 
(Salmeen and Barford, 2005), by ROS or DNCB binding, will inhibit the phosphatase 
activity, removing inhibition and allowing signal transduction to continue.   
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Figure 6-1 Potential molecular mechanisms driving keratinocyte responses to 
DNCB 
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In  addition  to  cysteine-rich  proteins,  some  receptor  tyrosine  kinases,  such  as 
EGFR/ErbB,  InsR  and  Ret,  have  extracellular  domains  with  a  high  proportion  of 
cysteine residues (reviewed in Lemmon and Schlessinger, 2010), which, if bound by 
DNCB, could lead to activation of the receptor and downstream MAPK and NF-B 
cascades.   We saw phosphorylation of  a large molecular weight protein, potentially 
activated following direct binding of DNCB to extracellular cysteine residues (e.g. ErbB 
receptors),  or  via  binding  to  a  ligand  induced  by  DNCB.  From  the  analysis  of  the 
transcriptomics data, we hypothesise that this protein is the ErbB4 receptor, driven by 
direct binding of DNCB or interaction with the ligand HB-EGF.  Other receptors such 
as the IL-1R or TLRs are also implicated in the gene expression data, based on changes 
in IL-1R/TLR downstream signalling and up-regulation of IL-1, IL-1, IL-1ra and IL-
33.  Some of these receptor-mediated signals may be part of a secondary stage of the 
response, triggered following up-regulation of their respective ligands during the initial 
reaction to DNCB. 
 
Our research has  highlighted  a number of other areas  that would be interesting for 
further study.  We have seen a specific cytokine response (IL-1, IL-6 and IL-8) to 
DNCB  induced  via  MAPK  and  NF-B  signalling  pathways  in  HaCaT  cells,  and  it 
would be interesting to see if the same response was found from primary keratinocytes.  
Given that many of the changes we observed may have been caused by nucleophilic 
substitution,  it  would  also  be  interesting  to  determine  whether  other  electrophilic 
chemical allergens induce a similar response, and if there are any differences between 
the pathways triggered.  We found a strong band in response to DNCB on the phospho-
tyrosine blot, which is likely to be an activated RTK, and we are keen to uncover the 
identity of this protein; we have hypothesised that it may be the ErbB4 receptor, and 
this  could  be  easily  tested.    DNCB-dependent  signalling  via  the  TLR/NLR  or  IL-1 
receptors is also likely from our data, and could be further characterised.  
 
We have seen the potential of keratinocytes to produce DAMPs (including cytokines) in 
response to sensitiser, and it would be interesting to see how this depends on the nature 
and kinetics of cell death, and what their functional effect would be on DCs.  It would 
also be interesting to determine how the cytokines released from keratinocytes at non-233 
 
cytotoxic concentrations act in conjunction with mediators from other cell types in skin 
to affect DC behaviour.  Co-culture of sensitiser-exposed keratinocytes or conditioned 
media with other skin cells, such as fibroblasts, macrophages, mast cells or T cells, 
would enable characterisation of the full variety of cytokines that could be induced from 
keratinocyte-derived  signals.    Exposing  PBMC-DC  to  secondary,  co-culture  media, 
combined with inhibition of individual cytokines, could then determine which of these 
mediators are capable of maturing DCs. 
 
It would be particularly appealing to investigate which proteins are haptenated in skin, 
and what antigenic peptides are presented.  To establish this, we could compare the 
repertoires  of  presented  peptides  following  elution  of  peptide:MHC  from  DCs  co-
cultured with keratinocytes pre-treated with sensitiser or vehicle control.  In addition to 
this, we would like to understand whether the processing and presentation pathways 
involved  in  generating  antigenic  peptide  are  directly  perturbed  by  sensitisers  or 
sensitiser-derived cytokines such as IL-6.  Or whether sensitiser can bind directly to, 
and distort the MHC groove altering the range of peptides with affinity to bind MHC.  It 
is  possible  that  there  is  an  autoimmune-like  aspect  to  the  development  of  CHS 
responses, due to atypical antigen presentation.  We would like to determine whether 
sensitiser-induced  IL-6  from  keratinocytes  has  a  functional  role  in  driving  atypical 
antigen presentation and autoimmune-like responses.   
 
Further study surrounding the role of the keratinocyte in elicitation, specifically, which 
cell types respond to the keratinocytes-derived chemokines produced, how they interact 
and potentially regulate T cell function, could be of great importance for modulation of 
skin immune responses or vaccine development.  A final but significant gap in our 
knowledge is the extent, phenotype and location of the memory T cells generated in 
CHS, particularly the density of hapten-antigen derived memory T cells residing in the 
skin as tissue- resident memory cells (Trm) and how long they prevail.  A large clinical 
study involving skin biopsies from allergic vs non allergic subjects could be designed to 
investigate this. 
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